

ANTIBACTERIAL AGENTS

CROSS REFERENCE

5 This application claims the benefit of U.S. Serial No. 60/405,464, filed on August 23, 2002, under 35 U.S.C. § 119(e)(i).

FIELD OF THE INVENTION

 The present invention relates to antibacterial agents that are useful for
10 sterilization, sanitation, antisepsis, and disinfection.

BACKGROUND

 The inappropriate growth of a variety of bacteria has been a problem for many years. Bacteria have caused degradation of natural product materials, infection in
15 humans and other animals, and spoilage of foods.

 Sterilization denotes the use of either physical or chemical agents to eliminate all viable bacteria from a material, while disinfection generally refers to the use of germicidal chemical agents to destroy the potential infectivity of a material. Sanitizing refers to procedures used to simply lower the bacterial content of utensils
20 used for food. Antisepsis refers to the topical application of chemicals to a body surface to kill or inhibit pathogenic microbes. Disinfectants are widely used for skin antisepsis in preparation for surgery.

 Bacteria are the smallest organisms that contain all the machinery required for growth and self-replication. A bacterium includes a rigid cell wall surrounding the
25 cytoplasmic membrane, which itself encloses a single naked chromosome without a nuclear membrane. The cytoplasmic membrane consists primarily of a bi-layer of lipid molecules.

 The fundamental criterion of bactericidal action is loss of the ability of the organism to propagate indefinitely, when placed in a suitable environment.
30 Bactericidal action suggests microbe damage of various types, including the triggering of irreversible damage to the cytoplasmic cell membrane or irreversible impairment of the DNA (or viral RNA replication. Accordingly, sterilization is not identical with destruction of microbes. Additionally, it is understood that damage to nucleic acids


(DNA or RNA) is not always irreversible, as it is known that ultraviolet light-induced damage to viral nucleic acids can be repaired by enzymatic and genetic mechanisms.

SUMMARY OF THE INVENTION

5 The invention relates to antibacterial agents that are useful for sterilization, sanitation, antiseptis, and disinfection.

 In one aspect, the invention features methods of using antibacterial agents of formula I for sterilizing, sanitizing, antiseptis, or disinfecting. The method includes applying the antibacterial agent to a location in need of sterilization, sanitation, antiseptis, and disinfection. Specifically, a method of sterilization, sanitation, antiseptis, and disinfection, includes applying antimicrobial compounds to a surface in need of sterilization, sanitation, antiseptis, and disinfection. The antimicrobial compounds are applied in a therapeutically acceptable amount, e.g., an amount sufficient to kill or hinder the growth of bacteria on the surface to be sterilized, sanitized, or disinfected.

10 In general, the antibacterial agents have the formula



or a pharmaceutically acceptable salt thereof,
wherein

20 X = NH


 Y = CO, CS, -C(=N-CN) or

 X and Y together form an alkene, or C₃-C₅ cycloalkyl;

 R₁ is -COOH;

 R₂ is an electron withdrawing group;

25 R₄ is an optionally substituted aryl, provided that the aryl is not simultaneously substituted with a sulfonamide and a urea or thiourea, further provided that the aryl is not solely substituted at the ortho-position relative to Y, and still further provided that the aryl is not substituted with a group selected from



W_1 is N or CH;

R_{10} is C₁-C₄ alkyl, C₁-C₄ substituted alkyl, Het, substituted Het, aryl, or substituted aryl; and

- 5 R_{15} is H, C₁-C₄ alkyl, C₁-C₄ substituted alkyl, Het, substituted Het, C₄-C₇ cycloalkyl.

DETAILED DESCRIPTION OF THE INVENTION

The term "halo" refers to a halogen atom selected from Cl, Br, I, and F.

The term "alkyl" refers to both straight- and branched-chain moieties. Unless
 10 otherwise specifically stated alkyl moieties include between 1 and 9 carbon atoms.

The term "alkenyl" refers to both straight- and branched-chain moieties containing at least one $-C=C-$. Unless otherwise specifically stated alkenyl moieties include between 1 and 9 carbon atoms.

The term "alkynyl" refers to both straight- and branched-chain moieties
 15 containing at least one $-C\equiv C-$. Unless otherwise specifically stated alkynyl moieties include between 1 and 9 carbon atoms. between 1 and 6 carbon atoms

The term "alkoxy" refers to $-O$ -alkyl groups.

The term "cycloalkyl" refers to a cyclic alkyl moiety. Unless otherwise specifically stated cycloalkyl moieties will include between 3 and 9 carbon atoms.

20 The term "cycloalkenyl" refers to a cyclic alkenyl moiety. Unless otherwise specifically stated cycloalkenyl moieties will include between 5 and 9 carbon atoms and at least one $-C=C-$ group within the cyclic ring.

The term "amino" refers to $-NH_2$.

The term “sulfonamide” refers to a $-S(O)_2-N(Q_{10})_2$

The term “aryl” refers to phenyl and naphthyl.

The term “het” refers to mono- or bi-cyclic ring systems containing at least one heteroatom selected from O, S, and N. Each mono-cyclic ring may be aromatic,
 5 saturated, or partially unsaturated. A bi-cyclic ring system may include a mono-cyclic ring containing at least one heteroatom fused with an cycloalkyl or aryl group. A bi-cyclic ring system may also include a mono-cyclic ring containing at least one heteroatom fused with another het, mono-cyclic ring system.

Examples of “het” include, but are not limited to, pyridine, thiophene, furan,
 10 pyrazoline, pyrimidine, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, 3-pyrazinyl, 4-oxo-2-imidazolyl, 2-imidazolyl, 4-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 4-oxo-2-oxazolyl, 5-oxazolyl, 1,2,3-oxathiazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole,
 15 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-isothiazole, 4-isothiazole, 5-isothiazole, 2-furanyl, 3-furanyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 3-pyrrolyl, 3-isopyrrolyl, 4-isopyrrolyl, 5-isopyrrolyl, 1,2,3-oxathiazole-1-oxide, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, 5-oxo-1,2,4-oxadiazol-3-yl, 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl, 3-oxo-1,2,4-thiadiazol-5-yl, 1,3,4-thiadiazol-5-yl, 2-oxo-1,3,4-thiadiazol-5-yl,
 20 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,3,4-tetrazol-5-yl, 5-oxazolyl, 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl, 1,3,4-oxadiazole, 4-oxo-2-thiazolyl, 5-methyl-1,3,4-thiadiazol-2-yl, thiazolodione, 1,2,3,4-thiatriazole, 1,2,4-dithiazolone, phthalimide, quinolinyl, morpholinyl, benzoxazolyl, diazinyl, triazinyl, quinolinyl, quinoxalinyl, naphthyridinyl, azetidyl, pyrrolidinyl, hydantoinyl, oxathiolanyl, dioxolanyl,
 25 imidazolidinyl, and azabicyclo[2.2.1]heptyl.

The term “heteroaryl” refers to a mono- or bicyclic het in which at least one cyclic ring is aromatic.

The term “substituted alkyl” refers to an alkyl moiety including 1-4 substituents selected from halo, het, cycloalkyl, cycloalkenyl, aryl, $-OQ_{10}$, $-SQ_{10}$, $-S(O)_2Q_{10}$,
 30 $-S(O)Q_{10}$, $-OS(O)_2Q_{10}$, $-C(=NQ_{10})Q_{10}$, $-C(=N-O-Q_{10})Q_{10}$, $-S(O)_2-N=S(O)(Q_{10})_2$, $-S(O)_2-N=S(Q_{10})_2$, $-NQ_{10}Q_{10}$, $-C(O)Q_{10}$, $-C(S)Q_{10}$, $-C(O)OQ_{10}$, $-OC(O)Q_{10}$, $-C(S)NQ_{10}Q_{10}$, $-N(Q_{10})C(S)NQ_{10}Q_{10}$, $-C(O)NQ_{10}Q_{10}$, $-C(O)C(Q_{16})_2OC(O)Q_{10}$, $-CN$,

=O, =S, -NQ₁₀C(O)Q₁₀, -NQ₁₀C(O)NQ₁₀Q₁₀, -S(O)₂NQ₁₀Q₁₀, -NQ₁₀S(O)₂Q₁₀, -NQ₁₀S(O)Q₁₀, -NQ₁₀SQ₁₀, -NO₂, and -SNQ₁₀Q₁₀. Each of the het, cycloalkyl, cycloalkenyl, and aryl being optionally substituted with 1-4 substituents independently selected from halo and Q₁₅.

5 The term “substituted aryl” refers to an aryl moiety having 1-3 substituents selected from -OQ₁₀, -SQ₁₀, -S(O)₂Q₁₀, -S(O)Q₁₀, -OS(O)₂Q₁₀, -C(=NQ₁₀)Q₁₀, -C(=NOQ₁₀)Q₁₀, -S(O)₂-N=S(O)(Q₁₀)₂, -S(O)₂-N=S(Q₁₀)₂, -NQ₁₀Q₁₀, -C(O)Q₁₀, -C(S)Q₁₀, -C(O)OQ₁₀, -OC(O)Q₁₀, -C(O)NQ₁₀Q₁₀, -C(O)C(Q₁₆)₂OC(O)Q₁₀, -CN, -NQ₁₀C(O)Q₁₀, -N(Q₁₀)C(S)NQ₁₀Q₁₀, -N(Q₁₀)C(S)Q₁₀, -NQ₁₀C(O)NQ₁₀Q₁₀, -S(O)₂NQ₁₀Q₁₀, -NQ₁₀S(O)₂Q₁₀, -NQ₁₀S(O)Q₁₀, -NQ₁₀SQ₁₀, -NO₂, -SNQ₁₀Q₁₀, alkyl, substituted alkyl, alkenyl, alkynyl, het, halo, cycloalkyl, cycloalkenyl, and aryl. The het, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, and aryl being optionally substituted with 1-3 substituents selected from halo and Q₁₅.

15 The term “substituted het” refers to a het moiety including 1-4 substituents selected from -OQ₁₀, -SQ₁₀, -S(O)₂Q₁₀, -S(O)Q₁₀, -OS(O)₂Q₁₀, -C(=NQ₁₀)Q₁₀, -C(=NOQ₁₀)Q₁₀, -S(O)₂-N=S(O)(Q₁₀)₂, -S(O)₂-N=S(Q₁₀)₂, -NQ₁₀Q₁₀, -C(O)Q₁₀, -C(S)Q₁₀, -C(O)OQ₁₀, -OC(O)Q₁₀, -C(O)NQ₁₀Q₁₀, -C(O)C(Q₁₆)₂OC(O)Q₁₀, -CN, =O, =S, -NQ₁₀C(O)Q₁₀, -NQ₁₀C(S)Q₁₀, -NQ₁₀C(O)NQ₁₀Q₁₀, -NQ₁₀C(S)NQ₁₀Q₁₀, -S(O)₂NQ₁₀Q₁₀, -NQ₁₀S(O)₂Q₁₀, -NQ₁₀S(O)Q₁₀, -NQ₁₀SQ₁₀, -NO₂, -SNQ₁₀Q₁₀, alkyl, substituted alkyl, het, halo, cycloalkyl, cycloalkenyl, and aryl. The het, cycloalkyl, cycloalkenyl, and aryl being optionally substituted with 1-3 substituents selected from halo and Q₁₅.

The term “substituted alkenyl” refers to a alkenyl moiety including 1-3 substituents -OQ₁₀, -SQ₁₀, -S(O)₂Q₁₀, -S(O)Q₁₀, -OS(O)₂Q₁₀, -C(=NQ₁₀)Q₁₀, -C(=NOQ₁₀)Q₁₀, -S(O)₂-N=S(O)(Q₁₀)₂, -S(O)₂-N=S(Q₁₀)₂, -NQ₁₀Q₁₀, -C(O)Q₁₀, -C(S)Q₁₀, -C(O)OQ₁₀, -OC(O)Q₁₀, -C(O)NQ₁₀Q₁₀, -C(S)NQ₁₀Q₁₀, -C(O)C(Q₁₆)₂OC(O)Q₁₀, -CN, =O, =S, -NQ₁₀C(S)Q₁₀, -NQ₁₀C(O)Q₁₀, -NQ₁₀C(O)NQ₁₀Q₁₀, -NQ₁₀C(S)NQ₁₀Q₁₀, -S(O)₂NQ₁₀Q₁₀, -NQ₁₀S(O)₂Q₁₀, -NQ₁₀S(O)Q₁₀, -NQ₁₀SQ₁₀, -NO₂, -SNQ₁₀Q₁₀, alkyl, substituted alkyl, het, halo, cycloalkyl, cycloalkenyl, and aryl. The het, cycloalkyl, cycloalkenyl, and aryl being optionally substituted with 1-3 substituents selected from halo and Q₁₅.

The term “substituted alkoxy” refers to an alkoxy moiety including 1-3 substituents -OQ₁₀, -SQ₁₀, -S(O)₂Q₁₀, -S(O)Q₁₀, -OS(O)₂Q₁₀, -C(=NQ₁₀)Q₁₀, -C(=NOQ₁₀)Q₁₀, -S(O)₂-N=S(O)(Q₁₀)₂, -S(O)₂-N=S(Q₁₀)₂, -NQ₁₀Q₁₀, -C(O)Q₁₀, -C(S)Q₁₀, -C(O)OQ₁₀, -OC(O)Q₁₀, -C(O)NQ₁₀Q₁₀, -C(S)NQ₁₀Q₁₀,
 5 -C(O)C(Q₁₆)₂OC(O)Q₁₀, -CN, =O, =S, -NQ₁₀C(S)Q₁₀, -NQ₁₀C(O)Q₁₀, -NQ₁₀C(O)NQ₁₀Q₁₀, -NQ₁₀C(S)NQ₁₀Q₁₀, -S(O)₂NQ₁₀Q₁₀, -NQ₁₀S(O)₂Q₁₀, -NQ₁₀S(O)Q₁₀, -NQ₁₀SQ₁₀, -NO₂, -SNQ₁₀Q₁₀, alkyl, substituted alkyl, het, halo, cycloalkyl, cycloalkenyl, and aryl. The het, cycloalkyl, cycloalkenyl, and aryl being optionally substituted with 1-3 substituents selected from halo and Q₁₅.

10 The term “substituted cycloalkenyl” refers to a cycloalkenyl moiety including 1-3 substituents -OQ₁₀, -SQ₁₀, -S(O)₂Q₁₀, -S(O)Q₁₀, -OS(O)₂Q₁₀, -C(=NQ₁₀)Q₁₀, -C(=NOQ₁₀)Q₁₀, -S(O)₂-N=S(O)(Q₁₀)₂, -S(O)₂-N=S(Q₁₀)₂, -NQ₁₀Q₁₀, -C(O)Q₁₀, -C(S)Q₁₀, -C(O)OQ₁₀, -OC(O)Q₁₀, -C(O)NQ₁₀Q₁₀, -C(S)NQ₁₀Q₁₀, -C(O)C(Q₁₆)₂OC(O)Q₁₀, -CN, =O, =S, -NQ₁₀C(S)Q₁₀, -NQ₁₀C(O)Q₁₀,
 15 -NQ₁₀C(O)NQ₁₀Q₁₀, -NQ₁₀C(S)NQ₁₀Q₁₀, -S(O)₂NQ₁₀Q₁₀, -NQ₁₀S(O)₂Q₁₀, -NQ₁₀S(O)Q₁₀, -NQ₁₀SQ₁₀, -NO₂, -SNQ₁₀Q₁₀, alkyl, substituted alkyl, het, halo, cycloalkyl, cycloalkenyl, and aryl. The het, cycloalkyl, cycloalkenyl, and aryl being optionally substituted with 1-3 substituents selected from halo and Q₁₅.

The term “substituted amino” refers to an amino moiety in which one or both
 20 of the amino hydrogens are replaced with a group selected from -OQ₁₀, -SQ₁₀, -S(O)₂Q₁₀, -S(O)Q₁₀, -OS(O)₂Q₁₀, -C(=NQ₁₀)Q₁₀, -C(=NOQ₁₀)Q₁₀, -S(O)₂-N=S(O)(Q₁₀)₂, -S(O)₂-N=S(Q₁₀)₂, -NQ₁₀Q₁₀, -C(O)Q₁₀, -C(S)Q₁₀, -C(O)OQ₁₀, -OC(O)Q₁₀, -C(O)NQ₁₀Q₁₀, -C(S)NQ₁₀Q₁₀, -C(O)C(Q₁₆)₂OC(O)Q₁₀, -CN, =O, =S, -NQ₁₀C(O)Q₁₀, -NQ₁₀C(S)Q₁₀, -NQ₁₀C(O)NQ₁₀Q₁₀, -NQ₁₀C(S)NQ₁₀Q₁₀, -
 25 S(O)₂NQ₁₀Q₁₀, -NQ₁₀S(O)₂Q₁₀, -NQ₁₀S(O)Q₁₀, -NQ₁₀SQ₁₀, -NO₂, -SNQ₁₀Q₁₀, alkyl, substituted alkyl, het, halo, cycloalkyl, cycloalkenyl, and aryl. The het, cycloalkyl, cycloalkenyl, and aryl being optionally substituted with 1-3 substituents selected from halo and Q₁₅.

Each Q₁₀ is independently selected from -H, alkyl, cycloalkyl, het,
 30 cycloalkenyl, and aryl. The het, alkyl, cycloalkyl, cycloalkenyl, and aryl being optionally substituted with 1-3 substituents selected from halo and Q₁₃.

Each Q_{11} is independently selected from -H, halo, alkyl, aryl, cycloalkyl, and het. The alkyl, aryl, cycloalkyl, and het being optionally substituted with 1-3 substituents independently selected from halo, -NO₂, -CN, =S, =O, and Q_{14} .

Each Q_{13} is independently selected from Q_{11} , -O Q_{11} , -S Q_{11} , -S(O)₂ Q_{11} ,
 5 -S(O) Q_{11} , -OS(O)₂ Q_{11} , -C(=N Q_{11}) Q_{11} , -S(O)₂-N=S(O)(Q_{11})₂, -S(O)₂-N=S(Q_{11})₂,
 -SC(O) Q_{11} , -N Q_{11} Q_{11} , -C(O) Q_{11} , -C(S) Q_{11} , -C(O)O Q_{11} , -OC(O) Q_{11} , -C(O)N Q_{11} Q_{11} ,
 -C(S)N Q_{11} Q_{11} , -C(O)C(Q_{16})₂OC(O) Q_{10} , -CN, =O, =S, -N Q_{11} C(O) Q_{11} , -N Q_{11} C(S) Q_{11} ,
 -N Q_{11} C(O)N Q_{11} Q_{11} , -N Q_{11} C(S)N Q_{11} Q_{11} , -S(O)₂N Q_{11} Q_{11} , -N Q_{11} S(O)₂ Q_{11} ,
 -N Q_{11} S(O) Q_{11} , -N Q_{11} S Q_{11} , -NO₂, and -SN Q_{11} Q_{11} .

10 Each Q_{14} is -H or a substituent selected from alkyl, cycloalkyl, phenyl, or naphthyl, each optionally substituted with 1-4 substituents independently selected from

-F, -Cl, -Br, -I, -O Q_{16} , -S Q_{16} , -S(O)₂ Q_{16} , -S(O) Q_{16} , -OS(O)₂ Q_{16} , -N Q_{16} Q_{16} , -C(O) Q_{16} ,
 -C(S) Q_{16} , -C(O)O Q_{16} , -NO₂, -C(O)N Q_{16} Q_{16} , -C(S)N Q_{16} Q_{16} , -CN, -N Q_{16} C(O) Q_{16} ,
 15 -N Q_{16} C(S) Q_{16} , -N Q_{16} C(O)N Q_{16} Q_{16} , -N Q_{16} C(S)N Q_{16} Q_{16} , -S(O)₂N Q_{16} Q_{16} , and
 -N Q_{16} S(O)₂ Q_{16} . The alkyl, cycloalkyl, and cycloalkenyl being further optionally substituted with =O or =S.

Each Q_{15} is alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, or naphthyl, each optionally substituted with 1-4 substituents independently selected from -F,
 20 -Cl, -Br, -I, -O Q_{16} , -S Q_{16} , -S(O)₂ Q_{16} , -S(O) Q_{16} , -OS(O)₂ Q_{16} , -C(=N Q_{16}) Q_{16} ,
 -S(O)₂-N=S(O)(Q_{16})₂, -S(O)₂-N=S(Q_{16})₂, -SC(O) Q_{16} , -N Q_{16} Q_{16} , -C(O) Q_{16} , -C(S) Q_{16} ,
 -C(O)O Q_{16} , -OC(O) Q_{16} , -C(O)N Q_{16} Q_{16} , -C(S)N Q_{16} Q_{16} , -C(O)C(Q_{16})₂OC(O) Q_{16} , -
 CN,
 -N Q_{16} C(O) Q_{16} , -N Q_{16} C(S) Q_{16} , -N Q_{16} C(O)N Q_{16} Q_{16} , -N Q_{16} C(S)N Q_{16} Q_{16} , -
 25 S(O)₂N Q_{16} Q_{16} , -N Q_{16} S(O)₂ Q_{16} , -N Q_{16} S(O) Q_{16} , -N Q_{16} S Q_{16} , -NO₂, and -SN Q_{16} Q_{16} .
 The alkyl, cycloalkyl, and cycloalkenyl being further optionally substituted with =O or =S.

Each Q_{16} is independently selected from -H, alkyl, and cycloalkyl. The alkyl and cycloalkyl optionally including 1-3 halos.

30 Mammal denotes human and animals.

Each Q_{17} is independently selected from -H, -OH, and alkyl optionally including 1-3 halos and -OH.

The term "electron withdrawing group" refers to the ability of a substituent to withdraw electrons relative to that of hydrogen if the hydrogen atom occupied the same position on the molecule. The term "electron withdrawing group" is well understood by one skilled in the art and is discussed in Advanced Organic Chemistry by J. March, John Wiley & Sons, New York, New York, (1985) and the discussion therein is incorporated herein by reference. Electron withdrawing groups include, but are not limited to, groups such as halo, nitro, carboxy, cyano, aryl optionally substituted, aromatic het (excluding pyridine) optionally substituted, $-\text{OC}(\text{Z}_n)_3$, $-\text{C}(\text{Z}_n)_3$, $-\text{C}(\text{Z}_n)_2-\text{O}-\text{C}(\text{Z}_m)_3$, $-(\text{CO})-\text{Q}_{17}$, $-\text{SO}_2-\text{C}(\text{Z}_n)_3$, $-\text{SO}_2\text{-aryl}$, $-\text{C}(\text{NQ}_{17})\text{Q}_{17}$, $-\text{CH}=\text{C}(\text{Q}_{17})_2$, $-\text{C}\equiv\text{C}-\text{Q}_{17}$, in which each Z_n and Z_m is independently H, halo, $-\text{CN}$, $-\text{NO}_2$, $-\text{OH}$, or $\text{C}_{1-4}\text{alkyl}$ optionally substituted with 1-3 halo, $-\text{OH}$, NO_2 , and provided that at least one of Z_n is halo, $-\text{CN}$, or NO_2 , and further provided that Q_{17} is not $-\text{OH}$ when the the electron withdrawing group is $-(\text{CO})-\text{Q}_{17}$.

It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, tautomeric, or stereoisomeric form, or mixture thereof, of a compound of the invention, which possesses the useful properties described herein.

In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, use of the compounds as pharmaceutically acceptable salts may be appropriate. Examples of pharmaceutically acceptable salts which are within the scope of the present invention include organic acid addition salts formed with acids which form a physiological acceptable anion and inorganic salts. Examples of pharmaceutically acceptable salts include, but are not limited to, the following acids acetic, aspartic, benzenesulfonic, benzoic, bicarbonic, bisulfuric, bitartaric, butyric, calcium edetate, camsylic, carbonic, chlorobenzoic, citric, edetic, edisylic, estolic, esyl, esylic, formic, fumaric, gluceptic, gluconic, glutamic, glycolylarsanilic, hexamic, hexylresorcinoic, hydrabamic, hydrobromic, hydrochloric, hydroiodic, hydroxynaphthoic, isethionic, lactic, lactobionic, maleic, malic, malonic, mandelic, methanesulfonic, methylnitric, methylsulfuric, mucic, muconic, napsylic, nitric, oxalic, p-nitromethanesulfonic, pamoic, pantothenic, phosphoric, monohydrogen phosphoric, dihydrogen phosphoric, phthalic, polygalactouronic, propionic, salicylic, stearic, succinic, sulfamic, sulfanilic, sulfonic, sulfuric, tannic, tartaric, teoclic toluenesulfonic, primary, secondary, and tertiary amines, substituted amines including

naturally occurring substituted amines, cyclic amines, such as arginine, betaine, caffeine, choline, N, N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylamino-ethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, and the like.

Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.

The antibacterial agents of this invention have useful activity against a variety of organisms. The in vitro activity of compounds of this invention can be assessed by standard testing procedures such as the determination of minimum inhibitory concentration (MIC) by agar dilution as described in "Approved Standard. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically", 3rd. ed., published 1993 by the National Committee for Clinical Laboratory Standards, Villanova, Pennsylvania, USA.

The antibacterial agents described herein are useful for sterilization, sanitation, antisepsis, and disinfection. The antibacterial agents can be applied to a location in need of sterilization, sanitation, antisepsis, or disinfection, by methods known to those skilled in the art. For instance, the antibacterial agents may be incorporated into a cleaning solution that is applied, such as by spraying or pouring, to an item in need of sterilization, sanitation, antisepsis, or disinfection. The antibacterial agents may be used alone or in combination, e.g., agents disclosed herein with one another or agent(s) disclosed herein with other antibacterial agents. The antibacterial agents may be applied in varying concentrations depending upon the bacterial susceptibility to antibacterial agent(s) being applied and the desired level of sterilization, sanitation, antisepsis, or disinfection.


The antibacterial compounds of this invention may be synthesized by various methods known to those skilled in the art. Non-limiting examples of synthetic schemes for producing the antibacterial agents are described below.

EXAMPLES

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, practice the present invention to its fullest extent. The following detailed examples describe how to prepare the various compounds and/or perform the various processes of the invention and are to be construed as merely illustrative, and not limitations of the preceding disclosure in any way whatsoever. Those skilled in the art will promptly recognize appropriate variations from the procedures both as to reactants and as to reaction conditions and techniques.

Example 1: Sulfonyl Derivatives

Scheme 1.1



a) oxalyl chloride; b) Methyl-2-amino-5-bromobenzoate; c) HN(Q₁₇)₂; d) KOH

15 Methyl 5-bromo-2-[[4-(chlorosulfonyl)benzoyl]amino]benzoate

Methyl 5-bromo-2-[[4-(chlorosulfonyl)benzoyl]amino]benzoate (**1**) was prepared as a common intermediate for the formation of sulfonamides by the procedure below: 4-(chlorosulfonyl)benzoic acid (18.37 g, 8.33 mmol) was suspended in CH₂Cl₂ (140 mL) and 4 drops of DMF. The solution was cooled to 0° C and oxalyl chloride (1.8 mL, 20.6 mmol) was added and stirred for 1 hour, removed from ice bath, and stirred overnight. The clear solution was concentrated *in vacuo*, redissolved in CH₂Cl₂, and concentrated *in vacuo*. The resulting product was dissolved in toluene (140 mL) and refluxed for 30 minutes to remove any HCl gas. After cooling to room temperature, methyl-2-amino-5-bromobenzoate (15.96 g, 69.4 mmol) was added, and the

suspension was refluxed overnight. The suspension was cooled to 0° C and filtered, washing with toluene and quickly with ethyl acetate. The solid was dried in a vacuum oven overnight to obtain sulfonyl chloride 1 (19.8 g, 66%). ¹H NMR (CDCl₃) δ 12.19, 8.82, 8.27-8.19, 7.73, 4.00; IR 1700, 1683, 1604, 1585, 1524 (s), cm⁻¹; MS (ESI-) for C₁₅H₁₁BrClNO₅S *m/z* 429.8 (M-H)⁻.

General Method A (sulfonamide preparation with anilines, primary, and secondary amines)

10 Methyl 5-bromo-2-({4-[(diethylamino)sulfonyl]benzoyl}amino)benzoate.

To a solution of the sulfonyl chloride 1, (694.1 mg, 1.61 mmol, 1.0 eq) in toluene (4.0 mL) was added diethyl amine (500 μL, 4.83 mmol, 3.0 eq). The suspension was shaken at 50° C for overnight. The product was extracted with EtOAc, washed with 1 N HCl and water, and concentrated *in vacuo*. The compound was dried in a vacuum oven at 50° C overnight to obtain 624.4 mg (83%). ¹H NMR (300 MHz, DMSO-*d*₆) δ 11.48, 8.31, 8.11, 8.05, 7.99, 7.87, 3.86, 3.20, 1.04; IR 1700, 1676 (s), 1600, 1519 (s), 1338, 1330, 1306 (s), cm⁻¹. Anal. Calcd for C₁₉H₂₁BrN₂O₅S: C, 48.62; H, 4.51; N, 5.97; Br, 17.02; S, 6.83. Found: C, 48.76; H, 4.53; N, 5.89; Br, 16.98; S, 6.73.

20 General Method B (hydrolysis of the methyl ester)

5-bromo-2-({4-[(diethylamino)sulfonyl]benzoyl}amino)benzoate, 8.

Methyl 5-bromo-2-({4-[(diethylamino)sulfonyl]benzoyl}amino)benzoate (329.6 mg, 0.704 mmol) was dissolved in 2 mL of dioxane and 0.2 mL of water. KOH (1 pellet, ~80 mg) was added to the mixture as it was heated at 50° C for 3 hours. The reaction was cooled, extracted with EtOAc, washed with 1 N HCl and brine, dried (Na₂SO₄), concentrated *in vacuo*, and dried in a vacuum oven at 50° C overnight to yield 313.8 mg (98%). ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.05, 8.55, 8.11, 8.09, 8.00, 7.86, 3.19, 1.04; IR 1703, 1661, 1202, 1185, cm⁻¹. MS (FAB) *m/z* (rel. intensity) 455 (MH⁺, 45), 457 (37), 455 (45), 240 (99). HRMS (FAB) calcd for

C₁₈H₁₉BrN₂O₅S + H₁ 455.0276, found 455.0260. Anal. Calcd for C₁₈H₁₉BrN₂O₅S: C, 47.48; H, 4.21; N, 6.15; Br, 17.55; S, 7.04. Found: C, 47.31; H, 4.25; N, 6.12.

5-bromo-2-({4-[(dimethylamino)sulfonyl]benzoyl}amino)benzoic acid 6, was prepared by method B from its methyl ester, i.e., Methyl 5-bromo-2-({4-

5 [(dimethylamino)sulfonyl]benzoyl}amino)benzoate, in a 47% yield. ¹H NMR (300 MHz, CDCl₃) δ 8.89, 8.31, 8.18, 7.96, 7.78, 2.78; IR 3135, 1700, 1350 (s), 1191 (s), cm⁻¹. MS (ESI-) for C₁₆H₁₅BrNO₅S *m/z* 426.9 (M-H, Br isotope)⁻. Anal. Calcd for C₁₆H₁₅BrN₂O₅S: C, 44.98; H, 3.54; N, 6.56; Br, 18.70; S, 7.50. Found: C, 44.82; H, 3.55; N, 6.46; Br, 18.43; S, 7.36.

10 **5-bromo-2-({4-[(1H-indol-5-ylamino)sulfonyl]benzoyl}amino)benzoate 7**, was prepared by general method B from PNU-263551 in a 52% yield. ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.05 (s, 1 H), 11.05 (s, 1 H), 10.00 (s, 1 H), 8.52 (d, *J* = 9 Hz, 1 H), 8.10 (d, *J* = 2 Hz, 1 H), 8.02 (d, *J* = 8 Hz, 2 H), 7.85 (m, 3 H), 7.30 (t, *J* = 1 Hz, 1 H), 7.25440 (s, 1 H), 7.24 (d, *J* = 9 Hz, 1 H), 6.82 (dd, *J* = 9, 1 Hz, 1 H), 6.34 (s, 1 H);
15 IR 1687, 1664, 1607, 1524, 1338, 1314, 1300, 1189, 1170 (s), 825, 801, 756, 743, 681, 616 (s), cm⁻¹. MS (FAB) *m/z* (rel. intensity) 514 (MH⁺, 55), 516 (59), 515 (67), 514 (55), 132 (99), 131 (97). HRMS (FAB) calcd for C₂₂H₁₆BrN₃O₅S + H₁ 514.0073, found 514.0066. HPLC [1] shows one main peak at 16.3 min (95%). Anal. Calcd for C₂₂H₁₆BrN₃O₅S: C, 51.37; H, 3.13; N, 8.17; Br, 15.53; S, 6.23. Found: C,
20 51.16; H, 3.23; N, 8.01.

5-bromo-2-[(4-[(3-furylmethyl)amino]sulfonyl]benzoyl)amino]benzoate 9, was prepared by method B from PNU-276173 in a 48% yield. ¹H NMR (300 MHz,

DMSO-*d*₆) δ 8.60 (d, *J* = 9 Hz, 1 H), 8.41 (t, *J* = 6 Hz, 1 H), 8.14 (d, *J* = 2 Hz, 1 H), 8.07 (d, *J* = 8 Hz, 2 H), 7.93 (d, *J* = 8 Hz, 2 H), 7.87 (dd, *J* = 9, 2 Hz, 1 H), 7.46 (s, 1
25 H), 6.28 (s, 1 H), 6.18 (s, 1 H), 4.08 (d, *J* = 6 Hz, 2 H); IR 3252, 1702, 1172 (s), 1165 (s), cm⁻¹. MS (FAB) *m/z* (rel. intensity) 479 (MH⁺, 13), 481 (14), 479 (13), 135 (99), 73 (64). HRMS (FAB) calcd for C₁₉H₁₅BrN₂O₆S + H₁ 478.9913, found 478.9922. Anal. Calcd for C₁₉H₁₅BrN₂O₆S: C, 47.61; H, 3.15; N, 5.84; Br, 16.67; S, 6.69. Found: C, 47.55; H, 3.22; N, 5.69; Br, 16.26; S, 6.60.

30 **5-bromo-2-[(4-{{4-(ethoxycarbonyl)-1-piperazinyl}sulfonyl}benzoyl)amino]benzoic acid 10** was prepared by method A followed by B with a 26% yield over both steps. The methyl ester was not fully characterized. ¹H NMR (300 MHz, DMSO-*d*₆)

δ 8.60 (d, $J = 9$ Hz, 1 H), 8.18 (d, $J = 8$ Hz, 2 H), 8.13 (d, $J = 2$ Hz, 1 H), 7.94 (d, $J = 8$ Hz, 2 H), 7.79 (dd, $J = 9, 2$ Hz, 1 H), 3.97 (q, $J = 7$ Hz, 2 H), 3.45 (br. s, 4 H), 2.95 (br. s, 4 H), 1.12 (t, $J = 7$ Hz, 3 H); IR 1692 (s), 1675 (s), 1584, 1518 (s), 1287, 1276, 1250, cm^{-1} . MS (FAB) m/z (rel. intensity) 540 (MH^+ , 46), 542 (44), 540 (46), 159 (95), 157 (99). HRMS (FAB) calcd for $\text{C}_{21}\text{H}_{22}\text{BrN}_3\text{O}_7\text{S} + \text{H}_1$ 540.0440, found 540.0428. HPLC [1] shows one major peak at 16.2 min (97%). Anal. Calcd for $\text{C}_{21}\text{H}_{22}\text{BrN}_3\text{O}_7\text{S}$: C, 46.67; H, 4.10; N, 7.78; Br, 14.79; S, 5.93. Found: C, 46.34; H, 4.19; N, 7.63; Br, 14.18; S, 5.79.

5-bromo-2-([4-([methyl[2-(2-pyridinyl)ethyl]amino)sulfonyl]benzoyl]amino) benzoic acid 11 was prepared by method A followed by B with a 57% yield over both steps. The methyl ester was not fully characterized. ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 12.19 (s, 1 H), 8.58 (d, $J = 9$ Hz, 1 H), 8.52 (d, $J = 4$ Hz, 1 H), 8.13 (d, $J = 3$ Hz, 1 H), 8.12 (d, $J = 6$ Hz, 2 H), 7.96 (d, $J = 8$ Hz, 2 H), 7.87 (dd, $J = 9, 2$ Hz, 1 H), 7.78 (td, $J = 8, 2$ Hz, 1 H), 7.35 (d, $J = 8$ Hz, 1 H), 7.30 (td, $J = 6, 2$ Hz, 1 H), 3.42 (t, $J = 7$ Hz, 2 H), 2.99 (t, $J = 8$ Hz, 2 H), 2.77 (s, 3 H); IR 1692 (s), 1518 (s), 1340 (s), 1297 (s), 1162 (s), 763 (s), 755 (s), 747 (s) cm^{-1} . MS (ES-) for $\text{C}_{22}\text{H}_{20}\text{BrN}_3\text{O}_5\text{S}$ m/z 518.0 ($\text{M}-\text{H}^+$, Br isotope); HRMS (FAB) calcd for $\text{C}_{22}\text{H}_{20}\text{BrN}_3\text{O}_5\text{S} + \text{H}_1$ 518.0386, found 518.0388. HPLC [1] shows one major peak (13.58 min, 99%).

2-([4-([benzylamino)sulfonyl]benzoyl]amino)-5-bromobenzoic acid 12 was prepared by method A followed by B with a 17% yield over both steps. The methyl ester was not fully characterized. ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 12.09 (s, 1 H), 8.60 (d, $J = 9$ Hz, 1 H), 8.39 (t, $J = 6$ Hz, 1 H), 8.14 (d, $J = 2$ Hz, 1 H), 8.08 (d, $J = 8$ Hz, 2 H), 7.97 (d, $J = 8$ Hz, 2 H), 7.88 (dd, $J = 9, 2$ Hz, 1 H), 7.30-7.20 (m, 5 H), 4.05 (d, $J = 6$ Hz, 2 H); HRMS (FAB) calcd for $\text{C}_{21}\text{H}_{17}\text{BrN}_2\text{O}_5\text{S} + \text{H}_1$ 489.0120, found 489.0129; HPLC [1] shows one major peak (20.60 min, 99%).

5-bromo-2-([4-([2-hydroxy-1-methylethyl]amino)sulfonyl]benzoyl]amino) benzoic acid 14 was prepared by method A followed by B with a 35% yield over both steps. The methyl ester was not fully characterized. ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 8.56 (d, $J = 9$ Hz, 1 H), 8.11 (d, $J = 2$ Hz, 1 H), 8.09 (d, $J = 8$ Hz, 2 H), 8.00 (d, $J = 8$ Hz, 2 H), 7.86 (dd, $J = 9, 2$ Hz, 1 H), 7.76 (d, $J = 7$ Hz, 1 H), 3.26 (m, 2 H), 3.12 (m, 1 H), 0.89 (d, $J = 6$ Hz, 3 H); MS (ES-) for $\text{C}_{17}\text{H}_{17}\text{BrN}_2\text{O}_6\text{S}$ m/z 454.9 ($\text{M}-\text{H}^+$); HPLC [1] shows one major peak (14.08 min, 96%).

5-bromo-2-({4-[(4-carboxyanilino)sulfonyl]benzoyl}amino)benzoic acid 15 was prepared from method A followed by method B in a 10% yield. The methyl ester was not fully characterized. ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.45 (br. s, 1 H), 11.15 (s, 1 H), 8.52 (d, *J* = 9 Hz, 1 H), 8.08 (d, *J* = 8 Hz, 3 H), 8.03 (d, *J* = 9 Hz, 2 H), 7.81 (d, *J* = 9 Hz, 3 H), 7.26 (d, *J* = 9 Hz, 2 H); HPLC [1] shows one major peak (15.15 min, 90%).

5-bromo-2-{{4-(3,4-dihydro-1(2H)-quinolinylsulfonyl)benzoyl}amino}benzoic acid 16 was prepared by method A followed by method B in a 48% yield. The methyl ester was not fully characterized. ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.05 (s, 1 H), 8.52 (d, *J* = 9 Hz, 1 H), 8.11 (d, *J* = 3 Hz, 1 H), 8.05 (d, *J* = 9 Hz, 2 H), 7.86 (dd, *J* = 9, 2 Hz, 1 H), 7.82 (d, *J* = 8 Hz, 2 H), 7.61 (d, *J* = 8 Hz, 1 H), 7.25-7.05 (m, 3 H), 3.83 (t, *J* = 6 Hz, 2 H), 2.45 (t, *J* = 7 Hz, 2 H), 1.63 (quintet, *J* = 6 Hz, 2 H); IR 1667, 1601, 1584, cm⁻¹. HRMS (FAB) calcd for C₂₃H₁₉BrN₂O₅S + H₁ 515.0276, found 515.0264. Anal. Calcd for C₂₃H₁₉BrN₂O₅S: C, 53.60; H, 3.72; N, 5.43. Found: C, 53.52; H, 3.96; N, 5.57.

5-bromo-2-{{4-({2-(3,5-dimethoxyphenyl)ethyl}amino)sulfonyl}benzoyl}amino}benzoic acid 17 was prepared by method A followed by B with a 56% yield over both steps. The methyl ester was not fully characterized. ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.60 (d, *J* = 9 Hz, 1 H), 8.13 (d, *J* = 3 Hz, 1 H), 8.09 (d, *J* = 8 Hz, 2 H), 7.95 (d, *J* = 9 Hz, 2 H), 7.87 (dd, *J* = 9, 2 Hz, 1 H), 6.79 (d, *J* = 8 Hz, 1 H), 6.73 (d, *J* = 2 Hz, 1 H), 6.64 (dd, *J* = 8, 2 Hz, 1 H), 3.70 (s, 3 H), 3.68 (s, 3 H), 3.02 (q, *J* = 6 Hz, 2 H), 2.61 (t, *J* = 7 Hz, 2 H); MS (FAB) *m/z* (rel. intensity) 563 (MH⁺, 86), 565 (86), 564 (82), 563 (86), 562 (56), 348 (77), 199 (46), 165 (56), 164 (32), 152 (49), 151 (99). HRMS (EI) calcd for C₂₄H₂₃BrN₂O₇S 562.0410, found 562.0438. HPLC [1] shows one major peak (16.16 min, 97%).

5-bromo-2-[(4-{{(3S)-3-hydroxypyrrolidinyl}sulfonyl}benzoyl)amino]benzoic acid 13 was prepared by method A followed by B in a 15% yield over both steps. The methyl ester was not fully characterized. ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.62 (d, *J* = 9 Hz, 1 H), 8.18 (d, *J* = 8 Hz, 2 H), 8.11 (d, *J* = 3 Hz, 1 H), 7.92 (d, *J* = 11 Hz, 2 H), 7.78 (dd, *J* = 9, 2 Hz, 1 H), 5.16 (m, 1 H), 3.50-3.20 (m, 4 H), 2.10-1.90 (m, 2 H); HPLC [1] shows one major peak (18.94 min, 97%).

5-bromo-2-({4-[(ethylanilino)sulfonyl]benzoyl}amino)benzoic acid 19 was

prepared by method A followed by B with a 75% yield over both steps. The methyl ester was not fully characterized. ¹H NMR (300 MHz, CD₃OD) δ 8.75 (d, *J* = 9 Hz, 1 H), 8.24 (d, *J* = 2 Hz, 1 H), 8.11 (d, *J* = 8 Hz, 2 H), 7.76 (dd, *J* = 9, 2 Hz, 1 H), 7.74 (d, *J* = 8 Hz, 2 H), 7.34 (m, 3 H), 7.06 (m, 2 H), 3.69 (q, *J* = 7 Hz, 2 H), 1.07 (t, *J* = 7 Hz, 3 H); MS (ES⁻) for C₂₂H₁₉BrN₂O₅S *m/z* 502.8 (M-H⁺; Br isotope); HRMS (FAB) calcd for C₂₂H₁₉BrN₂O₅S +H₁ 503.0276, found 503.0265. HPLC [1] shows one major peak (18.60 min, 99%).

5-bromo-2-({4-[(3,5-dimethoxyanilino)sulfonyl]benzoyl}amino)benzoic acid 20

was prepared by method A followed by B with a 69% yield over both steps. The methyl ester was not fully characterized. ¹H NMR (300 MHz, CD₃OD) δ 8.73 (d, *J* = 9 Hz, 1 H), 8.24 (d, *J* = 2 Hz, 1 H), 8.09 (d, *J* = 9 Hz, 2 H), 7.96 (d, *J* = 9 Hz, 2 H), 7.74 (dd, *J* = 9, 2 Hz, 1 H), 6.32 (s, 1 H), 6.31 (s, 1 H), 6.20 (s, 1 H), 3.70 (s, 6 H); MS (ES⁻) for C₂₂H₁₉BrN₂O₇S *m/z* 532.8 (M-H⁺); HPLC [1] shows one major peak (17.06 min, 96%).

5-bromo-2-[(4-[(2-hydroxy-2-phenylethyl)(methyl)amino]sulfonyl]

benzoyl]amino] benzoic acid 21 was prepared by method A followed by B with a 15% yield over both steps. The methyl ester was not fully characterized. ¹H NMR (300 MHz, CD₃OD) δ 12.10 (s, 1 H), 8.57 (d, *J* = 9 Hz, 1 H), 8.12 (d, *J* = 2 Hz, 1 H), 8.11 (d, *J* = 9 Hz, 2 H), 7.95 (d, *J* = 8 Hz, 2 H), 7.87 (dd, *J* = 9, 3 Hz, 1 H), 7.35-7.27 (m, 5 H), 4.76 (t, *J* = 7 Hz, 1 H), 3.22-3.13 (m, 2 H), 2.77 (s, 3 H); MS (FAB) *m/z* (rel. intensity) 533 (MH⁺, 61), 535 (64), 533 (61), 517 (99), 516 (24), 515 (90), 318 (46), 152 (27), 134 (25), 132 (33), 44 (44). HRMS (FAB) calcd for C₂₃H₂₁BrN₂O₆S +H₁ 533.0382, found 533.0386. HPLC [1] shows one major peak (17.06, 97%).

5-bromo-2-{{4-(2,3-dihydro-1H-indol-1-ylsulfonyl)benzoyl}amino}benzoic acid 22

was prepared by method A followed by B in a 55% yield over both steps. The methyl ester was not fully characterized. ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.00 (s, 1 H), 8.51 (d, *J* = 9 Hz, 1 H), 8.10-8.01 (m, 5 H), 7.84 (dd, *J* = 9, 3 Hz, 1 H), 7.50 (d, *J* = 8 Hz, 1 H), 7.22 (t, *J* = 8 Hz, 1 H), 7.17 (d, *J* = 8 Hz, 1 H), 7.00 (t, *J* = 7 Hz, 1 H), 3.98 (t, *J* = 8 Hz, 2 H), 2.93 (t, *J* = 8 Hz, 2 H); IR 1687, 1667, 1601, 1525 (s), 1365 (s), 1245 (s), 1172 (s), cm⁻¹. MS (FAB) *m/z* (rel. intensity) 501 (MH⁺, 36), 503 (41), 502 (43), 501 (36), 500 (31), 286 (35), 118 (99). HRMS (FAB) calcd for

C₂₂H₁₇BrN₂O₅S + H₂O 501.0120, found 501.0118. Anal. Calcd for C₂₂H₁₇BrN₂O₅S: C, 52.71; H, 3.42; N, 5.59; Br, 15.94; S, 6.39. Found: C, 52.65; H, 3.47; N, 5.58; Br, 15.88; S, 6.24.

5-bromo-2-({4-[(5-methoxy-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)

5 **benzoic acid 23** was prepared by method A followed by B in a 17% yield over both steps. The methyl ester was not fully characterized. ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.05 (s, 1 H), 8.51 (d, *J* = 9 Hz, 1 H), 8.10 (d, *J* = 2 Hz, 1 H), 8.05 (d, *J* = 8 Hz, 2 H), 7.95 (d, *J* = 9 Hz, 2 H), 7.86 (dd, *J* = 9, 2 Hz, 1 H), 7.42 (d, *J* = 9 Hz, 1 H), 6.78 (d, *J* = 8 Hz, 1 H), 6.77 (s, 1 H), 3.96 (t, *J* = 8 Hz, 2 H), 3.68 (s, 3 H), 2.80 (t, *J* = 8 Hz, 2 H); IR 1702, 1606, 1518, 1489 (s), 1358, 1199 (s), 1168 (s), cm⁻¹. MS (FAB) *m/z* (rel. intensity) 531 (MH⁺, 29), 533 (30), 531 (29), 530 (38), 148 (99). HRMS (EI) calcd for C₂₃H₁₉BrN₂O₆S 530.0148, found 530.0156. Anal. Calcd for C₂₃H₁₉BrN₂O₆S: C, 51.99; H, 3.60; N, 5.27; Br, 15.04; S, 6.03. Found: C, 52.08; H, 3.61; N, 5.29.

15 **5-bromo-2-({4-[(5-fluoro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)**

benzoic acid 24 was prepared by method A followed by B with a 41% yield over both steps. The methyl ester was not fully characterized. ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.05 (s, 1 H), 8.51 (d, *J* = 9 Hz, 1 H), 8.10 (d, *J* = 2 Hz, 1 H), 8.07 (d, *J* = 9 Hz, 2 H), 7.99 (d, *J* = 9 Hz, 2 H), 7.85 (dd, *J* = 9, 2 Hz, 1 H), 7.49 (dd, *J* = 10, 5 Hz, 1 H), 7.07-7.02 (m, 2 H), 4.01 (t, *J* = 8 Hz, 2 H), 2.89 (t, *J* = 8 Hz, 2 H); MS (ES⁻) for C₂₂H₁₆BrN₂O₅S *m/z* 518.9 (M-H⁺, Br isotope); HPLC [2] shows one major peak (6.35 min, 96%).


2-{{4-[(1H-benzimidazol-1-yl)sulfonyl]benzoyl}amino}-5-bromobenzoic acid 26 was

prepared from method A followed by hydrolysis of the methyl ester by the hydrolysis
25 procedure in method C below. ¹H NMR (300 MHz, DMSO-*d*₆) δ 11.98 (s, 1 H), 8.91 (s, 1 H), 8.47 (d, *J* = 9 Hz, 1 H), 8.41 (d, *J* = 9 Hz, 2 H), 8.13 (d, *J* = 9 Hz, 2 H), 8.09 (d, *J* = 2 Hz, 1 H), 7.93 (d, *J* = 7 Hz, 1 H), 7.85 (dd, *J* = 9, 3 Hz, 1 H), 7.78 (d, *J* = 7 Hz, 1 H), 7.47 (t, *J* = 6 Hz, 1 H), 7.40 (t, *J* = 6 Hz, 1 H); IR 1686, 1607, 1522, 1391, 1296, 1262, 1190, cm⁻¹. MS (ESI⁻) for C₂₁H₁₄BrN₃O₅S *m/z* 497.7 (M-H)⁻. HPLC [2]
30 shows one major peak at 6.01 min (96%). Anal. Calcd for C₂₁H₁₄BrN₃O₅S: C, 50.21; H, 3.21; N, 8.36; Br, 15.91; S, 6.38. Found: C, 50.06; H, 2.85; N, 7.93; Br, 15.34; S, 6.22.

General Method C (sulfonamide preparation with indoles and pyrrole):

Reaction of sulfonyl chloride intermediate **1** with indole derivatives requires modified conditions. Deprotonation of the indole nitrogen with sodium hydride in THF and reaction with the sulfonyl chloride **1** provided the desired intermediate methyl esters. Two equivalents of the indole anion were required because of competitive deprotonation of the amide in **1**. Attempted hydrolysis of such methyl esters with aqueous KOH results in hydrolysis of the newly formed sulfonamide. Therefore, dealkylative deesterification conditions were utilized (Scheme 1.2).

Scheme 1.2



a) R^{*}, NaH, THF; b) MeI, NaCN

* R = indoles, pyrrole, indazole, and benzoxazolinone


5-bromo-2-([4-[(5-fluoro-1H-indol-1-yl)sulfonyl]benzoyl]amino)benzoic acid 26 was prepared by the following procedure: 5-fluoroindole (497.1 mg, 3.68 mmol, 2.2 eq) was dissolved in anhydrous THF (8 mL) and cooled to 0⁰ C. NaH (60% dispersion in mineral oil, 150 mg, 3.75 mmol, 2.2 eq) was added and the cloudy mixture was stirred for 1 hr. at 0-25⁰ C. The suspension was then cooled to 0⁰ C and Methyl 5-bromo-2-([4-(chlorosulfonyl)benzoyl]amino)benzoate (722.0 mg, 1.68 mmol, 1.0 eq) was added neat and stirred overnight at room temperature. After quenching with water, the product was extracted with EtOAc and washed with 1 N HCl, concentrated *in vacuo*, triturated with MeOH, filtered and washed with MeOH. A mixture of the carboxylic acid and ester (469.0 mg) was obtained. The mixture of products were both committed to the hydrolysis conditions: 4 mL dioxane, 0.4 mL water, and 1 KOH pellet (~90 mg) were added to the mixture of acid and ester and shook at 50⁰ C for 3 hrs. The hydrolysis was monitored by HPLC. The product was

dissolved in EtOAc and washed with 1 N HCl, concentrated *in vacuo*, triturated with MeOH, filtered, and washed with MeOH to obtain 246.8 mg (28%) of 5-bromo-2-({4-
 5 [(5-fluoro-1H-indol-1-yl)sulfonyl]benzoyl}amino)benzoic acid. ¹H NMR (300 MHz, DMSO-*d*₆) δ 11.95 (s, 1 H), 8.43 (d, *J* = 9 Hz, 1 H), 8.19 (d, *J* = 9 Hz, 2 H), 8.07 (d, *J* = 3 Hz, 1 H), 8.05 (d, *J* = 9 Hz, 2 H), 7.96 (dd, *J* = 9, 4 Hz, 1 H), 7.91 (d, *J* = 4 Hz, 1 H), 7.82 (dd, *J* = 9, 2 Hz, 1 H), 7.42 (dd, *J* = 9, 3 Hz, 1 H), 7.20 (td, *J* = 9, 3 Hz, 1 H), 6.86 (d, *J* = 4 Hz, 1 H); IR (drift) 1692, 1670, 1601, 1524 (s), 1462, 1388 (s), 1290, 1242, 1234, 1218 (s), 1181 (s), 1140 (s), 742, 649 (s), 607 (s), cm⁻¹. MS (ESI-) for C₂₂H₁₄BrFN₂O₅S *m/z* 516.9 (M-H, Br isotope)⁻. HPLC [2] shows one major peak at
 10 6.56 min (98%). Anal. Calcd for C₂₂H₁₄BrFN₂O₅S: C, 51.08; H, 2.73; N, 5.41; Br, 15.44; S, 6.20. Found: C, 51.05; H, 2.64; N, 5.39.


Other compounds were prepared by the above procedure making non-critical variations.

5-bromo-2-{{4-(1H-indol-1-ylsulfonyl)benzoyl}amino}benzoic acid, 5-bromo-2-({4-
 15 [(6-fluoro-1H-indol-1-yl)sulfonyl]benzoyl}amino)benzoic acid, 5-bromo-2-({4-[(5-chloro-1H-indol-1-yl)sulfonyl]benzoyl}amino)benzoic acid, 5-bromo-2-({4-[(6-chloro-1H-indol-1-yl)sulfonyl]benzoyl}amino)benzoic acid, 5-bromo-2-({4-[(6-chloro-5-fluoro-1H-indol-1-yl)sulfonyl]benzoyl}amino)benzoic acid, 5-bromo-2-{{4-[(1H-pyrrol-1-ylsulfonyl)benzoyl]amino}benzoic acid, 5-bromo-2-({4-[(5-methoxy-
 20 1H-indol-1-yl)sulfonyl]benzoyl}amino)benzoic acid, 5-bromo-2-{{4-(1H-pyrrolo[2,3-b]pyridin-1-ylsulfonyl)benzoyl}amino}benzoic acid

Scheme 1.3




Preparation of Methyl 3-bromo-5-[(5-bromo-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoate




- 5 A solution of 5-bromoindoline (528 mg, 2.67 mmol, Lancaster) and triethylamine (650 μ L, 4.67 mmol) in CH_2Cl_2 (8 mL) was added to a solution of methyl 3-bromo-5-(chlorosulfonyl)benzoate (737 mg, 2.35 mmol) in CH_2Cl_2 (10 mL). The mixture was stirred overnight and then diluted to 100 mL with CH_2Cl_2 . This solution was washed with 2 X 100 mL of 1 M aqueous HCl and 100 mL of brine. The CH_2Cl_2 was
- 10 evaporated in the presence of silica gel, and the product was purified by chromatography using a Biotage Flash 40 M silica cartridge with a gradient from 50% CH_2Cl_2 /heptane to 75% CH_2Cl_2 /heptane as eluent. Yield was 945 mg of pale yellow solid.

- 15 **Preparation of 3-Bromo-5-[(5-bromo-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoic acid**



To a mixture of the corresponding methyl ester (841 mg, 1.77 mmol) in methanol (20 mL) was added 1 M aqueous sodium hydroxide (3.0 mL). The mixture was stirred in a 50 °C oil bath for 10 minutes and then at 60 °C for 15 minutes. The mixture was still a slurry, so 10 mL of dioxane was added. Heat was removed after an additional 40 minutes. The reaction mixture was added to a separatory funnel with 100 mL of 1 M aqueous HCl, and the product was extracted into 100 mL of CH₂Cl₂. The organics were washed with an additional 100 mL of 1 M aqueous HCl followed by 100 mL of water. They were then dried over MgSO₄ and evaporated yielding 807 mg of white solid.


Methyl 5-bromo-2-({3-bromo-5-[(5-bromo-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)benzoate



To 3-bromo-5-[(5-bromo-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoic acid (583 mg, 1.26 mmol) in CH₂Cl₂ (25 mL) was added DMF (20 µL) and oxalyl chloride (220 µL, 2.52 mmol). The mixture was stirred for 1 hour, and the solvent and excess oxalyl chloride were removed by rotary evaporation. The residue was dissolved in CH₂Cl₂ (10 mL), and methyl 2-amino-5-bromobenzoate (267 mg, 1.16 mmol, Avocado) in pyridine (4 mL) was added. The mixture was stirred overnight and then added to a separatory funnel with 100 mL of CH₂Cl₂. Some THF was added to help solubility. This mixture was washed with 2 X 100 mL of 1 M aqueous HCl and 100 mL of brine. The organics were evaporated, and the residue was dissolved in hot THF. This solution was evaporated in the presence of silica gel, and the product was purified by chromatography using a Biotage Flash 40 M silica cartridge with a gradient from 50% CH₂Cl₂/heptane to 100% CH₂Cl₂ as eluent. Yield was 603 mg of white solid.


General Method D: (hydrolysis of the methyl ester)

5-Bromo-2-({3-bromo-5-[(5-bromo-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)benzoic acid



To a mixture of the corresponding methyl ester (374 mg, 0.556 mmol) in dioxane (30 mL) was added 1 M aqueous sodium hydroxide (1.1 mL). The mixture was stirred in a 60 °C oil bath for 90 minutes. The reaction mixture was added to a separatory funnel with 100 mL of 1 M aqueous HCl, and the product was extracted into 100 mL of CH₂Cl₂. The organics were washed with an additional 100 mL of 1 M aqueous HCl followed by 100 mL of water. They were then dried over MgSO₄ and evaporated. The residue was recrystallized from hot ethanol/THF. The solids were washed with ethanol and then dried at 100 °C under vacuum yielding 266 mg of white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.14 (s, 1 H), 8.48 (d, *J* = 8.7 Hz, 1 H), 8.36 (s, 1 H), 8.31 (s, 1 H), 8.19 (s, 1 H), 8.12 (d, *J* = 2.0 Hz, 1 H), 7.86 (dd, *J* = 8.7, 2.5 Hz, 1 H), 7.39-7.49 (m, 3 H), 4.04 (t, *J* = 8.4 Hz, 2 H), 2.99 (t, *J* = 8.4 Hz, 2 H).


Preparation of Methyl 4-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoate



To 4-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoic acid (456 mg, 1.35 mmol) in CH₂Cl₂ (30 mL) was added DMF (15 μL) and oxalyl chloride (150 μL, 1.72 mmol). The mixture was stirred for 5 hours, and the solvent and excess oxalyl chloride were removed by rotary evaporation. The residue was dissolved in CH₂Cl₂

(10 mL). Methanol (2 mL) and pyridine (2 mL) in CH₂Cl₂ (6 mL) were added. The mixture was stirred for 30 minutes and then added to a separatory funnel with 100 mL of CH₂Cl₂. This solution was washed with 100 mL of 1 M aqueous HCl, 100 mL of saturated aqueous NaHCO₃, another 100 mL of HCl, and 100 mL of brine. The
5 CH₂Cl₂ was dried over MgSO₄ and evaporated yielding 464 mg of white solid.


Preparation of {4-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]phenyl}methanol



10


To a solution of methyl 4-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoate (396 mg, 1.13 mmol) in THF (20 mL) was added lithium borohydride (0.40 mL of 2.0 M solution in THF, 0.80 mmol, Aldrich). HPLC analysis after 1.5 hours indicated <10% reaction, so lithium aluminum hydride (0.60 mL of 1.0 M solution in THF,
15 Aldrich) was added at -78 °C. The mixture was stirred at -78 °C for 15 minutes and then warmed to room temperature. The reaction was quenched by the addition of water (25 µL) followed by 6 M aqueous NaOH (25 µL) followed by another portion of water (75 µL). The mixture was filtered, and the filtrate was evaporated in the presence of silica gel. The product was purified by chromatography using a Biotage
20 Flash 40 M silica cartridge with a gradient from CH₂Cl₂ to 10% EtOAc in CH₂Cl₂ as eluent. Yield was 290 mg of white solid.

Preparation of *t*-butyl 2-nitrobenzoate




A 22 L round bottom flask, equipped with an mechanical stirrer, thermocouple, and a 1 L addition funnel, was charged with 500 g (2.99 moles, 1.0 equiv) of 2-nitrobenzoic acid (Avocado Research Chemicals Ltd, 98%) and 1.44 kg (11.97 moles, 4 equiv) of anhydrous magnesium sulfate (EM Science, 98%). To the solids were charged 12.5 L (25 mL/g) of CH₂Cl₂ (EM Science, 99.96%) and 1.43 L (2.99 moles, 1.0 equiv) of *t*-butyl alcohol (Aldrich, 99 + % A.C.S. Reagent). The addition funnel was charged with 1.59 mL (2.99 moles, 1.0 equiv) of concentrated sulfuric acid (Mallinckrodt, 95.7%) and the entire system was sealed via use of a Teflon cap (loose fit; internal pressure does not exceed 11 psi; theory = 10.5 psi). The resulting suspension was cooled to 16 °C using a water bath and 159 mL (2.99 moles, 1.0 equiv) of concentrated sulfuric acid was added at a rate of 2.8 mL/min, maintaining an internal temperature less than 25 °C. The resulting off-white suspension was stirred at room temperature for 14 hours at which time the HPLC assay indicated the reaction was at 92% conversion. The suspension was sparged with nitrogen for 15 min using ½ inch ID Teflon tubing and filtered through a sintered glass funnel (course) with the aid of house vacuum (ca. 16 torr; filtration time of 1.0 h). The cake was rinsed with CH₂Cl₂ (500 mL, 1 mL/g). The combined filtrates were charged to a 30 L wash tank and diluted with 2 L of water (pH = 1.0). To the resulting biphasic mixture was added 2.5 L of 10% NaOH over a 15 min period (8 °C exotherm; pH = 12.0). The resulting yellow-colored aqueous layers were separated from the clear, colorless organic layer. The organic layer was concentrated *in vacuo* at 16 torr using a 37 °C water bath to provide a 93% yield (621g, 2.78 moles) as a light yellow oil. To ensure removal of residual CH₂Cl₂, the oil was dissolved in 2 L of absolute ethanol (AAPER, 200 proof) and concentrated *in vacuo* at 16 torr using a 57 °C water bath. The potency of the material was determined to be 99.2% (GC) and 99.0% (HPLC) and was taken on directly to the next step without further purification.

Preparation of *t*-butyl 2-aminobenzoate



Escat 10 catalyst (18.63 g, 3 wt%) was charged to the 10L autoclave followed by *t*-butyl nitrobenzoate (621g, 2.78 moles) in ethanol (7L). The vessel was sealed and purged three times with nitrogen (60 psig) and three times with hydrogen (60 psig). The vessel was then pressurized to 50 psig with hydrogen and allowed to run holding the exotherm at 40 °C through external cooling. The reaction was run until the hydrogen uptake stopped (45 minutes). The reaction was determined to be complete by both TLC and HPLC after 1 h and 10 min. The reaction was filtered through a 0.4 μ filter to remove the catalyst, and the catalyst cake was rinsed with ethanol (1.5 L). The product solution was then concentrated *in vacuo* at 16 torr using a 45 °C water bath to a volume of 1620 mL (3 mL/g) and taken on directly into the next step. An aliquot of the solution was concentrated and analyzed by both NMR and GC. The GC potency of the final product was 100%, and the NMR spectra were consistent with the structure of the title compound.


Preparation of *t*-butyl 2-amino-5-iodobenzoate



A 12 L round bottom flask, equipped with a thermocouple, nitrogen adapter and a 1 L addition funnel, was charged with a solution of *t*-butyl 2-aminobenzoate (537g, 2.78 moles; lot 36648-tjb-40) in ethanol (1620 ml, 3 ml/g). To this golden solution was added water (615.6 ml) resulting in a biphasic mixture. This mixture was cooled to between 15 and 20 °C with a cold-water bath. A 1.0 M solution of ICl in CH₂Cl₂ (Aldrich lot #14127JO, 3.11 L, 3.11 moles, 1.12 equiv.) was charged in portions to the addition funnel and was added to the rapidly stirred mixture maintaining the temperature between 15 and 25 °C. The addition time was 2.25 hours and the temperature range observed was 16.5 to 20.4 °C. The resulting red brown mixture was stirred at room temperature for 1 hour at which time the GC assay showed the reaction was complete. The reaction was diluted with 920 mL of water and quenched with 456 mL of 38% aq. sodium bisulfite (Webb Chem lot #10464519) resulting in a slight exotherm to 24.0 °C. This mixture was stirred for 15 minutes before separating the

phases. The methylene chloride layer was combined with water (3.7L) and stirred for 15 minutes before separating the phases. A NaOH solution was prepared by diluting 10% NaOH (460ml) in water (2.3L). To the methylene chloride layer was added this dilute NaOH solution (2.1L). The pH of the basic phase was 6.56. The phases were separated and the methylene chloride layer was concentrated to a low volume *in vacuo* at 16 torr using a bath temp of 45 °C. Pyridine (4L) was added, and the resulting solution was concentrated to ca. 1.0 mL/g *in vacuo* at 16 torr using a 62 °C water bath. The low volume pyridine/product mixture was diluted with pyridine to the target volume of 3.1L (3.5 mL/g). A sample (10mL) was concentrated removing the pyridine on the rotovap and high vacuum to yield 3.12 g of an orange brown solid of 96% potency by GC. GC assay of pyridine solution indicated that neither EtOH nor methylene chloride were present, so the solution was taken on directly into the next step.


Preparation of *t*-butyl 2-amino-5-cyanobenzoate




A 5 L Morton flask equipped with a mechanical stirrer (sturdy blade), thermocouple, and a reflux condenser was charged with 299g (3.34 moles, 1.2 equiv) of CuCN (Aldrich, 99%). To the slowly stirred CuCN was added a cool (10 °C) solution of *t*-butyl 2-amino-5-iodobenzoate (887g, 2.78 moles, 1.0 equiv) in pyridine (3.5 mL/g including the volume occupied by *t*-butyl 2-amino-5-iodobenzoate). The resulting orange suspension was heated to 115 °C over 45 min to produce a black solution. The solution was maintained at 115 °C for 14 h at which point GC indicated the reaction was complete. The solution was cooled to 90 °C and transferred by ½ inch ID Teflon cannula to a stirred suspension of solka floc (powdered cellulose, 460 g) in 14 L of methyl-*tert*-butyl ether (EM Science, 99.95%) at 2 °C, maintaining an internal temperature less than 13 °C. The resulting yellow-green suspension was filtered through a sintered glass frit (course frit, 16 torr vacuum) and the cake was rinsed with 4 L of MTBE (EM Science, 99.95%). The filtrate was washed (1 x 8 L H₂O, 3 x 2 L

of 10% NH_4OH in 23% NH_4Cl), and the organics were concentrated *in vacuo* at 16 torr using a 50 °C water bath to a volume of 3 L (3.4 mL/g). The solution was split in half and crystallized in two portions. One half of the solution was charged to a 22 L flask containing heptanes (8L). The flask was set up for atmospheric distillation and heptanes (4L) was added to bring total volume of heptanes to 12 L. The mixture was distilled atmospherically to remove 4 L of distillate (pot temp of 98 °C; head temp of 96 °C). The pot was charged with 4 L of heptanes, and another 4 L of distillate was removed. A second 4 L charge of heptanes was made and 2.4 L of distillate was removed via atmospheric distillation; thus reducing the pot volume to 8.9 L (20mL/g). GC assay of the final distillate indicated the following volume percent ratios of pyridine and MTBE, respectively: 2.08% and 1.51 %. The heating mantle was removed, and the solution was cooled to induce crystallization (crystal formation was first noted at about 56 °C). The slurry was stirred at room temperature for 4 h, and the solids were isolated by vacuum filtration on a 3L frit. The cake was slurry washed with room temperature heptanes (2 x 500 ml) and dried on a nitrogen press to produce 224.2 g of an off-white solid (GC potency of 100%). Crystallization of the second half of the material produced another 241 g; thus a 70% yield from 2-nitrobenzoic acid was achieved.

An alternative methodology for producing t-butyl 2-amino-5-cyanobenzoate is shown below.




5-Cyano-2-({3-[(3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)benzoic acid




To a solution of 3-(chlorosulfonyl)benzoic acid (456 mg, 2.07 mmol, Aldrich) in CH_2Cl_2 (15 mL) was added DMF (15 μL) followed by oxalyl chloride (270 μL , 3.10 mmol). After stirring for 1.5 hours, the solvent and excess oxalyl chloride were removed by rotary evaporation. The residue was dissolved in toluene (15 mL), and methyl 2-amino-5-cyanobenzoate (370 mg, 2.10 mmol) was added. The mixture was heated in a 105 $^\circ\text{C}$ oil bath for 2 hours, and the toluene was then removed by rotary evaporation. The residue was dissolved in CH_2Cl_2 (6 mL), and a mixture of 3,3-dimethylindoline, described by Kucerovy et al. in *Synth. Commun.* **1992**, 22(5), 729-733, (342 mg, 2.32 mmol) and triethylamine (600 μL , 4.31 mmol) in CH_2Cl_2 (6 mL) was added. This mixture was stirred overnight and then added to a separatory funnel with 100 mL of CH_2Cl_2 . This solution was washed with 2 X 100 mL of 1 M aqueous HCl and 100 mL of brine. The CH_2Cl_2 was evaporated in the presence of silica gel, and the product was purified by chromatography using a Biotage Flash 40 M silica cartridge with a gradient from CH_2Cl_2 to 1% EtOAc in CH_2Cl_2 as eluent. Yield was 728 mg of white solid as the methyl ester. The methyl ester was hydrolyzed according to method D yielding 292 mg of white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 12.57 (s, 1 H), 8.80 (d, $J = 8.7$ Hz, 1 H), 8.41-8.44 (m, 2 H), 8.24 (d, $J = 7.9$ Hz, 1 H), 8.09-8.14 (m, 2 H), 7.83 (t, $J = 7.9$ Hz, 1 H), 7.55 (d, $J = 8.1$ Hz, 1 H), 7.24 (t, $J = 7.7$ Hz, 1 H), 7.18 (d, $J = 7.7$ Hz, 1 H), 7.02 (t, $J = 7.5$ Hz, 1 H), 3.73 (s, 2 H), 1.08 (s, 6 H).

5-Bromo-2-[(4-[(4-chlorophenyl)(methyl)amino]sulfonyl}benzoyl)amino]benzoic acid




Dimethyl formamide (15 μ L) and oxalyl chloride (1.5 mL, 17 mmol) were added sequentially to a mixture of 4-[[[(4-chlorophenyl)(methyl)amino]sulfonyl}benzoic acid (2.82 g, 8.66 mmol) in CH_2Cl_2 (60 mL). The resulting solution was stirred for 3 hours after which the solvent and excess oxalyl chloride were removed by rotary evaporation. The residue was dissolved in CH_2Cl_2 (50 mL), and methyl 2-amino-5-bromobenzoate (1.83 g, 7.95 mmol, Avocado) in pyridine (15 mL) was added. The mixture was stirred overnight and then added to a separatory funnel with 150 mL of CH_2Cl_2 . The resulting solution was washed with 2 X 100 mL of 1M aqueous HCl and 100 mL of brine. The CH_2Cl_2 was evaporated in the presence of silica gel, and the product was purified by chromatography using a Biotage Flash 40 s silica cartridge with CH_2Cl_2 as the eluent. Product was isolated as 3.73 g (87%) of a white solid as the methyl ester. The methyl ester was hydrolyzed according to method B. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 12.12 (s, 1 H), 8.56 (d, J = 8.7 Hz, 1 H), 8.10-8.14 (m, 3 H), 7.88 (dd, J = 8.7, 2.5 Hz, 1 H), 7.74 (d, J = 8.1 Hz, 2 H), 7.43 (d, J = 8.7 Hz, 2 H), 7.18 (d, J = 8.7 Hz, 2 H), 3.18 (s, 3 H).

Preparation of 4-Bromo-3-(2,3-dihydro-1H-indol-1-ylsulfonyl)benzoic acid



A solution of indoline (4.1 g, 34 mmol, Aldrich) and triethylamine (7.0 mL, 50 mmol) in methanol (20 mL) was added by cannula to solid 4-bromo-3-(chlorosulfonyl)benzoic acid (7.30 g, 24.4 mmol) with stirring in an ice bath. The mixture was allowed to warm slowly to room temperature and stirred overnight. It was added to a separatory funnel with 80 mL of aqueous 1 M NaOH, and this solution was washed with 2 X 100 mL of CH_2Cl_2 . The aqueous layer was then acidified with concentrated HCl. The precipitate was washed with water followed by heptane and then recrystallized from toluene/ethanol. The crystals were washed with toluene followed by heptane and then dried at 100 $^\circ\text{C}$ under vacuum yielding 2.75 g of white solid. A second crop of 1.39 g of tan solid was also collected.


Preparation of 4-Cyano-3-(2,3-dihydro-1H-indol-1-ylsulfonyl)benzoic acid



5 A mixture of copper (I) cyanide (755 mg, 8.43 mmol) and 4-bromo-3-(2,3-dihydro-1H-indol-1-ylsulfonyl)benzoic acid (2.05 g, 5.36 mmol) in NMP (15 mL) was heated to 160 °C under nitrogen for 1 hour. The mixture was added to a flask with 150 mL of EtOAc and 100 mL of water and stirred for 30 minutes. It was then filtered through a plug of celite. The phases were separated, and the water was extracted with an
10 additional 2 X 100 mL of EtOAc. The combined EtOAc was washed with 3 X 100 mL of water and dried over MgSO₄. The solvent was removed, and the brown residue was recrystallized from hot ethanol. The crystals were washed with methanol followed by heptane and then dried at 100 °C under vacuum. Yield was 1.25 g of tan solid.

15


5-Bromo-2-[[4-cyano-3-(2,3-dihydro-1H-indol-1-ylsulfonyl)benzoyl]amino]benzoic acid



To 4-cyano-3-(2,3-dihydro-1H-indol-1-ylsulfonyl)benzoic acid (1.22 g, 3.72 mmol) in
20 CH₂Cl₂ (30 mL) was added DMF (20 µL) and oxalyl chloride (650 µL, 7.45 mmol). The mixture was stirred for 2.3 hours, and the solvent and excess oxalyl chloride were removed by rotary evaporation. The residue was dissolved as best as possible in CH₂Cl₂ (30 mL), and methyl 2-amino-5-bromobenzoate (762 mg, 3.31 mmol, Avocado) in pyridine (15 mL) was added. The mixture was stirred overnight and then

added to a separatory funnel with 100 mL of CH₂Cl₂. This solution was washed with 2 X 100 mL of 1 M aqueous HCl and 100 mL of brine. The CH₂Cl₂ was evaporated in the presence of silica gel, and the product was purified by chromatography using a Biotage Flash 40 M silica cartridge with CH₂Cl₂ as eluent. Yield was 1.31 g of yellow solid. The methyl ester was hydrolyzed according to Method D to yield 615 mg of yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.24 (s, 1 H), 8.57 (s, 1 H), 8.51 (d, *J* = 8.7 Hz, 1 H), 8.37 (d, *J* = 7.6 Hz, 1 H), 8.32 (d, *J* = 7.6 Hz, 1 H), 8.14 (d, *J* = 2.5 Hz, 1 H), 7.88 (dd, *J* = 8.9, 2.3 Hz, 1 H), 7.43 (d, *J* = 8.1 Hz, 1 H), 7.16-7.24 (m, 2 H), 7.01 (t, *J* = 7.6 Hz, 1 H), 4.20 (t, *J* = 8.4 Hz, 2 H), 3.05 (t, *J* = 8.4 Hz, 2 H).


Preparation of Methyl 3-(chlorosulfonyl)-2-methylbenzoate



A flask was charged with methyl 2-methyl-3-nitrobenzoate (Aldrich, 5.0 g, 25.6 mmol) and tin (II) chloride dihydrate (28.9 g, 128 mmol, 5.0 eq). The solids were suspended in EtOAc (80 mL), and upon heating to reflux under N₂ the solids completely dissolved. After two hours the cooled reaction was poured into 350 mL EtOAc and then washed 4x with 1.0M NaOH, 1x with water and 1x with brine (350 mL each). The organic layer was dried over Na₂SO₄, filtered and the solvent evaporated. The resultant crude oil (2.9 g) was suspended in 60 mL of a 2:1 solution of concentrated HCl and glacial acetic acid. The reaction was cooled to -10 °C and a solution of sodium nitrite (1.33g, 19.34 mmol) in 3.0 mL water was added drop wise over stirring at a rate that maintained the internal reaction temperature below -5 °C. The reaction became an orange solution as the SM slowly dissolved. In a separate flask, copper (I) chloride (435 mg, 25 mol%) was suspended in 30 mL of a saturated (30% w/w) solution of sulfur dioxide gas in glacial acetic acid. The mixture was cooled on an ice bath over stirring, and after 2.5 hours the diazonium solution was added portion wise to the copper mixture over 15 minutes. The addition evolved gas and produced a lime green solution, which came to RT and was stirred overnight. The reaction was poured into ice water (200 mL) to afford an oil at the bottom of a pale blue solution. The solution was extracted 2x with CH₂Cl₂ (150 mL ea) and the organic phase was washed 2x with saturated NaHCO₃ and brine (250 mL ea). The

golden organic solution was dried over Na₂SO₄, filtered and the solvent evaporated. The crude residue was purified on a Biotage Flash 40M+ (100g) silica cartridge using a gradient of 20% heptane in CH₂Cl₂ to 100% CH₂Cl₂. The combined fractions were evaporated and the product was dried under high vacuum at RT to afford 2.2 g of pale pink solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.96 (dd, *J* = 7.7, 1.5 Hz, 1 H), 7.59 (dd, *J* = 7.7, 1.5 Hz, 1 H), 7.23 (t, *J* = 7.7 Hz, 1 H), 3.82 (s, 3 H), 2.56 (s, 3 H).


Preparation of 3-[[4-(chlorophenyl)(methyl)amino]sulfonyl]-2-methylbenzoate



Methyl 3-(chlorosulfonyl)-2-methylbenzoate, (494 mg, 1.99 mmol) was taken up in dry CH₂Cl₂ (10 mL) and treated with 4-chloro-N-methylaniline (1.01 mL, 8.35 mmol, Aldrich) in dry pyridine (15 mL). The bright yellow solution was heated to 75 °C. After one hour HPLC indicated the reaction was complete and the mixture was poured into EtOAc (125 mL). The organic phase was washed 3x with 1.0M HCl, 1x with saturated NaHCO₃ and 1x with brine (100 mL each). After drying over Na₂SO₄ the solution was filtered and the solvent was evaporated to afford an amber oil, which was purified on a Biotage Flash 40M+ (100g) silica cartridge using a linear gradient of 35% to 5% heptane in CH₂Cl₂. The solvent was evaporated from the product fractions and the product was dried under high vacuum at RT to afford 637 mg (90%) of a colorless oil. 508 mg, 1.44 mmol of the oil was dissolved in MeOH (15 mL) and treated with 1.0M LiOH (3.0 mL, 3.0 mmol). After stirring at 40 °C for 1 hour and then overnight at RT, the reaction was complete by HPLC and OAMS showed the correct *m/z* for product. The reaction was poured into 1.0M HCl (100 mL), and the white precipitate was extracted into EtOAc (150 mL). The organic layer was then 1x with 1.0M HCl and 1x with brine (125 mL each). The organic layer was dried over MgSO₄, filtered and evaporated to dryness. The resultant product was dried under vacuum at 100 °C overnight to afford 461 mg (94%) of off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.41 (br s, 1 H), 7.94 (d, *J* = 3.3 Hz, 1 H), 7.92 (d, *J* = 3.1

Hz, 1H), 7.49 (t, $J = 7.9$ Hz, 1 H), 7.39-7.47 (m, 2 H), 7.22-7.31 (m, 2 H), 3.21 (s, 3 H), 2.45 (s, 3 H).

5-Bromo-2-[(3-[[4-chlorophenyl](methyl)amino]sulfonyl}-2-methylbenzoyl)amino]benzoic acid




3-[[4-chlorophenyl](methyl)amino]sulfonyl}-2-methylbenzoate (404 mg, 1.19 mmol) was suspended in dry CH_2Cl_2 (10 mL) and DMF (10 μL) under N_2 . The solution was treated with oxalyl chloride (Aldrich, 0.192 mL, 2.2 mmol) and stirred while gas evolved. After one hour the excess solvent and oxalyl chloride were evaporated and the resultant residue was taken up in dry CH_2Cl_2 (10 mL). Methyl-2-amino-5-bromobenzoate (Aldrich, 230 mg, 1.0 mmol) was added as a solution in pyridine (3 mL) and the amber solution stirred at RT. After 2 hours HPLC indicated the reaction was complete. The mixture was diluted with CH_2Cl_2 (100 mL) and washed 2x with 1.0M HCl followed by brine (100 mL each). The organic layer was evaporated and purified on a Biotage Flash 25M+ (40 g) silica cartridge using CH_2Cl_2 . The combined fractions were evaporated and the product was dried under vacuum at 100 $^\circ\text{C}$ to afford 535mg (97%) of a glass-like solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.88 (s, 1 H), 8.05 (d, $J = 8.9$ Hz, 1 H), 7.99 (d, $J = 2.3$ Hz, 1 H), 7.93 (D, $J = 7.5$ Hz, 1 H), 7.86 (dd, $J = 8.8, 2.4$ Hz, 1 H), 7.80 (d, $J = 7.3$ Hz, 1 H), 7.57 (t, $J = 7.9$ Hz, 1 H), 7.45 (d, $J = 8.7$ Hz, 2 H), 7.29 (d, $J = 8.7$ Hz, 2 H), 3.83 (s, 3 H), 3.24 (s, 3 H), 2.39 (s, 3 H). 322 mg of the methyl ester solid was dissolved in hot dioxane (10 mL), and after cooling was treated with 1.0M LiOH (1.0 mL, 1.0 mmol). After stirring overnight at RT the reaction was complete by HPLC and OAMS showed correct m/z for the product. The solvent was evaporated and the residue was poured into 1.0M HCl (100 mL) to afford a white precipitate. The product was extracted into EtOAc (125 mL) and washed 3x with 1.0M HCl, and 1x with brine (100 mL each). The organic layer was dried over Na_2SO_4 , filtered and evaporated to dryness. The crude product was recrystallized from hot MeOH/EtOH. The resultant product was dried at 100 $^\circ\text{C}$ under

vacuum to afford 213 mg (68%) of white crystals. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 11.35 (s, 1 H), 8.39 (d, $J = 8.9$ Hz, 1 H), 8.07 (d, $J = 2.5$ Hz, 1 H), 7.92 (dd, $J = 8.1$, 1.0 Hz, 1 H), 7.81-7.89 (m, 2 H), 7.56 (t, $J = 7.8$ Hz, 1 H), 7.41-7.48 (m, 2 H), 7.24-7.34 (m, 2 H), 3.23 (s, 3 H), 2.39 (s, 3 H).


5

Preparation of 3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]-2-methylbenzoic acid



Methyl 3-(chlorosulfonyl)-2-methylbenzoate, (673 mg, 2.71 mmol) was taken up in
10 dry CH_2Cl_2 (5 mL) and dry pyridine (5 mL). The golden solution was cooled to -10 $^\circ\text{C}$ and treated with 5-chloroindoline (1.01 mL, 8.35 mmol, Aldrich) in dry CH_2Cl_2 (5 mL) to afford an intensely red-orange solution. A precipitate formed as the reaction warmed to RT. After one hour HPLC indicated the reaction was complete and the mixture was diluted to 150 mL with CH_2Cl_2 . The organic phase was washed 1x with
15 1.0M HCl, 1x with 1.0M NaOH, 1x with 1.0M HCl and 1x with brine (125 mL each). After drying over Na_2SO_4 the solution was filtered and the solvent was evaporated. The resultant product was dried under high vacuum at RT to afford 900 mg (90%) of a peach colored oil. 780mg (2.13 mmol) of the oil was dissolved in MeOH (15 mL) and treated with 1.0M LiOH (5.0 mL, 5.0 mmol). After stirring at 40 $^\circ\text{C}$ for 1 hour and
20 then overnight at RT, the reaction was complete by HPLC and OAMS showed the correct m/z for product. The reaction was poured into 1.0M HCl (125 mL), and the yellowish precipitate was extracted into EtOAc (150 mL). The organic layer was then 2x with 1.0M HCl, 1x with water and 1x with brine (125 mL each). The organic layer was dried over MgSO_4 , filtered and evaporated to dryness. The resultant product was
25 dried under vacuum at 100 $^\circ\text{C}$ overnight to afford 711 mg (95%) of pinkish-orange solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 13.46 (br s, 1 H), 7.98 (d, $J = 8.1$ Hz, 1 H), 7.93 (d, $J = 7.7$ Hz, 1 H), 7.50 (t, $J = 7.9$ Hz, 1 H), 7.34 (d, $J = 1.7$ Hz, 1 H), 7.19 (dd, $J = 8.5$, 2.1 Hz, 1 H), 7.09 (d, $J = 8.5$ Hz, 1 H), 4.05 (t, $J = 8.5$ Hz, 2 H), 3.12 (t, $J = 8.5$ Hz, 2 H), 2.66 (s, 3 H).


2-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]-2-methylbenzoyl}amino)-5-cyanobenzoic acid



5
3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]-2-methylbenzoic acid (553 mg, 01.57 mmol) was suspended in dry CH₂Cl₂ (15 mL) and DMF (10 μL) under N₂. The solution was treated with oxalyl chloride (0.274 mL, 3.14 mmol, Aldrich) and stirred while gas evolved. The reaction became homogenous and after one hour the excess
10 solvent and oxalyl chloride was evaporated and the resultant residue was taken up in dry CH₂Cl₂ (10 mL). Methyl-2-amino-5-cyanobenzoate (PHA-522499, 264 mg, 1.5 mmol) was added as a solution in pyridine (4 mL) and the amber solution stirred at RT. After 2.5 days HPLC indicated the reaction was nearly complete. After briefly boiling the reaction and cooling, the mixture was diluted to 150 mL with CH₂Cl₂ and
15 washed 2x with 1.0M HCl followed by brine (125 mL each). The organic layer was dried over Na₂SO₄, filtered and evaporated. The resultant crude product was purified on a Biotage Flash 25M+ (40 g) silica cartridge using a linear gradient of 0-2% EtOAc in CH₂Cl₂. The resultant product still contained a small amount of residual cyanoanthranilate. The combined fractions were evaporated and the product was
20 purified a second time on a Biotage Flash 40M+ (100 g) silica cartridge using 100% CH₂Cl₂. The combined fractions were evaporated and dried under high vacuum at RT to afford 594mg (77%) of an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.21 (s, 1 H), 8.29 (d, *J* = 1.9 Hz, 1 H), 8.26 (d, *J* = 8.7 Hz, 1 H), 8.11 (dd, *J* = 8.6, 2.0 Hz, 1 H), 7.99 (dd, *J* = 8.1, 1.0 Hz, 1 H), 7.84 (dd, *J* = 7.7, 1.0 Hz, 1 H), 7.60 (t, *J* = 7.9
25 Hz, 1 H), 7.36 (d, *J* = 1.7 Hz, 1 H), 7.21 (dd, *J* = 8.7, 2.3 Hz, 1 H), 7.16 (d, *J* = 8.7 Hz, 1 H), 4.09 (t, *J* = 8.6 Hz, 2 H), 3.84 (s, 3 H), 3.15 (t, *J* = 8.4 Hz, 2 H), 2.61 (s, 3 H). The methyl ester was hydrolyzed as described above to afford 300 mg (77%) of white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.73 (s, 1 H), 8.62 (d, *J* = 8.7 Hz, 1 H), 8.36 (d, *J* = 2.1 Hz, 1 H), 8.10 (dd, *J* = 8.7, 2.1 Hz, 1 H), 7.97 (d, *J* = 8.1 Hz, 1 H), 7.90 (d,

$J = 6.8$ Hz, 1 H), 7.57 (t, $J = 7.9$ Hz, 1 H), 7.37 (s, 1 H), 7.20 (dd, $J = 8.7, 2.1$ Hz, 1 H), 7.16 (d, $J = 8.5$ Hz, 1 H), 4.07 (t, $J = 8.6$ Hz, 2 H), 3.15 (t, $J = 8.5$ Hz, 2 H), 2.62 (s, 3 H).


5 **Preparation of 3-[[4-Chlorophenyl)(methyl)amino]sulfonyl]-2-methoxybenzoic acid**



Methyl 3-amino-2-methoxybenzoate (1.27 g, 6.72 mmol) was dissolved in 30 mL of a 2:1 solution of concentrated HCl and glacial acetic acid. The reaction was cooled to –
10 °C and a solution of sodium nitrite (696 mg, 10.1 mmol) in 3.0 mL water was added drop wise over stirring at a rate that maintained the internal reaction temperature below –5 °C. The reaction became a cloudy yellow-orange suspension. In a separate flask, copper (I) chloride (166 mg, 25 mol%) was suspended in 30 mL of a saturated (30% w/w) solution of sulfur dioxide gas in glacial acetic acid. The mixture was cooled on an ice bath over stirring, and after 30 minutes diazonium solution was added portion wise to the copper mixture over 15 minutes. The addition evolved gas and produced a dark green solution. The reaction was warmed to RT and was stirred for 3 hours with sulfur dioxide bubbling into the solution. The reaction was poured into ice water (200 mL) to afford a fine white precipitate in a pale blue solution. The solution was extracted 3x with EtOAc (150 mL ea) and the organic phase was neutralized by washing 3x with saturated NaHCO₃ (300 mL ea). The organic phase was then washed 2x with water and 1x with brine (250 mL ea). The golden organic solution was dried over Na₂SO₄, filtered and the solvent evaporated. The crude residue was dried under high vacuum to afford a dark red oil. The oil was taken up in pyridine (15 mL) and treated with 4-chloro-N-methylaniline (0.280 mL, 2.3 mmol, Aldrich). The amber solution was heated stirred at RT, and after one hour HPLC indicated the reaction was complete. The mixture was diluted to 150 mL with DCM and then washed 2x with 1.0M HCl, 1x with 1.0M NaOH and 1x with brine (125 mL each). The solvent was evaporated to afford an amber oil, which was

purified on a Biotage Flash 40M (90g) silica cartridge using a linear gradient of 0 to 0.75% EtOAc in CH₂Cl₂. The solvent was evaporated from the product fractions and the product was dried under high vacuum at RT to afford 614 mg (72%) of a straw colored oil as the methyl ester. The methyl ester was hydrolyzed as described above to afford 544 mg (97%) of peach colored solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.50 (s, 1 H), 7.99 (dd, *J* = 7.7, 1.9 Hz, 1 H), 7.80 (dd, *J* = 7.9, 1.7 Hz, 1 H), 7.36-7.42 (m, 2 H), 7.30 (t, *J* = 7.9 Hz, 1 H), 7.19-7.26 (m, 2 H), 3.83 (s, 3 H), 3.32 (s, 3 H).


5-Bromo-2-[(3-[(4-chlorophenyl)(methyl)amino]sulfonyl}-2-methoxybenzoyl)amino]benzoic acid



3-[(4-Chlorophenyl)(methyl)amino]sulfonyl}-2-methoxybenzoic acid (PHA-733277, 474 mg, 0.133 mmol) was dissolved in dry CH₂Cl₂ (10 mL) and DMF (25 μL) under N₂. The solution was treated with oxalyl chloride (0.232 mL, 2.66 mmol, Aldrich) and stirred while gas evolved. The reaction was stirred at RT and after one hour the excess solvent and oxalyl chloride was evaporated and the resultant residue was taken up in dry CH₂Cl₂ (10 mL). Methyl-2-amino-5-bromobenzoate (288 mg, 1.25 mmol, Avocado) was added as a solution in pyridine (3 mL) and the amber solution stirred at RT. After 90 minutes HPLC indicated the reaction was complete. The mixture was diluted to 150 mL with CH₂Cl₂ and washed 2x with 1.0M HCl followed by brine (100 mL each). The organic layer was dried over Na₂SO₄, filtered and evaporated. The resultant crude product was purified on a Biotage Flash 40M (90 g) silica cartridge using CH₂Cl₂. The combined fractions were evaporated and dried under vacuum at 100 °C to afford 530mg (72%) of an off-white solid as the methyl ester. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.52 (s, 1 H), 8.48 (d, *J* = 8.7 Hz, 1 H), 8.10 (d, *J* = 2.5 Hz, 1 H), 7.98 (dd, *J* = 7.8, 1.8 Hz, 1 H), 7.91 (dd, *J* = 8.9, 2.5 Hz, 1 H), 7.81 (dd, *J* = 7.9, 1.7 Hz, 1 H), 7.32-7.43 (m, 5 H), 3.89 (s, 3 H), 3.82 (s, 3 H), 3.40 (s, 3 H). The corresponding methyl ester was hydrolyzed as described above to afford a white solid.


¹H NMR (400 MHz, DMSO-*d*₆) δ 12.02 (s, 1 H), 8.70 (d, *J* = 9.1 Hz, 1 H), 8.14 (d, *J* = 2.5 Hz, 1 H), 8.01 (dd, *J* = 7.7, 1.2 Hz, 1 H), 7.90 (dd, *J* = 9.0, 2.4 Hz, 1 H), 7.76 (dd, *J* = 7.9, 1.5 Hz, 1 H), 7.11-7.44 (m, 5 H), 3.81 (s, 3 H), 3.39 (s, 3 H).

5 **5-bromo-2-[(4-{[methyl(pyridin-2-yl)amino]sulfonyl}benzoyl)amino]benzoic acid**




4-{[methyl(pyridin-2-yl)amino]sulfonyl}benzoic acid (292 mg, 1.0 mmol) was suspended in CH₂Cl₂ (10 mL) and (COCl)₂ added (725 mg, 0.5 mL, 5.7 mmol). A catalytic amount of DMF was then added and the mixture stirred for 4 hrs. The solvent was then removed *in vacuo* to give the acid chloride as an oil. The oil was dissolved in CHCl₃ (10 mL). Methyl 2-amino-5-bromobenzoate (230 mg, 1.0 mmol) was added followed by pyridine (1 mL). The solution was stirred at room temperature for an additional 12 hrs then poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na₂SO₄ and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography (20% EtOAc in hexane) to provide 317 mg of the desired methyl ester (63%). The ester was treated with LiOH in 1:1:1 THF/MeOH/H₂O for 12 hrs followed by acidification and extraction with EtOAc. The organic solution was dried over Na₂SO₄ and then concentrated *in vacuo*. The title compound (281 mg, 91%, 57% overall) was obtained as a tan solid after recrystallization from MeOH. ¹H NMR (400 MHz, DMSO) 3.72 (s, 3H), 7.28 (dd, 1H), 7.56 (d, 1H), 7.81-7.91 (m, 4H), 8.07 (d, 2H), 8.12 (d, 1H), 8.32 (dd, 1H), 8.54 (d, 1H), 12.10 (s, 1H). ¹³C NMR (100 MHz, DMSO) 36.10, 101.83, 115.38, 120.21, 120.30, 122.15, 122.90, 128.33, 128.42, 133.62, 136.95, 138.77, 139.91, 140.30, 148.52, 153.13, 163.81, 168.81. MS (FAB) *m/z* (rel. intensity) 490 (MH⁺, 30), 492 (32), 490 (30), 414 (28), 413 (83), 109 (31), 107 (36), 95 (25), 91 (99), 57 (73), 55 (28). HRMS (FAB) calcd for C₂₀H₁₆BrN₃O₅S +H₁, 490.0073, found 490.0067.

5-bromo-2-[[3-(1H-indol-1-ylsulfonyl)benzoyl]amino]benzoic acid



3-(1H-indol-1-ylsulfonyl)benzoic acid (301 mg, 1.0 mmol) was suspended in CH₂Cl₂ (10 mL) and (COCl)₂ added (725 mg, 0.5 mL, 5.7 mmol). A catalytic amount of DMF was then added and the mixture stirred for 4 hrs. The solvent was then removed *in vacuo* to give the acid chloride as an oil. The oil was dissolved in CHCl₃ (10 mL). Methyl 2-amino-5-bromobenzoate (230 mg, 1.0 mmol) was added followed by pyridine (1 mL). The solution was stirred at room temperature for an additional 12 hrs then poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na₂SO₄ and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography (10% EtOAc in hexane) to provide 287 mg of the desired methyl ester (56%). The ester was treated with LiOH in 1:1:1 THF/MeOH/H₂O for 12 hrs followed by acidification and extraction with EtOAc. The organic solution was dried over Na₂SO₄ and then concentrated *in vacuo*. The title compound (53 mg, 11%, 6% overall) was obtained as a white solid after recrystallization from MeOH. ¹H NMR (400 MHz, DMSO) 6.90 (d, 1H), 7.27 (t, 1H), 7.37 (t, 1H), 7.62 (d, 1H), 7.82 (t, 1H), 7.87-7.89 (m, 2H), 8.00 (d, 1H), 8.05 (d, 1H), 8.19-8.25 (m, 3H), 8.47 (s, 1H), 11.35 (s, 1H).


5-bromo-2-[[3-(2,3-dihydro-1H-indol-1-ylsulfonyl)benzoyl]amino]benzoic acid



3-(2,3-dihydro-1H-indol-1-ylsulfonyl)benzoic acid (305 mg, 1.0 mmol) was suspended in CH₂Cl₂ (10 mL) and (COCl)₂ added (725 mg, 0.5 mL, 5.7 mmol). A catalytic amount of DMF was then added and the mixture stirred for 4 hrs. The solvent was then removed *in vacuo* to give the acid chloride as an oil. The oil was dissolved in CHCl₃ (10 mL). Methyl 2-amino-5-bromobenzoate (230 mg, 1.0 mmol)

was added followed by pyridine (1 mL). The solution was stirred at room temperature for an additional 12 hrs then poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na₂SO₄ and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography (10% EtOAc in hexane) to provide 381 mg of the desired methyl ester (74%). The ester was treated with LiOH in 1:1:1 THF/MeOH/H₂O for 12 hrs followed by acidification and extraction with EtOAc. The organic solution was dried over Na₂SO₄ and then concentrated *in vacuo*. The title compound (344 mg, 93%, 68% overall) was obtained as a white solid after recrystallization from MeOH. H NMR (400 MHz, DMSO) 2.94 (t, 2H), 4.00 (t, 2H), 6.99 (t, 1H), 7.15-7.23 (m, 2H), 7.52 (d, 1H), 7.80 (t, 1H), 7.89 (dd, 1H), 8.05-8.07 (m, 2H), 8.20 (d, 1H), 8.28 (d, 1H), 8.35 (s, 1H), 11.40 (s, 1H).


5-bromo-2-[[4-(pyrrolidin-1-ylsulfonyl)benzoyl]amino]benzoic acid



4-(pyrrolidin-1-ylsulfonyl)benzoic acid (255 mg, 1.0 mmol) was suspended in CH₂Cl₂ (10 mL) and (COCl)₂ added (725 mg, 0.5 mL, 5.7 mmol). A catalytic amount of DMF was then added and the mixture stirred for 4 hrs. The solvent was then removed *in vacuo* to give the acid chloride as an oil. The oil was dissolved in CHCl₃ (10 mL). Methyl 2-amino-5-bromobenzoate (230 mg, 1.0 mmol) was added followed by pyridine (1 mL). The solution was stirred at room temperature for an additional 12 hrs then poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na₂SO₄ and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography (10% EtOAc in hexane) to provide 331 mg of the desired methyl ester (71%). The ester was treated with LiOH in 1:1:1 THF/MeOH/H₂O for 12 hrs followed by acidification and extraction with EtOAc. The organic solution was dried over Na₂SO₄ and then concentrated *in vacuo*. The title compound (308 mg, 96%, 68% overall) was obtained as a pale yellow solid


after recrystallization from MeOH. ¹H NMR (400 MHz, DMSO) 1.67 (m, 4H), 3.19 (m, 4H), 7.88 (dd, 1H), 8.02 (d, 2H), 8.12-8.16 (m, 3H), 8.58 (d, 1H), 12.10 (s, 1H).

5-cyano-2-{{4-(pyrrolidin-1-ylsulfonyl)benzoyl}amino}benzoic acid



5 4-(pyrrolidin-1-ylsulfonyl)benzoic acid (255 mg, 1.0 mmol) was suspended in CH₂Cl₂ (10 mL) and (COCl)₂ added (725 mg, 0.5 mL, 5.7 mmol). A catalytic amount of DMF was then added and the mixture stirred for 4 hrs. The solvent was then removed *in vacuo* to give the acid chloride as an oil. The oil was dissolved in CHCl₃ (10 mL).
10 Methyl 2-amino-5-cyanobenzoate (176 mg, 1.0 mmol) was added followed by pyridine (1 mL). The solution was stirred at room temperature for an additional 12 hrs then poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na₂SO₄ and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography (10% EtOAc in hexane) to
15 provide 293 mg of the desired methyl ester (71%). The ester was treated with LiOH in 1:1:1 THF/MeOH/H₂O for 12 hrs followed by acidification and extraction with EtOAc. The organic solution was dried over Na₂SO₄ and then concentrated *in vacuo*. The title compound (262 mg, 92%, 65% overall) was obtained as a pale yellow solid after recrystallization from MeOH. ¹H NMR (400 MHz, DMSO) 1.67 (m, 4H), 3.20
20 (m, 4H), 8.04 (d, 2H), 8.11-8.18 (m, 3H), 8.42 (d, 1H), 8.80 (d, 1H), 12.25 (s, 1H).

5-bromo-2-{{3-(pyrrolidin-1-ylsulfonyl)benzoyl}amino}benzoic acid




3-(pyrrolidin-1-ylsulfonyl)benzoic acid (255 mg, 1.0 mmol) was suspended in CH₂Cl₂
25 (10 mL) and (COCl)₂ added (725 mg, 0.5 mL, 5.7 mmol). A catalytic amount of

DMF was then added and the mixture stirred for 4 hrs. The solvent was then removed *in vacuo* to give the acid chloride as an oil. The oil was dissolved in CHCl_3 (10 mL). Methyl 2-amino-5-bromobenzoate (230 mg, 1.0 mmol) was added followed by pyridine (1 mL). The solution was stirred at room temperature for an additional 12 hrs
5 then poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na_2SO_4 and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography (10% EtOAc in hexane) to provide 333 mg of the desired methyl ester (71%). The ester was treated with LiOH in 1:1:1 THF/MeOH/ H_2O for 12 hrs followed by acidification and extraction with
10 EtOAc. The organic solution was dried over Na_2SO_4 and then concentrated *in vacuo*. The title compound (309 mg, 96%, 68% overall) was obtained as a pale yellow solid after recrystallization from MeOH. ^1H NMR (400 MHz, DMSO) 1.67 (m, 4H), 3.20 (m, 4H), 7.85-7.89 (m, 2H), 8.08 (d, 1H), 8.13 (d, 1H), 8.25 (d, 1H), 8.32 (s, 1H), 8.60 (d, 1H), 12.20 (s, 1H).

15


5-cyano-2-({3-[(2-methylpyrrolidin-1-yl)sulfonyl]benzoyl}amino)benzoic acid



3-[(2-methylpyrrolidin-1-yl)sulfonyl]benzoic acid (269 mg, 1.0 mmol) was suspended in CH_2Cl_2 (10 mL) and $(\text{COCl})_2$ added (725 mg, 5.7 mmol). A catalytic amount of
20 DMF was then added and the mixture stirred for 4 hrs. The solvent was then removed *in vacuo* to give the acid chloride as an oil. The oil was dissolved in CHCl_3 (10 mL). Methyl 2-amino-5-cyanobenzoate (176 mg, 1.0 mmol) was added followed by pyridine (1 mL). The solution was stirred at room temperature for an additional 12 hrs then poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The
25 combined organic solutions were dried over Na_2SO_4 and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography (10% EtOAc in hexane) to provide 350 mg of the desired methyl ester (82%). The ester was treated with LiOH in 1:1:1 THF/MeOH/ H_2O for 12 hrs followed by acidification and extraction with EtOAc. The organic solution was dried over Na_2SO_4 and then concentrated *in vacuo*.

The title compound (308 mg, 91%, 75% overall) was obtained as a white solid after recrystallization from MeOH. ¹H NMR (400 MHz, DMSO) 1.25 (d, 3H), 1.41-1.47 (m, 2H), 1.59-1.67 (m, 1H), 1.77-1.83 (m, 1H), 3.12-3.18 (m, 1H), 3.36-3.42 (m, 1H), 3.69 (m, 1H), 7.88 (t, 1H), 8.12 (d, 1H), 8.13 (d, 1H), 8.25 (d, 1H), 8.34 (s, 1H), 8.42 (d, 1H), 8.83 (d, 1H), 12.55 (s, 1H).

5-cyano-2-({3-[(2,5-dimethylpyrrolidin-1-yl)sulfonyl]benzoyl}amino)benzoic acid




3-[(2,5-dimethylpyrrolidin-1-yl)sulfonyl]benzoic acid (283 mg, 1.0 mmol) was suspended in CH₂Cl₂ (10 mL) and (COCl)₂ added (725 mg, 5.7 mmol). A catalytic amount of DMF was then added and the mixture stirred for 4 hrs. The solvent was then removed *in vacuo* to give the acid chloride as an oil. The oil was dissolved in CHCl₃ (10 mL). Methyl 2-amino-5-cyanobenzoate (176 mg, 1.0 mmol) was added followed by pyridine (1 mL). The solution was stirred at room temperature for an additional 12 hrs then poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na₂SO₄ and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography (10% EtOAc in hexane) to provide 293 mg of the desired methyl ester (66%). The ester was treated with LiOH in 1:1:1 THF/MeOH/H₂O for 12 hrs followed by acidification and extraction with EtOAc. The organic solution was dried over Na₂SO₄ and then concentrated *in vacuo*. The title compound (273 mg, 97%, 64% overall) was obtained as a tan solid after recrystallization from MeOH. ¹H NMR (400 MHz, DMSO) 1.29 (d, 6H), 1.49 (m, 4H), 3.67 (m, 2H), 7.88 (t, 1H), 8.12 (d, 1H), 8.13 (d, 1H), 8.25 (d, 1H), 8.34 (s, 1H), 8.42 (d, 1H), 8.83 (d, 1H), 12.55 (s, 1H).

25

5-cyano-2-{{3-(pyrrolidin-1-ylsulfonyl)benzoyl}amino}benzoic acid was produced from methyl 2-{{3-(chlorosulfonyl)benzoyl}amino}-5-cyanobenzoate. ¹H NMR (300 MHz, DMSO) 1.67 (m, 4H), 3.20 (m, 4H), 7.88 (t, 1H), 8.09-8.14 (m, 2H), 8.26 (d, 1H), 8.33 (s, 1H), 8.42 (d, 1H), 8.83 (d, 1H), 12.56 (s, 1H)

00855 US1


5-chloro-2-[[3-(morpholin-4-ylsulfonyl)benzoyl]amino]benzoic acid



3-(morpholin-4-ylsulfonyl)benzoic acid (271 mg, 1.0 mmol) was suspended in CH₂Cl₂ (10 mL) and (COCl)₂ added (725 mg, 5.7 mmol). A catalytic amount of DMF was then added and the mixture stirred for 4 hrs. The solvent was then removed *in vacuo* to give the acid chloride as an oil. The oil was dissolved in CHCl₃ (10 mL). Methyl 2-amino-5-chlorobenzoate (185 mg, 1.0 mmol) was added followed by pyridine (1 mL). The solution was stirred at room temperature for an additional 12 hrs then poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na₂SO₄ and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography (20% EtOAc in hexane) to provide 382 mg of the desired methyl ester (87%). The ester was treated with LiOH in 1:1:1 THF/MeOH/H₂O for 12 hrs followed by acidification and extraction with EtOAc. The organic solution was dried over Na₂SO₄ and then concentrated *in vacuo*. The title compound (351 mg, 95%, 83% overall) was obtained as a white solid after recrystallization from MeOH. ¹H NMR (400 MHz, DMSO) 2.93 (m, 4H), 3.65 (m, 4H), 7.77 (dd, 1H), 7.91 (t, 1H), 7.99-8.02 (m, 2H), 8.25-8.29 (m, 2H), 8.65 (d, 1H), 12.17 (s, 1H).


5-bromo-2-[[3-(morpholin-4-ylsulfonyl)benzoyl]amino]benzoic acid and 2-[[3-(morpholin-4-ylsulfonyl)benzoyl]amino]-5-nitrobenzoic acid were produced in a similar fashion utilizing appropriate starting materials.

5-fluoro-2-[[3-(morpholin-4-ylsulfonyl)benzoyl]amino]benzoic acid



3-(morpholin-4-ylsulfonyl)benzoic acid (271 mg, 1.0 mmol) was suspended in CH_2Cl_2 (10 mL) and $(\text{COCl})_2$ added (725 mg, 5.7 mmol). A catalytic amount of DMF was then added and the mixture stirred for 4 hrs. The solvent was then removed *in vacuo* to give the acid chloride as an oil. The oil was dissolved in CHCl_3 (10 mL). Methyl 2-amino-5-fluorobenzoate (170 mg, 1.0 mmol) was added followed by pyridine (1 mL). The solution was stirred at room temperature for an additional 12 hrs then poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na_2SO_4 and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography (20% EtOAc in hexane) to provide 367 mg of the desired methyl ester (87%). The ester was treated with LiOH in 1:1:1 THF/MeOH/ H_2O for 12 hrs followed by acidification and extraction with EtOAc. The organic solution was dried over Na_2SO_4 and then concentrated *in vacuo*. The title compound (328 mg, 92%, 80% overall) was obtained as a white solid after recrystalization from MeOH. ^1H NMR (400 MHz, DMSO) 2.93 (m, 4H), 3.65 (m, 4H), 7.58 (m, 1H), 7.77 (dd, 1H), 7.90 (t, 1H), 8.00 (d, 1H), 8.26-8.29 (m, 2H), 8.60 (dd, 1H), 12.02 (s, 1H).


5-cyano-2-{[3-(piperidin-1-ylsulfonyl)benzoyl]amino}benzoic acid



3-(piperidin-1-ylsulfonyl)benzoic acid (269 mg, 1.0 mmol) was suspended in CH_2Cl_2 (10 mL) and $(\text{COCl})_2$ added (725 mg, 5.7 mmol). A catalytic amount of DMF was then added and the mixture stirred for 4 hrs. The solvent was then removed *in vacuo* to give the acid chloride as an oil. The oil was dissolved in CHCl_3 (10 mL). Methyl 2-amino-5-cyanobenzoate (176 mg, 1.0 mmol) was added followed by pyridine (1


mL). The solution was stirred at room temperature for an additional 12 hrs then poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na₂SO₄ and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography (10% EtOAc in hexane) to provide 307 mg of the desired methyl ester (72%). The ester was treated with LiOH in 1:1:1 THF/MeOH/H₂O for 12 hrs followed by acidification and extraction with EtOAc. The organic solution was dried over Na₂SO₄ and then concentrated *in vacuo*. The title compound (279 mg, 94%) was obtained as a white solid after recrystallization from MeOH. ¹H NMR (400 MHz, DMSO) 1.37 (m, 2H), 1.56 (m, 4H), 2.95 (m, 4H), 7.90 (t, 1H), 8.02 (d, 1H), 8.13 (dd, 1H), 8.27 (m, 2H), 8.42 (d, 1H), 8.83 (1H), 12.55 (s, 1H).

5-cyano-2-([3-(1H-indol-1-ylsulfonyl)benzoyl]amino)benzoic acid



Indole (150 mg, 1.25 mmol) was dissolved in 15 ml of THF. NaH (100 mg, 60% disp. in oil, 2.5 mmol) was added and resulting suspension stirred for 1 h. Methyl 2-([3-(chlorosulfonyl)benzoyl]amino)-5-cyanobenzoate (378 mg, 1.0 mmol) was then added and the reaction stirred at room temperature of 12 hr. The mixture was poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na₂SO₄ and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography, providing 252 mg (55%) of the desired methyl ester. The ester was treated with LiOH in 1:1:1 THF/MeOH/H₂O for 12 hrs followed by acidification and extraction with EtOAc. The organic solution was dried over Na₂SO₄ and then concentrated *in vacuo*. The title compound (24 mg, 10%) was obtained as a tan solid after recrystallization from MeOH. ¹H NMR (400 MHz, DMSO) 6.89 (d, 1H), 7.28 (t, 1H), 7.37 (t, 1H), 7.61 (d, 1H), 7.81-7.86 (m, 2H), 8.01 (d, 1H), 8.11 (dd, 1H), 8.24 (t, 2H), 8.42 (d, 1H), 8.52 (t, 1H), 8.75 (d, 1H).

5-cyano-2-([3-[(5-methoxy-1H-indol-1-yl)sulfonyl]benzoyl]amino)benzoic acid



5-Methoxyindole (190 mg, 1.25 mmol) was dissolved in 15 ml of THF. NaH (100 mg, 60% disp. in oil, 2.5 mmol) was added and resulting suspension stirred for 1 h. Methyl 2-{{3-(chlorosulfonyl)benzoyl}amino}-5-cyanobenzoate (378 mg, 1.0 mmol) was then added and the reaction stirred at room temperature of 12 hr. The mixture was poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na₂SO₄ and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography, providing 236 mg (48%) of the desired methyl ester. The ester was treated with LiOH in 1:1:1 THF/MeOH/H₂O for 12 hrs followed by acidification and extraction with EtOAc. The organic solution was dried over Na₂SO₄ and then concentrated *in vacuo*. The title compound (31 mg, 13%) was obtained as a white solid after recrystallization from MeOH. ¹H NMR (400 MHz, DMSO) 3.73 (s, 3H), 6.81 (d, 1H), 6.97 (dd, 1H), 7.11 (d, 1H), 7.79 (d, 1H), 7.82 (t, 1H), 7.89 (d, 1H), 8.11 (dd, 1H), 8.21 (t, 1H), 8.42 (d, 1H), 8.48 (t, 1H), 8.76 (d, 1H).

15


5-cyano-2-({3-[(7-methoxy-1H-indol-1-yl)sulfonyl]benzoyl}amino)benzoic acid was produced using 7-Methoxyindole. ¹H NMR (400 MHz, DMSO) 3.84 (s, 3H), 6.79 (d, 1H), 6.83 (d, 1H), 7.29 (t, 1H), 7.61 (d, 1H), 7.75 (d, 1H), 7.80 (m, 2H), 8.17 (d, 1H), 8.28 (d, 1H), 8.32 (d, 1H), 8.56 (t, 1H), 8.73 (d, 1H).

20

5-cyano-2-({3-[(6-methoxy-1H-indol-1-yl)sulfonyl]benzoyl}amino)benzoic acid was produced using 6-Methoxyindole. ¹H NMR (300 MHz, DMSO) 3.85 (s, 3H), 6.78 (d, 1H), 6.89 (dd, 1H), 7.47-7.49 (m, 2H), 7.71 (d, 1H), 7.79-7.85 (m, 2H), 8.20 (d, 1H), 8.29 (d, 1H), 8.34 (d, 1H), 8.59 (t, 1H), 8.75 (d, 1H).

25


2-({3-[(5-chloro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-5-cyanobenzoic acid



5-Chloroindole (190 mg, 1.25 mmol) was dissolved in 15 ml of THF. NaH (100 mg, 60% disp. in oil, 2.5 mmol) was added and resulting suspension stirred for 1 h. Methyl 2-{{3-(chlorosulfonyl)benzoyl}amino}-5-cyanobenzoate (378 mg, 1.0 mmol) was then added and the reaction stirred at room temperature of 12 hr. The mixture was poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na₂SO₄ and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography, providing 311 mg (63%) of the desired methyl ester. The ester was treated with LiOH in 1:1:1 THF/MeOH/H₂O for 12 hrs followed by acidification and extraction with EtOAc. The organic solution was dried over Na₂SO₄ and then concentrated *in vacuo*. The title compound (27 mg, 9%) was obtained as a white solid after recrystallization from MeOH. H NMR (400 MHz, DMSO) 6.88 (d, 1H), 7.42 (dd, 1H), 7.71 (d, 1H), 7.85 (t, 1H), 7.94 (d, 1H), 8.02 (d, 1H), 8.12 (dd, 1H), 8.25 (m, 2H), 8.43 (d, 1H), 8.52 (t, 1H), 8.76 (d, 1H).

5-cyano-2-({3-[(5-fluoro-1H-indol-1-yl)sulfonyl]benzoyl}amino)benzoic acid was produced utilizing 5-Fluoroindole. H NMR (400 MHz, DMSO) 6.89 (d, 1H), 7.23 (dt, 1H), 7.44 (dd, 1H), 7.85 (t, 1H), 7.96 (d, 1H), 8.00 (dd, 1H), 8.13 (dd, 1H), 8.22 (d, 1H), 8.27 (d, 1H), 8.37 (d, 1H), 8.51 (m, 2H).


5-cyano-2-{{3-[(1-methyl-1-phenylethyl)sulfonyl]benzoyl}amino}benzoic acid




Methyl 2-{{3-(chlorosulfonyl)benzoyl}amino}-5-cyanobenzoate (378 mg, 1.0 mmol) was dissolved in 15 mL of CHCl_3 . N-methyl-N-[(1R)-1-phenylethyl]amine (270 mg, 2.0 mmol) and Et_3N (1 mL) were then added and the reaction stirred at room temperature for 12 hr. The mixture was poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na_2SO_4 and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography, providing 400 mg (84%) of the desired methyl ester. The ester was treated with LiOH in 1:1:1 $\text{THF}/\text{MeOH}/\text{H}_2\text{O}$ for 12 hrs followed by acidification and extraction with EtOAc . The organic solution was dried over Na_2SO_4 and then concentrated *in vacuo*. The title compound (300 mg, 77%) was obtained as a white solid after recrystallization from MeOH . $^1\text{H NMR}$ (300 MHz, DMSO) 1.23 (d, 3H), 2.61 (s, 3H), 5.22 (q, 1H), 7.26-7.35 (m, 5H), 7.87 (t, 1H), 8.12 (d, 1H), 8.13 (d, 1H), 8.25 (d, 1H), 8.36 (s, 1H), 8.42 (d, 1H), 8.83 (d, 1H), 12.55 (s, 1H).

5-cyano-2-{{3-({methyl[(1S)-1-phenylethyl]amino}sulfonyl)benzoyl}amino}benzoic acid was produced from N-methyl-N-[(1S)-1-phenylethyl]amine. $^1\text{H NMR}$ (300 MHz, DMSO) 1.23 (d, 3H), 2.61 (s, 3H), 5.22 (q, 1H), 7.26-7.35 (m, 5H), 7.87 (t, 1H), 8.12 (d, 1H), 8.13 (d, 1H), 8.25 (d, 1H), 8.36 (s, 1H), 8.42 (d, 1H), 8.83 (d, 1H), 12.55 (s, 1H).

Scheme 1.4




2-[(4-{{(2-aminophenyl)(methyl)amino}sulfonyl}benzoyl)amino]-5-bromobenzoic acid



- 4-{{2-[(tert-butoxycarbonyl)amino]phenyl}(methyl)amino)sulfonyl}benzoic (406 mg, 1.0 mmol) was suspended in CH_2Cl_2 (10 mL) and $(\text{COCl})_2$ added (725 mg, 5.7 mmol). A catalytic amount of DMF was then added and the mixture stirred for 4 hrs.
- 5 The solvent was then removed *in vacuo* to give the acid chloride as an oil. The oil was dissolved in CHCl_3 (10 mL). Methyl 2-amino-5-bromobenzoate (230 mg, 1.0 mmol) was added followed by pyridine (1 mL). The solution was stirred at room temperature for an additional 12 hrs then poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na_2SO_4
- 10 and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography to provide 346 mg of the desired methyl ester (56%). The ester was treated with LiOH in 1:1:1 THF/MeOH/ H_2O for 12 hrs followed by acidification. The resulting solid was dried in the air then dissolved in CH_2Cl_2 /TFA and stirred for 10 additional hours. The solvent was removed *in vacuo* and the remaining solid was
- 15 recrystallized from MeOH to give the title compound (163 mg, 58%) as a white solid. ^1H NMR (400 MHz, DMSO) 3.12 (s, 3H), 6.36-6.43 (m, 2H), 6.78 (d, 1H), 6.99-7.04 (m, 1H), 7.83-7.93 (m, 3H), 8.13-8.16 (m, 2H), 8.28-8.29 (m, 1H), 8.60 (t, 1H), 12.21 (s, 1H).

- 20 **2-[(3-{{(2-aminophenyl)(methyl)amino)sulfonyl}benzoyl}amino]-5-cyanobenzoic acid**



3-{{2-[(tert-butoxycarbonyl)amino]phenyl}(methyl)amino)sulfonyl}benzoic (406 mg, 1.0 mmol) was suspended in CH_2Cl_2 (10 mL) and $(\text{COCl})_2$ added (725 mg, 5.7


mmol). A catalytic amount of DMF was then added and the mixture stirred for 4 hrs. The solvent was then removed *in vacuo* to give the acid chloride as an oil. The oil was dissolved in CHCl_3 (10 mL). Methyl 2-amino-5-cyanobenzoate (176 mg, 1.0 mmol) was added followed by pyridine (1 mL). The solution was stirred at room temperature for an additional 12 hrs then poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na_2SO_4 and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography to provide 344 mg of the desired methyl ester (61%). The ester was treated with LiOH in 1:1:1 THF/MeOH/ H_2O for 12 hrs followed by acidification. The resulting solid was dried in the air then dissolved in CH_2Cl_2 /TFA and stirred for 10 additional hours. The solvent was removed *in vacuo* and the remaining solid was recrystallized from MeOH to give the title compound (34 mg, 12%) as a white solid. ^1H NMR (400 MHz, DMSO) 3.11 (s, 1H), 6.37 (m, 2H), 6.76 (d, 1H), 7.00 (m, 1H), 7.84-7.93 (m, 2H), 8.31 (dd, 1H), 8.31 (m, 2H), 8.42 (d, 1H), 8.83 (d, 1H), 12.55 (s, 1H).

Preparation of Methyl 2-amino-5-formylbenzoate

To a solution of methyl anthranilate (7.75 g, 51.3 mmol, Aldrich) in DMF (50 mL) was added NIS (11.5 g, 51.3 mmol, Aldrich). The solution was stirred for 63 hours before being added to a separatory funnel with 200 mL of MTBE and washed with 5 X 200 mL of water. The organics were dried over MgSO_4 and evaporated yielding 13.8 g of tan solid as methyl 2-amino-5-iodobenzoate. A mixture of methyl 2-amino-5-iodobenzoate (3.13 g, 11.3 mmol) and tetrakis(triphenylphosphine)palladium(0) (282 mg, 0.244 mmol, Strem) was placed under 1 atm of CO. THF (20 mL) was added, and the solution was heated to 60 °C. Tri-*n*-butyltin hydride (3.7 mL, 12.7 mmol, Aldrich) was added dropwise with rapid stirring over 4 hours. The dark orange solution was heated a further 45 minutes and then added to a separatory funnel with 150 mL of EtOAc. This solution was washed with 2 X 150 mL of saturated aqueous NaHCO_3 followed by 100 mL of brine. It was dried over MgSO_4 and evaporated leaving a brown oil that was purified by chromatography using a Biotage Flash 40 M silica cartridge with a gradient from CH_2Cl_2 to 5% EtOAc in CH_2Cl_2 as eluent. This chromatography failed to remove all of the tin, so the product was re-


chromatographed using a Biotage Flash 40 M silica cartridge with 5% EtOAc in CH_2Cl_2 as eluent. Yield was 863 mg of white solid.

5-Formyl-2-{{3-(morpholin-4-ylsulfonyl)benzoyl}amino}benzoic acid




5 To 3-(morpholin-4-ylsulfonyl)benzoic acid (1.12 g, 4.13 mmol) in CH_2Cl_2 (60 mL) was added DMF (20 μL) and oxalyl chloride (450 μL , 5.16 mmol). The mixture was stirred for 3.75 hours, and the solvent and excess oxalyl chloride were removed by rotary evaporation. The residue was dissolved in CH_2Cl_2 (20 mL), and methyl 2-amino-5-formylbenzoate (637 mg, 3.56 mmol) in pyridine (8 mL) was added. The mixture was stirred overnight and then added to a separatory funnel with 100 mL of CH_2Cl_2 . This solution was washed with 2 X 100 mL of 1 M aqueous HCl and 100 mL of brine. The CH_2Cl_2 was evaporated in the presence of silica gel, and the product was purified by chromatography using a Biotage Flash 40 M silica cartridge with a gradient from 5% EtOAc in CH_2Cl_2 to 10% EtOAc in CH_2Cl_2 as eluent. Yield was 636 mg of yellow solid as the methyl ester. To a mixture of the corresponding methyl ester (318 mg, 0.735 mmol) in dioxane (15 mL) was added 1 M aqueous sodium hydroxide (1.5 mL). The mixture was stirred at room temperature for 2 hours. The reaction mixture was added to a separatory funnel with 100 mL of 1 M aqueous HCl, and the product was extracted into 100 mL of EtOAc. The EtOAc was washed with an additional 100 mL of 1 M aqueous HCl followed by 100 mL of water. It was then dried over MgSO_4 and evaporated. The residue was recrystallized from hot ethanol. The solids were washed with ethanol followed by heptane and then dried at 100 $^\circ\text{C}$ under vacuum yielding 64 mg of tan solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 12.65 (s, 1 H), 10.00 (s, 1 H), 8.89 (d, J = 8.7 Hz, 1 H), 8.60 (d, J = 2.1 Hz, 1 H), 8.29-8.33 (m, 2 H), 8.20 (dd, J = 8.7, 2.1 Hz, 1 H), 8.03 (d, J = 8.1 Hz, 1 H), 7.93 (t, J = 7.8 Hz, 1 H), 3.63-3.68 (m, 4 H), 2.92-2.97 (m, 4 H).

5-bromo-2-{{3-(morpholin-4-ylsulfonyl)benzoyl}amino}benzoic acid



3-(morpholin-4-ylsulfonyl)benzoic acid (271 mg, 1.0 mmol) was suspended in CH_2Cl_2 (10 mL) and $(\text{COCl})_2$ added (725 mg, 5.7 mmol). A catalytic amount of DMF was then added and the mixture stirred for 4 hrs. The solvent was then removed *in vacuo* to give the acid chloride as an oil. The oil was dissolved in CHCl_3 (10 mL). Methyl 2-amino-5-bromobenzoate (230 mg, 1.0 mmol) was added followed by pyridine (1 mL). The solution was stirred at room temperature for an additional 12 hrs then poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na_2SO_4 and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography (20% EtOAc in hexane) to provide 367 mg of the desired methyl ester (76%). The ester was treated with LiOH in 1:1:1 THF/MeOH/ H_2O for 12 hrs followed by acidification and extraction with EtOAc. The organic solution was dried over Na_2SO_4 and then concentrated *in vacuo*. The title compound (328 mg, 92%, 70% overall) was obtained as a white solid after recrystallization from MeOH. ^1H NMR (400 MHz, DMSO) 2.93 (m, 4H), 3.65 (m, 4H), 7.88 (dd, 1H), 7.90 (d, 1H), 8.00 (d, 1H), 8.13 (d, 1H), 8.25-8.29 (m, 2H), 8.59 (d, 1H), 12.21 (s, 1H).

2-[[3-(morpholin-4-ylsulfonyl)benzoyl]amino]-5-nitrobenzoic acid




3-(morpholin-4-ylsulfonyl)benzoic acid (271 mg, 1.0 mmol) was suspended in CH_2Cl_2 (10 mL) and $(\text{COCl})_2$ added (725 mg, 5.7 mmol). A catalytic amount of DMF was then added and the mixture stirred for 4 hrs. The solvent was then removed *in vacuo* to give the acid chloride as an oil. The oil was dissolved in CHCl_3 (10 mL). Methyl 2-amino-5-nitrobenzoate (196 mg, 1.0 mmol) was added followed by pyridine (1 mL).

The solution was stirred at room temperature for an additional 12 hrs then poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na₂SO₄ and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography (20% EtOAc in hexane) to provide 108 mg of the desired methyl ester (24%). The ester was treated with LiOH in 1:1:1 THF/MeOH/H₂O for 12 hrs followed by acidification and extraction with EtOAc. The organic solution was dried over Na₂SO₄ and then concentrated *in vacuo*. The title compound (70 mg, 67%, 16% overall) was obtained as a yellow solid after recrystallization from MeOH. ¹H NMR (400 MHz, DMSO) 2.94 (m, 4H), 3.65 (m, 4H), 7.94 (t, 1H), 8.04 (d, 1H), 8.29-8.33 (m, 2H), 8.55 (dd, 1H), 8.80 (d, 1H), 8.91 (d, 1H), 12.76 (s, 1H)

Methyl 2-({3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-5-formylbenzoate was prepared as described above using 3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoic acid. **2-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-5-formylbenzoic acid** was prepared by hydrolyzing the corresponding methyl ester. ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.69 (s, 1 H), 10.00 (s, 1 H), 8.87 (d, *J* = 8.7 Hz, 1 H), 8.61 (d, *J* = 2.1 Hz, 1 H), 8.40 (s, 1 H), 8.27 (d, *J* = 7.9 Hz, 1 H), 8.19 (dd, *J* = 8.7, 2.1 Hz, 1 H), 8.09 (d, *J* = 8.5 Hz, 1 H), 7.84 (t, *J* = 7.8 Hz, 1 H), 7.53 (d, *J* = 8.5 Hz, 1 H), 7.24-7.29 (m, 2 H), 4.02 (t, *J* = 8.5 Hz, 2 H), 2.95 (t, *J* = 8.4 Hz, 2 H).


2-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-5-[(E)-(methoxyimino)methyl]benzoic acid



A slurry of methyl 2-({3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-5-formylbenzoate (475 mg, 0.952 mmol) and O-methylhydroxylamine hydrochloride (526 mg, 6.30 mmol, Aldrich) in 1:1 ethanol/pyridine (25 mL) was stirred for 2 days. The mixture was then added to a separatory funnel with 120 mL of CH₂Cl₂. This solution was washed with 2 X 100 mL of 1 M aqueous HCl followed by 100 mL of brine. The CH₂Cl₂ was evaporated in

the presence of silica gel, and the product was purified by chromatography using a Biotage Flash 40 M silica cartridge with a gradient from CH₂Cl₂ to 2% EtOAc in CH₂Cl₂ as eluent. Yield was 411 mg of white solid as the methyl ester. To a mixture of the corresponding methyl ester (288 mg, 0.545 mmol) in dioxane (20 mL) was added 1 M aqueous sodium hydroxide (1.5 mL). The mixture was stirred at room temperature for 4.5 hours and then in a 50 °C oil bath for 30 minutes. The reaction mixture was added to a separatory funnel with 100 mL of 1 M aqueous HCl, and the product was extracted into 100 mL of EtOAc. The EtOAc was washed with an additional 100 mL of 1 M aqueous HCl followed by 100 mL of water. It was then dried over MgSO₄ and evaporated. The residue was recrystallized from hot ethanol/THF. The solids were washed with ethanol followed by heptane and then dried at 100 °C under vacuum yielding 127 mg of white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.40 (s, 1 H), 8.70 (d, *J* = 8.7 Hz, 1 H), 8.38 (s, 1 H), 8.31 (d, *J* = 2.1 Hz, 1 H), 8.30 (s, 1 H), 8.25 (d, *J* = 7.9 Hz, 1 H), 8.07 (d, *J* = 8.1 Hz, 1 H), 7.91 (dd, *J* = 8.7, 2.1 Hz, 1 H), 7.83 (t, *J* = 7.9 Hz, 1 H), 7.52 (d, *J* = 8.5 Hz, 1 H), 7.24-7.29 (m, 2 H), 4.02 (t, *J* = 8.5 Hz, 2 H), 3.91 (s, 3 H), 2.95 (t, *J* = 8.4 Hz, 2 H).


2-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-5-[(E)-(hydroxyimino)methyl]benzoic acid




A slurry of methyl 2-({3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-5-formylbenzoate (627 mg, 1.26 mmol) and hydroxylamine hydrochloride (656 mg, 9.44 mmol, Mallinckrodt) in 1:1 ethanol/pyridine (25 mL) was stirred for 2 days. The mixture was then added to a separatory funnel with 120 mL of CH₂Cl₂. This solution was washed with 2 X 100 mL of 1 M aqueous HCl followed by 100 mL of brine. The CH₂Cl₂ was evaporated in the presence of silica gel, and the product was purified by chromatography using a Biotage Flash 40 M silica cartridge with 5% EtOAc in CH₂Cl₂ as eluent. Yield was 478 mg of white solid as the methyl ester. To a mixture of the corresponding methyl ester (363 mg, 0.706 mmol) in dioxane (20 mL) was added 1 M aqueous sodium

hydroxide (1.5 mL). The mixture was stirred at room temperature for 4.5 hours. The reaction mixture was added to a separatory funnel with 100 mL of 1 M aqueous HCl, and the product was extracted into 100 mL of EtOAc. The EtOAc was washed with an additional 100 mL of 1 M aqueous HCl followed by 100 mL of water. It was then dried over MgSO₄ and evaporated. The residue was recrystallized from hot ethanol/THF. The solids were washed with ethanol followed by heptane and then dried at 100 °C under vacuum yielding 280 mg of white solid. Because NMR and CHN analysis were consistent with this material containing residual solvent, 200 mg of the material was heated in 50 mL of methanol. Solvent was removed, and the residue was again dried at 100 °C under vacuum yielding 183 mg of white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.37 (s, 1 H), 11.31 (s, 1 H), 8.68 (d, *J* = 8.7 Hz, 1 H), 8.38 (s, 1 H), 8.29 (d, *J* = 1.9 Hz, 1 H), 8.25 (d, *J* = 7.9 Hz, 1 H), 8.20 (s, 1 H), 8.07 (d, *J* = 8.1 Hz, 1 H), 7.90 (dd, *J* = 8.8, 2.0 Hz, 1 H), 7.83 (t, *J* = 7.9 Hz, 1 H), 7.53 (d, *J* = 8.5 Hz, 1 H), 7.24-7.29 (m, 2 H), 4.01 (t, 8.5, 2 H), 2.95 (t, *J* = 8.4 Hz, 2 H).


Scheme 1.5




Scheme 1.6




Scheme 1.7



5 Scheme 1.8




Scheme 1.9




10


Scheme 1.10




Scheme 1.11



Scheme 1.12



Scheme 1.13



Compounds produced via the above-described synthetic schemes include, but are not limited to, the following:

5-Chloro-2-({4-[(dipropylamino)sulfonyl]benzoyl}amino)benzoic acid

5-Chloro-2-({4-[(dipropylamino)sulfonyl]-3-nitrobenzoyl}amino)benzoic acid

5-Chloro-2-{{4-[(dipropylamino)sulfonyl]-3-(hydroxyamino)benzoyl}amino} benzoic acid hydrochloride

5 2-({3-Amino-4-[(dipropylamino)sulfonyl]benzoyl}amino)-5-chlorobenzoic acid hydrochloride

2-{{4-(Benzylsulfanyl)-3-nitrobenzoyl}amino}-5-chlorobenzoic acid

5-Chloro-2-({4-[(dipropylamino)sulfanyl]-3-nitrobenzoyl}amino)benzoic acid

Methyl 5-chloro-2-({4-[(dipropylamino)sulfinyl]-3-nitrobenzoyl}amino)benzoate


10 5-Chloro-2-{{4-(2,3-dihydro-1H-indol-1-ylsulfonyl)-3-nitrobenzoyl}amino} benzoic acid

Cyano 2-{{3-(2,3-dihydro-1H-indol-1-ylsulfonyl)benzoyl}amino}-5-ethynylbenzoic acid

Methyl 2-({3-amino-4-[(dipropylamino)sulfonyl]benzoyl}amino)-5-chlorobenzoate


15 2-({3-Bromo-4-[(dipropylamino)sulfonyl]benzoyl}amino)-5-chlorobenzoic acid

Scheme 1.16



Preparation of 4-([4-chloro(methyl)anilino]sulfonyl)benzoic acid

5




10

A solution of 4-chloro-N-methylaniline (10.0 g, 0.0706 mol, 1.1 eq) and triethylamine (7.78 g, 0.0770 mol, 1.2 eq) in 140 mL of methanol, cooled in an ice bath at 0-5°C, was treated portionwise over a one minute period with solid 4-chlorosulfonyl benzoic acid (14.2 g, 0.0642 mol, 1.0eq). After the addition was complete, the cooling bath was removed and the reaction mixture was stirred under a nitrogen atmosphere while

warming to room temperature on its own. After 5.5 h, the contents were poured into 270 mL of ice water containing 130 mL of 3 N NaOH, washed the milky solution with methylene chloride (2 X 100 mL), acidified the aqueous layer with 35 mL of concentrated HCl. After cooling the mixture in an ice bath, the white precipitated product was collected and dried in a vacuum oven at 70°C overnight to yield 14.92 g (71%) of **2**. ¹H NMR (DMSO-*d*₆) δ 13.53 (brs, 1 H), 8.11 (dd, *J* = 2, 7 Hz, 2 H), 7.63 (dd, *J* = 2, 7 Hz, 2 H), 7.42 (dd, *J* = 2, 7 Hz, 2 H), 7.14 (dd, *J* = 2, 7 Hz, 2 H), 3.15 (s, 3 H) ppm.

Scheme 1.17




To 21 mL of carbon tetrachloride at room temperature was added benzoyl peroxide (0.095 g, 0.393 mmol, 0.10 eq). The solution was slowly heated to reflux at which time N-bromosuccinimide (0.769 g, 4.32 mmol, 1.1 eq) was added at once followed by a slurry of compound **72** (1.64 g, 3.93 mmol, 1.0 eq) in 9 mL of carbon tetrachloride plus 6 mL of carbon tetrachloride as a rinse. Vigorous refluxing was continued for 2 h, the reaction mixture filtered hot and the solids rinsed with additional hot carbon tetrachloride. The filtrate was concentrated at reduced pressure to give more than theoretical amount of crude bromomethyl compound **73**. This was dissolved in 35 mL of acetone, treated with NaCN (0.289 g, 5.90 mmol, 1.5 eq) and

NaI (0.029 g, 0.197 mmol, 0.05 eq) and the mixture refluxed for 24 h. An additional 0.50 eq (0.096 g) of NaCN was added and refluxing continued for 3 h longer. The cooled reaction mixture was filtered, the filtrate concentrated at reduced pressure, the residue dissolved in ethyl acetate and washed successively with 10 mL of water and 10 mL of 50% saturated brine. The combined aqueous washings were back extracted once with ethyl acetate, the combined organic extracts dried with anhydrous sodium sulfate and the filtrate concentrated *in vacuo*. Chromatography with 100 g of silica gel, packed and eluted with acetone-methylene chloride-heptane (1:4:5), afforded cyanomethyl ester **74** in 20% yield (based on **72**) as a white solid. Base hydrolysis of **74** (0.297 g, 0.670 mmol) in 4 mL of methylene chloride, 4 mL of methanol and 1 mL of water using 1N NaOH (3.02 mL, 4.5 eq) at room temperature gave a 55% yield of acid **75** as a white solid. **73**: TLC (silica gel GF): $R_f = 0.36$ acetone-methylene chloride-hexane(1:3:6); ^1H NMR (CDCl_3) δ 8.89 (d, $J = 7$ Hz, 1 H), 8.41 (t, $J = 1$ Hz, 1 H), 8.27 (m, 1 H), 8.14 (d, $J = 2$ Hz, 1 H), 7.97 (m, 1 H), 7.75 (t, $J = 6$ Hz, 1 H), 7.66 (dd, $J = 2, 6$ Hz, 1 H), 4.52 (s, 2 H), 3.98 (s, 3 H), 3.78 (t, $J = 3$ Hz, 4 H), 3.10 (t, $J = 4$ Hz, 4 H) ppm.

Scheme 1.18 outlines the solid phase synthesis of halogenated anthranilic acid substrates **5**.


20 Scheme 1.18



00833 US 1


Resin bound iodide **6** was stannylated using the conditions shown in Scheme 10.2. Hunigs base, although not directly involved in the reactions, was used as a proton scavenger. A library based on this template was successfully prepared using Suzuki cross-coupling conditions.

Scheme 1.19



Applying the Stille conditions to the template, stannylated product **9** was prepared from iodide **5b**. The reaction was monitored via observance of the protodestannylation product after TFA cleavage from resin. Stannylation of the corresponding solid-phase bromide **5a** was less successful.


Scheme 1.20



Attempts at coupling aryl bromides and iodides with the stannylated resin gave some product, but not in quantities suitable for library production (Scheme 1.21). Protodestannylation and homocoupling were the major competing reactions, leaving


product purities in the 25 % range. The reactions were monitored by HPLC (at 210 nm), and product identities were confirmed by LC/MS.

Scheme 1.21




Suzuki coupling chemistry was conducted under the conditions shown in Scheme 1.22.

Scheme 1.22



The cross-coupling reaction from the other direction is shown in Scheme 1.23, in which purchased aryl tin compounds were coupled with the resin-bound iodide.


Scheme 1.23



The best results in the case of tributylphenyl tin were obtained in toluene with 1,1'-bis(diphenylphosphino)-ferrocene as ligand and a reaction time of 2.5 hours at 115 °C.

In the case of 2-(tributylstannyl) thiophene, toluene was the solvent of choice and tricyclohexylphosphine, triphenyl arsine, and 1,1'-bis(diphenylphosphino)-ferrocene worked equally well after 2.5 hours at 115 °C.

Table 1.1: Commercially Available Aryl Tin Compounds




Installation of Ketones via Palladium-Catalyzed Coupling with Acid Chlorides


Acid chlorides were coupled with 9 (see scheme 1.20) using similar, but milder conditions (Scheme 10.7). The ketone product (13) was produced using triphenylphosphine as ligand and THF as solvent in 75 % yield and 70 % purity. A




















carbon monoxide atmosphere was used to eliminate small amounts of the corresponding aryl-aryl product formation (**12**), while Hunigs base was employed as the proton scavenger to help avoid protodestannylation.

Scheme 1.24



Scheme 1.25


5 **Table 1.2:** Diversity Elements (no. of ≥ 70 % pure products/no. attempted)

sulfonyl chlorides	amines	acid chlorides	
 (39/96)	 (12/24)	 (7/16)	 (0/16)
 (33/96)	 (12/24)	 (6/16)	 (6/16)
	 (11/24)	 (1/16)	Iodo (11/16)
	 (6/24)	 (4/16)	H (13/16)
	 (6/24)	 (6/16)	
	 (9/24)	 (3/16)	
	 (4/24)	 (7/16)	
		 (8/16)	

Derivatization of Aryl Ketones: Derivatizing the ketones as oximes, alkoxyamines, hydrazones, and amines


- 5 Oximes and alkoxyamines (**20**) were prepared in reasonable purities from their corresponding hydroxylamine hydrochlorides and resin **19** in pyridine (Scheme 1.26). Hydrazone, sulfonylhydrazone, and acyl-hydrazone formations (**21**) using literature conditions, however, were sluggish and could never be pushed to completion.

10 **Scheme 1.26**




- Amines **22** were prepared on solid-phase using reductive amination. Imine formation, mediated by titanium isopropoxide, typically took four to six hours to go to completion. The sodium triacetoxy borohydride reduction was allowed to proceed overnight to give good quality amine products.
- 15

Scheme 1.30




***t*-Butyl 2-((3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl)amino)-5-iodobenzoate, a, Compound 11.1**



3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoic acid (2.3 g, 6.9 mmol, 1 equivalent) and oxyl chloride (2.6 g, 20.5 mmol, 3 equivalent) were dissolved in methylene chloride (30 ml), followed by the addition of DMF (0.4 ml). Gas evolution was observed. The mixture was stirred at room temperature for 2 h later, then heptane (30 ml) was added. The solution was concentrated to dryness, and the residue was redissolved in DCM (30 ml), followed by the dropwise addition of PHA-561052 (2.2 g, 6.9 mmol, 1 equivalent) in DCM (20 ml) and pyridine (1.2 ml). The resulting solution was stirred overnight, then diluted with MTBE (200 ml) and washed with 0.1N HCl, 1N NaOH, brine, dried (MgSO₄), filtered, and concentrated *in vacuo*. The residue was recrystallized from heptane to afford 2.4 g (55%) of 1 as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.34 (s, 1 H), 8.67 (d, *J* = 9.0 Hz, 1 H), 8.54 (s, 1 H), 8.33 (m, 1 H), 8.24 (d, *J* = 8.5 Hz, 1 H), 7.97 (d, *J* = 8.4 Hz, 1 H), 7.88 (d, *J* = 8.5 Hz, 1 H), 7.64 (m, 2 H), 7.17 (d, *J* = 8.5 Hz, 1 H), 7.06 (s, 1 H), 4.08 (t, *J* = 8.5 Hz, 2 H), 2.95 (t, *J* = 8.4 Hz, 2 H), 1.67 (s, 9 H).


2-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-5-iodobenzoic acid



5 General method E: (Hydrolysis of the alkyl ester)

Ester **11.1** (150mg, 0.24mmol) was dissolved in DCM (6 ml), followed by the addition of TFA (1.2 ml). The solution was shaken overnight, then diluted with DCM (5 ml) and heptane (1 ml). The solution was concentrated *in vacuo* to dryness, the
 10 residue was pumped for about 1h, then triturated with methanol, filtered to afford 102mg(75%) of a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.25 (s, 1 H), 8.44 (d, *J* = 9 Hz, 1 H), 8.33 (s, 2 H), 8.31 (m, 1 H), 8.05 (m, 2 H), 7.81 (t, *J* = 8.5 Hz, 1 H), 7.71 (d, *J* = 9 Hz, 1 H), 7.24 (m, 2 H), 4.01 (t, *J* = 8.1 Hz, 2 H), 2.95 (t, 2 H).

***t*-Butyl 4-({3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)[1,1'-biphenyl]-3-carboxylate, 2a**



5

General method F:

Ester **11.1** (150 mg, 0.235 mmol) and tetrakis(triphenylphosphine) palladium(0) (13.6 mg, 0.01175 mmol) were placed in a 50ml one-necked round bottom flask. The system was evacuated and filled with argon several times. Then tributylstannylbenzene (91.75 mg, 0.25 mmol) in toluene (10 ml) was added. The resulting solution was heated at 100°C overnight, cooled to room temperature, then KF (87mg,) was added. The mixture was stirred at room temperature for 2h, filtered through celite. The filtrate was concentrated *in vacuo* and the residue was purified by silica gel chromatography (EtOAc/heptane 1/25, 1/10) to afford 120 mg (88%) of **11.2a** as a yellow solid.


15

General method G:

00833 US1

Ester **11.1** (150 mg, 0.235 mmol) and dichlorobis(triphenylphosphine) palladium (II) (8.4 mg, 0.012 mmol) were placed in a 50 ml one-necked round bottom flask. The system was evacuated and filled with argon several times. Then tributylstannylbenzene (91.7 mg, 0.25 mmol) in THF (10 ml) was added. The resulting solution was heated at 80°C overnight, cooled to room temperature, KF (87 mg) was added. The mixture was stirred at room temperature for 2h, filtered through celite. The filtrate was concentrated *in vacuo* and the residue was purified by silica gel chromatography (EtOAc/heptane 1/25, 1/10) to afford 101 mg (74%) of **11.2a** as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.60 (s, 1 H), 8.42 (s, 1 H), 8.35 (d, *J* = 9 Hz, 1 H), 8.27 (d, *J* = 8 Hz, 1 H), 8.15 (d, *J* = 2 Hz, 1 H), 8.06 (d, *J* = 8 Hz, 1 H), 7.98 (d, *J* = 9 Hz, 1 H), 7.84 (t, *J* = 8 Hz, 1 H), 7.70 (d, *J* = 7 Hz, 2 H), 7.50 (m, 3 H), 7.41 (t, *J* = 7 Hz, 1 H), 7.25 (d, *J* = 7 Hz, 2 H), 4.05 (t, *J* = 8 Hz, 2 H), 2.97 (t, *J* = 8 Hz, 2 H), 1.53 (s, 9 H).

t*-Butyl 4'-chloro-4-({3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)[1,1'-biphenyl]-3-carboxylate, **11.2c*




General method H:

Ester **11.1** (160 mg, 0.25 mmol), tetrakis(triphenylphosphine) palladium(0) (14.5 mg, 0.0125 mmol), sodium carbonate (101 mg, 0.95 mmol) and 4-chlorobenzenboronic acid (43 mg, 0.275 mmol) were placed in a 100ml one-necked round bottom flask. The system was evacuated and filled with argon several times. Then THF (50 ml) and distilled water (5 ml) were added. The solution was heated at reflux temperature for 20h, the solvent was removed in *vacuo* and residue was purified by silica gel

chromatography (EtOAc/heptane 1/25, 1/10) to get 92 mg (59%) of **11.2c** as a yellow solid. ^1H NMR (300 MHz, CDCl_3) δ 12.40 (s, 1 H), 8.93 (d, $J = 9$ Hz, 1 H), 8.59 (s, 1 H), 8.28 (d, $J = 8$ Hz, 1 H), 8.24 (d, $J = 2.3$ Hz, 1 H), 7.95 (d, $J = 8$ Hz, 1 H), 7.80 (dd, $J = 2.5, 8.2$ Hz, 1 H), 7.64 (m, 6 H), 7.20 (d, $J = 8$ Hz, 1 H), 7.08 (s, 1 H), 4.12 (t, $J =$
 5 8 Hz, 2 H), 2.98 (t, $J = 8$ Hz, 2 H), 1.71 (s, 9 H).


5-cyano-2-({3-[(1-pyrrolidinylsulfonyl)methyl]benzoyl}amino)benzoic acid PHA-



3-(chloromethyl)benzoic acid **51**, gave thiomethyl compound **52** in 82% yield⁷. In a manner similar to that described for the preparation of compound **13** above, compound **52** was sequentially treated with gaseous chlorine to obtain the crude sulfonic acid **53** in theoretical yield followed by reaction with thionyl chloride which provided the crude acid chloride **54** as a waxy white solid. This was reacted directly
 15 with anthranilate **21** to provide sufficiently pure sulfonyl chloride **55**, which was reacted with pyrrolidine to give a 26% yield of ester **56**. Subsequent hydrolysis with trifluoroacetic acid afforded the acid **57** in 83% yield as a white solid. **57**: ^1H NMR

(DMSO-*d*₆) δ 12.48 (s, 1 H), 8.86 (d, J = 7 Hz, 1 H), 8.42 (d, J = 2 Hz, 1 H), 8.12 (dd, J = 2, 7 Hz, 1 H), 8.05 (s, 1 H), 7.95 (d, J = 6 Hz, 1 H), 7.72 (d, J = 6 Hz, 1 H), 7.64 (t, J = 6 Hz, 1 H), 4.58 (s, 2 H), 3.20 (t, J = 5 Hz, 4 H), 1.82 (m, 4 H) ppm.

- 5 **2-[(1,3-Benzoxazol-2-ylcarbonyl)amino]-5-cyanobenzoic acid** (36310-jcr-135a, PHA-734774, SPS# 0281864)



- To a solution of benzyl 1,3-benzoxazole-2-carboxylate (233 mg, 0.920 mmol) in 1:1
 10 ethanol/THF (20 mL) was added palladium on carbon (56 mg of 5%, Aldrich) and triethylamine (180 μ L, 1.29 mmol, Aldrich). The mixture was stirred under 1 ATM of hydrogen for 2 hours and then filtered through a plug of celite. Removal of the solvent left the triethylamine salt as an orange oil (the protonated form of the acid rapidly decarboxylates and should be avoided). This oil was dissolved in CH₂Cl₂ (20
 15 mL) and treated with DMF (20 μ L) followed by oxalyl chloride (220 μ L, 2.52 mmol, Aldrich). Solvent and excess oxalyl chloride were removed by rotary evaporation after 76 hours. The residue was dissolved in CH₂Cl₂ (20 mL), and benzyl 2-amino-5-cyanobenzoate (250 mg, 0.991 mmol) in pyridine (8 mL) was added. The mixture was stirred overnight and then added to a separatory funnel with 100 mL of CH₂Cl₂.
 20 This solution was washed with 2 X 100 of 1.0 M HCl and 100 mL of brine. Product was adsorbed onto silica gel and purified on a Biotage Flash 40 M silica gel cartridge using CH₂Cl₂ as eluent. Product was collected as 218 mg of white solid as the benzyl ester. A mixture of benzyl 2-[(1,3-benzoxazol-2-ylcarbonyl)amino]-5-cyanobenzoate (168 mg, 0.423 mmol) and palladium on carbon (33 mg of 5%, Aldrich) in 2:1
 25 THF/ethanol (30 mL) was stirred under 1 ATM of hydrogen for 25 minutes. The mixture was filtered through a plug of celite and then evaporated. The residue was dried at 100 °C under vacuum yielding 116 mg of white solid. ¹H NMR (400 MHz, DMSO-D₆) δ ppm 7.56 (t, J =7.67 Hz, 1 H) 7.63 (t, J =7.88 Hz, 1 H) 7.94 (d, J =8.29 Hz, 1 H) 8.00 (d, J =7.67 Hz, 1 H) 8.16 (dd, J =8.81, 1.97 Hz, 1 H) 8.45 (d, J =2.07 Hz,
 30 1 H) 8.87 (d, J =8.71 Hz, 1 H) 13.16 (s, 1 H).

The following compounds were produced via the methods described above using appropriate starting materials and making non-critical variations.

- 5 4-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)[1,1'-biphenyl]-3-carboxylic acid
- 2-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-5-(2-furyl)benzoic acid
- 2-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-5-(2-thienyl)benzoic acid
- 10 2-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-5-(2-pyrazinyl)benzoic acid,
- 2-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-5-(1-methyl-1H-pyrrol-2-yl)benzoic acid
- 15 4'-Chloro-4-({3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)[1,1'-biphenyl]-3-carboxylic acid
- 4-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-3'-nitro[1,1'-biphenyl]-3-carboxylic acid
- 4-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-4'-cyano[1,1'-biphenyl]-3-carboxylic acid
- 20 2-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-5-(5-chloro-2-thienyl)benzoic acid
- 2-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-5-(4-methyl-2-thienyl)benzoic acid
- 25 4-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-4'-fluoro[1,1'-biphenyl]-3-carboxylic acid
- 4-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-2'-(trifluoromethyl)[1,1'-biphenyl]-3-carboxylic acid
- 4-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-3',5'-bis(trifluoromethyl)[1,1'-biphenyl]-3-carboxylic acid
- 30 2-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-5-(5-methyl-2-thienyl)benzoic acid


- 4-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-2',4'-difluoro[1,1'-biphenyl]-3-carboxylic acid
- 4'-*t*-Butyl-4-({3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)[1,1'-biphenyl]-3-carboxylic acid
- 5 4-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-3'-(trifluoromethyl)[1,1'-biphenyl]-3-carboxylic acid
- 4-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-4'-(trifluoromethyl)[1,1'-biphenyl]-3-carboxylic acid
- 4-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-2'-methyl[1,1'-biphenyl]-3-carboxylic acid
- 10

- 2-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-5-(3,5-dimethyl-4-isoxazolyl)benzoic acid
- 2-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-5-(2,4-dimethoxy-5-pyrimidinyl)benzoic acid
- 5 2-[(3-[(4-Chlorophenyl)(methyl)amino]sulfonyl}benzoyl)amino]-5-(trifluoromethyl)benzoic acid,
- 2-[(3-Bromo-5-[(4-chlorophenyl)(methyl)amino]sulfonyl}benzoyl)amino]-5-chlorobenzoic acid
- 5-Bromo-2-[(3-[(4-chlorophenyl)(methyl)amino]sulfonyl}-5-nitrobenzoyl)amino]benzoic acid
- 10 2-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-5-cyanobenzoic acid
- 5-Bromo-2-({3-cyano-5-(2,3-dihydro-1H-indol-1-ylsulfonyl)benzoyl}amino}benzoic acid
- 15 5-Cyano-2-({3-(2,3-dihydro-1H-indol-1-ylsulfonyl)-5-methylbenzoyl}amino}benzoic acid
- Methyl 2-({3-[2-(acetyloxy)ethyl]-5-(2,3-dihydro-1H-indol-1-ylsulfonyl)benzoyl}amino}-5-cyanobenzoate
- 5-Cyano-2-({3-(2,3-dihydro-1H-indol-1-ylsulfonyl)-5-(2-hydroxyethyl)benzoyl}amino}benzoic acid
- 20 2-({3-Bromo-5-(2,3-dihydro-1H-indol-1-ylsulfonyl)benzoyl}amino}-5-chlorobenzoic acid
- 5-Chloro-2-[(3-[(4-chlorophenyl)(methyl)amino]sulfonyl}benzoyl)amino]benzoic acid
- 25 2-[(3-Bromo-5-[(4-chlorophenyl)(methyl)amino]sulfonyl}benzoyl)amino]-5-cyanobenzoic acid
- 5-cyano-2-[(3-[(2-hydroxyphenyl)(methyl)amino]sulfonyl}benzoyl)amino]benzoic acid
- 5-Bromo-2-[(5-[(4-chlorophenyl)(methyl)amino]sulfonyl}-2-methoxybenzoyl)amino]benzoic acid
- 30 5-Bromo-2-[(5-[(4-chlorophenyl)(methyl)amino]sulfonyl}-2-methylbenzoyl)amino]benzoic acid

- 5-Bromo-2-[(2-bromo-5-{{(4-chlorophenyl)(methyl)amino}sulfonyl} benzoyl)amino]benzoic acid
- 5-Bromo-2-[(3-{{(4-chlorophenyl)(methyl)amino}sulfonyl}-4-methoxybenzoyl)amino]benzoic acid
- 5 5-Bromo-2-[(3-{{(4-chlorophenyl)(methyl)amino}sulfonyl}-4-methylbenzoyl)amino]benzoic acid
- 5-Bromo-2-[(4-bromo-3-{{(4-chlorophenyl)(methyl)amino}sulfonyl} benzoyl)amino]benzoic acid
- 2-[(3-{{(4-Chlorophenyl)(methyl)amino}sulfonyl} benzoyl)amino]-5-nitrobenzoic acid
- 10 2-[(4-{{(4-Chlorophenyl)(methyl)amino}sulfonyl} benzoyl)amino]-5-nitrobenzoic acid
- 5-Bromo-2-[(3-{{(4-chlorophenyl)(methyl)amino}sulfonyl}-4-morpholin-4-ylbenzoyl)amino]benzoic acid
- 5-Bromo-2-[(3-bromo-5-{{(4-chlorophenyl)(methyl)amino}sulfonyl} benzoyl)amino] benzoic acid
- 15 2-{{[3-Bromo-5-(2,3-dihydro-1H-indol-1-ylsulfonyl)benzoyl]amino}-5-cyanobenzoic acid
- 2-{{[3-Bromo-5-(morpholin-4-ylsulfonyl)benzoyl]amino}-5-chlorobenzoic acid
- 5-Chloro-2-{{[3-(2,3-dihydro-1H-indol-1-ylsulfonyl)-5-methylbenzoyl]amino} benzoic acid
- 20 5-Iodo-2-{{[3-(morpholin-4-ylsulfonyl)benzoyl]amino} benzoic acid
- 2-({4-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl} amino)-5-cyanobenzoic acid
- 2-{{[3-(Morpholin-4-ylsulfonyl)benzoyl]amino}-5-thiocyanatobenzoic acid

25 **Example 2: Amine, Ether, and Thioether Derivatives**

Preparation of 3-Bromo-4-fluorobenzoic acid




- 3-Bromo-4-fluoro-benzaldehyde (10.0 g, 49 mmol) in H₂O (150 mL, followed by the
- 30 addition of KMnO₄ (15.5 g, 98 mmol) heated at reflux (foams extensively) for 1 h,

then added additional KMnO_4 (15.5 g, 98 mmol) and continued heating for another 3 h. The reaction was cooled to rt, then filtered through Celite. The solution was acidified with HCl, and the resulting white precipitate was filtered off, to afford 6.1 g (56%) of a white solid.

5


Preparation of 3-Anilinobenzoic acid



Methyl 3-bromobenzoate (1000 mg, 4.65 mmol), $\text{Pd}_2(\text{dba})_3$ (53 mg, 0.058 mmol), Cs_2CO_3 (2120 mg, 1.4 mmol) and N-[2'-(dicyclohexylphosphino)-1,1'-biphenyl-2-yl]-N,N-dimethylamine (27mg, 0.07 mmol) were placed in a 100ml one-necked round bottom flask. The system was evacuated and filled with argon several times. Then aniline (519 mg, 5.58 mmol) was added, followed by the addition of toluene (50 ml). The solution was heated at 100°C for 20h, the solvent was removed in vacuo and residue was purified by silica gel chromatography (EtOAc/heptane 1/3) to get 180 mg (18%) of methyl ester as a yellow solid, which was hydrolyzed by LiOH (50 mg) in THF (4 ml) and water (1 ml) to afford 140 mg (82%) of **3-Anilinobenzoic acid** as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.02 (s, 1 H), 7.65 (s, 1 H), 7.33 (d, J = 7.5 Hz, 1 H), 7.19 (t, J = 8.3 Hz, 2 H), 7.10 (d, J = 7.7 Hz, 1 H), 7.03 (d, J = 7.6 Hz, 2 H), 6.96 (m, 1 H), 6.76 (t, J = 7.3 Hz, 1 H);

20

2-[(3-Anilinobenzoyl)amino]-5-cyanobenzoic acid



Prepared according to the general methods described above: **3-Anilinobenzoic acid** (140 mg, 0.66 mmol) and PHA-561053 (130 mg, 0.59 mmol) afforded 61 mg (25%)


25

of t-butyl ester as a yellow solid, which was hydrolyzed to 48 mg (91%) of a green solid.

Analytical data for PHA-610938

¹H NMR (300 MHz, DMSO-*d*₆) δ 8.81 (d, *J* = 9.0 Hz, 1 H), 8.46 (s, 1 H), 8.35 (d, *J* = 2.2 Hz, 1 H), 7.82 (dd, *J* = 1.9, 8.8 Hz, 1 H), 7.72 (s, 1 H), 7.42 (m, 2 H), 7.27 (m, 3 H), 7.14 (d, *J* = 7.8 Hz, 2 H), 6.88 (t, *J* = 7.3 Hz, 1 H).


Preparation of 3-[(Pyridin-4-ylmethyl)thio]benzoic acid



10

Water (10 mL) was added to a flask containing 3-mercaptopbenzoic acid (2.08 g, 13.5 mmol, Aldrich) and sodium hydroxide (1.16 g, 29.0 mmol). To the resulting solution was added 4-picolyl chloride hydrochloride (2.31 g, 14.1 mmol, Aldrich) and ethanol (20 mL). The mixture was heated in a 75 °C oil bath for 1 hour and then added to a separatory funnel with 100 mL of water and 100 mL of CH₂Cl₂. This resulted in a suspension in the aqueous layer. This suspension was washed with an additional 100 mL of CH₂Cl₂ and then filtered. The solid was then dried at 100 °C under vacuum yielding 2.80 g of white solid.


Preparation of 3-[(Phenylthio)methyl]benzoic acid



20

To a solution of the corresponding methyl ester described by Holoboski, M.A.; Koft, E. in *J. Org. Chem.*, **1992**, 57, 965-969, (1.23 g, 4.76 mmol) in methanol (15 mL) was added 1.0 M aqueous NaOH (8.0 mL). The resulting mixture was heated in a 50 °C oil bath for 1.5 hours. Most of the methanol was removed by rotary evaporation, and the residue was added to a separatory funnel with 100 mL of 1.0 M aqueous HCl and 100 mL of CH₂Cl₂. The CH₂Cl₂ was washed with another 100 mL of 1.0 M aqueous HCl followed by 100 mL of water and then dried over Na₂SO₄. Solvent was removed, and the residue was dried at 100 °C yielding 1.11 g of white solid.

5-Bromo-2-({3-[(phenylthio)methyl]benzoyl}amino)benzoic acid



To 3-[(phenylthio)methyl]benzoic acid (400 mg, 1.64 mmol) in CH₂Cl₂ (15 mL) was added DMF (20 µL) and oxalyl chloride (200 µL, 2.29 mmol). The mixture was stirred for 1.5 hours, and the solvent and excess oxalyl chloride were removed by rotary evaporation. The residue was dissolved in CH₂Cl₂ (15 mL), and methyl 2-amino-5-bromobenzoate (330 mg, 1.43 mmol, Avocado) in pyridine (8 mL) was added. The mixture was stirred overnight and then added to a separatory funnel with 100 mL of CH₂Cl₂. This solution was washed with 2 X 100 mL of 1 M aqueous HCl and 100 mL of brine. The CH₂Cl₂ was evaporated in the presence of silica gel, and the product was purified by chromatography using a Biotage Flash 40 M silica cartridge with a gradient from 50% CH₂Cl₂/heptane to 75% CH₂Cl₂/heptane as eluent. Yield was 544 mg of white solid as the methyl ester.

To a mixture of the corresponding methyl ester (386 mg, 0.845 mmol) in dioxane (20 mL) was added 1 M aqueous sodium hydroxide (2.0 mL). The mixture was stirred for at room temperature for 1.25 hours and then at 50 °C for 1.5 hours. The reaction mixture was added to a separatory funnel with 100 mL of 1 M aqueous HCl, and the product was extracted into 100 mL of CH₂Cl₂. The CH₂Cl₂ was washed with an additional 100 mL of 1 M aqueous HCl followed by 100 mL of brine. It was then dried over Na₂SO₄ and evaporated. The residue was recrystallized from hot ethanol (8

mL). The solids were washed with ethanol followed by heptane and then dried at 100 °C under vacuum yielding 279 mg of white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.08 (s, 1 H), 8.64 (d, *J* = 9.2 Hz, 1 H), 8.12 (d, *J* = 2.5 Hz, 1 H), 7.97 (s, 1 H), 7.86 (dd, *J* = 9.2, 2.5 Hz, 1 H), 7.80 (d, *J* = 7.6 Hz, 1 H), 7.61 (d, *J* = 7.6 Hz, 1 H), 7.51 (t, *J* = 7.6 Hz, 1 H), 7.35 (d, *J* = 7.1 Hz, 2 H), 7.29 (t, *J* = 7.9 Hz, 2 H), 7.18 (t, *J* = 7.1 Hz, 1 H), 7.35 (s, 2 H).


Other compounds produced via the above-described methodology using appropriate starting materials and making non-critical variations include:

- 10 2-{{3-(benzylthio)benzoyl}amino}-5-bromobenzoate
- 2-{{3-(Benzyloxy)benzoyl}amino}-5-bromobenzoic acid
- 5-Bromo-2-{{3-(ethylthio)benzoyl}amino}benzoic acid
- Methyl-5-Bromo-2-({3-[(pyridin-4-ylmethyl)thio]benzoyl}amino)benzoate
- 5-Bromo-2-({3-[(pyridin-4-ylmethyl)thio]benzoyl}amino)benzoic acid
- 15 5-bromo-2-({3-[(pyridin-4-ylmethyl)thio]benzoyl}amino)benzoic acid hydrochloride
- 5-Bromo-2-[(3-phenoxybenzoyl)amino]benzoic acid
- 5-Bromo-2-{{3-(phenylthio)benzoyl}amino}benzoic acid
- 5-Cyano-2-[(3-phenoxybenzoyl)amino]benzoic acid
- 5-Cyano-2-({3-[(pyridin-4-ylmethyl)thio]benzoyl}amino)benzoic acid
- 20 5-Cyano-2-({3-[(pyridin-4-ylmethyl)thio]benzoyl}amino)benzoic acid hydrochloride
- 2-{{3-(Benzyloxy)benzoyl}amino}-5-cyanobenzoic acid
- 2-{{3-(Benzylthio)benzoyl}amino}-5-cyanobenzoic acid
- 5-cyano-2-({3-[(1-phenylethyl)thio]benzoyl}amino)benzoic acid
- 5-cyano-2-{{3-(cyclopentylthio)benzoyl}amino}benzoic acid
- 25 5-cyano-2-{{3-(cyclopentylsulfinyl)benzoyl}amino}benzoic acid
- 5-Chloro-2-[(4-methoxy-3-nitrobenzoyl)amino]benzoic acid
- 2-{{4-(Benzylsulfanyl)-3-bromobenzoyl}amino}-5-chlorobenzoic acid
- 5-Cyano-2-{{3-(3-fluorophenoxy)benzoyl}amino}benzoic acid
- 5-Cyano-2-{{3-(2-methylphenoxy)benzoyl}amino}benzoic acid
- 30 5-Cyano-2-{{3-(4-methoxyphenoxy)benzoyl}amino}benzoic acid
- 5-Cyano-2-{{3-(3-nitrophenoxy)benzoyl}amino}benzoic acid

Example 3: KETONE DERIVATIVES


2-[(3-Benzoylbenzoyl)amino]-5-bromobenzoic acid

5




To 3-benzoylbenzoic acid (633 mg, 2.80 mmol, Aldrich) in CH_2Cl_2 (20 mL) was added DMF (20 μL) and oxalyl chloride (450 μL , 5.16 mmol). The mixture was stirred for 1.7 hours, and the solvent and excess oxalyl chloride were removed by rotary evaporation. The residue was dissolved in CH_2Cl_2 (20 mL), and methyl 2-amino-5-bromobenzoate (565 mg, 2.46 mmol, Avocado) in pyridine (6 mL) was added. The mixture was stirred overnight and then added to a separatory funnel with 100 mL of CH_2Cl_2 . This solution was washed with 2 X 100 mL of 1 M aqueous HCl and 100 mL of brine. The CH_2Cl_2 was evaporated in the presence of silica gel, and the product was purified by chromatography using a Biotage Flash 40 M silica cartridge with a gradient from 75% CH_2Cl_2 /heptane to 100% CH_2Cl_2 as eluent. Yield was 825 mg of white solid as the methyl ester. To a mixture of the corresponding methyl ester (645 mg, 1.47 mmol) in dioxane (20 mL) was added 1 M aqueous sodium hydroxide (3.0 mL). The mixture was stirred in a 50 $^\circ\text{C}$ oil bath for 2 hours. The reaction mixture was added to a separatory funnel with 100 mL of 1 M aqueous HCl, and the product was extracted into 100 mL of CH_2Cl_2 . The organics were washed with an additional 100 mL of 1 M aqueous HCl followed by 100 mL of water. They were then dried over MgSO_4 and evaporated. The residue was recrystallized from hot ethanol/THF. The solids were washed with ethanol followed by pentane and then dried at 100 $^\circ\text{C}$ under vacuum yielding 329 mg of white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 12.17 (s, 1 H), 8.61 (d, J = 9.2 Hz, 1 H), 8.31 (s, 1 H), 8.23 (d, J = 7.6 Hz, 1 H), 8.12 (d, J = 2.0 Hz, 1 H), 7.99 (d, J = 7.6 Hz, 1 H), 7.87 (dd, J = 9.2, 2.5 Hz, 1 H), 7.77-7.82 (m, 3 H), 7.73 (t, J = 7.4 Hz, 1 H), 7.61 (t, J = 7.6 Hz, 2 H).

5-Bromo-2-({3-[hydroxy(phenyl)methyl]benzoyl}amino)benzoic acid



Solid sodium borohydride (82 mg, 2.2 mmol) was added in one portion to a slurry of methyl 2-[(3-benzoylbenzoyl)amino]-5-bromobenzoate (826 mg, 1.88 mmol) in 40 mL of 1:1 methanol/THF. The mixture was stirred for 75 minutes before being quenched by the addition of 1 M aqueous HCl (50 mL). The organics were removed by rotary evaporation, and the product was extracted into 100 mL + 50 mL of CH₂Cl₂. The CH₂Cl₂ was evaporated in the presence of silica gel, and the product was purified by chromatography using a Biotage Flash 40 M silica cartridge with a gradient from CH₂Cl₂ to 5% EtOAc/CH₂Cl₂ as eluent. Yield was 433 mg of white solid as the methyl ester. To a mixture of the corresponding methyl ester (348 mg, 0.788 mmol) in dioxane (20 mL) was added 1 M aqueous sodium hydroxide (1.5 mL). The mixture was stirred at room temperature overnight and then heated in a 50 °C oil bath for 30 minutes. The reaction mixture was added to a separatory funnel with 100 mL of 1 M aqueous HCl, and the product was extracted into 100 mL of CH₂Cl₂. The organics were washed with an additional 100 mL of 1 M aqueous HCl followed by 100 mL of water. They were then dried over MgSO₄ and evaporated. The residue was recrystallized from hot ethanol (10 mL). The solids were washed with ethanol followed by pentane and then dried at 100 °C under vacuum yielding 130 mg of white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.12 (s, 1 H), 8.66 (d, *J* = 8.7 Hz, 1 H), 8.13 (d, *J* = 2.5 Hz, 1 H), 8.05 (s, 1 H), 7.85 (dd, *J* = 9.2, 2.5 Hz, 1 H), 7.79 (d, *J* = 7.6 Hz, 1 H), 7.62 (d, *J* = 8.1 Hz, 1 H), 7.51 (t, *J* = 7.6 Hz, 1 H), 7.42 (d, *J* = 7.1 Hz, 2 H), 7.32 (t, *J* = 7.6 Hz, 2 H), 7.22 (t, *J* = 7.1 Hz, 1 H), 6.07 (br s, 1 H), 5.81 (s, 1 H).

5-Bromo-2-({3-[(methoxyimino)(phenyl)methyl]benzoyl}amino)benzoic acid (PHA-522146)



Methyl 2-[(3-benzoylbenzoyl)amino]-5-bromobenzoate (763 mg, 1.74 mmol) was dissolved in 60 mL of 1:1 EtOH/pyridine with warming. After this solution was allowed to cool, solid O-methylhydroxylamine hydrochloride (350 mg, 4.19 mmol, Aldrich) was added in one portion. The resulting slurry was stirred at room

5 temperature for 6 days, after which it was a solution. The solvents were removed by rotary evaporation, and the residue was dissolved in 100 mL of CH₂Cl₂. This solution was washed with 2 X 100 mL of 1 M aqueous HCl and 100 mL of brine. The CH₂Cl₂ was dried over MgSO₄ and evaporated leaving 785 mg of white solid that was approximately a 1:1 mixture of oxime isomers by ¹H NMR. To a mixture of the


10 corresponding methyl ester (470 mg, 1.01 mmol) in dioxane (15 mL) was added 1 M aqueous sodium hydroxide (2.0 mL). The mixture was stirred at room temperature overnight. The reaction mixture was added to a separatory funnel with 100 mL of 1 M aqueous HCl, and the product was extracted into 100 mL of CH₂Cl₂. The organics were washed with an additional 100 mL of 1 M aqueous HCl followed by 100 mL of

15 water. They were then dried over MgSO₄ and evaporated. The orange residue was recrystallized from hot ethanol (10 mL). The solids were washed with ethanol followed by heptane and then dried at 100 °C under vacuum yielding 255 mg of white solid that was approximately a 1:1 mixture of oxime isomers by ¹H NMR. Due to the presence of 2 isomers, the NMR is difficult to assign. At 400 MHz in DMSO-*d*₆, the

20 amide protons appear as singlets at 12.10 and 12.07 ppm. The aromatic protons appear between 7.32 and 8.63 ppm. The methyl peaks appear as singlets at 3.93 and 3.92 ppm.

25

5-cyano-2-[[3-(cyclopentylcarbonyl)benzoyl]amino]benzoic acid



tert-Butyl 5-cyano-2-[(3-iodobenzoyl)amino]benzoate (1.0 g, 2.23 mmol) was dissolved in 20 ml of CH₂Cl₂. Hexamethylditin (1.1 g, 3.35 mmol) and allylpalladium chloride dimer (73 mg, 0.2 mmol) were then added and the mixture stirred at room temperature for 5 hr. The reaction was diluted with CH₂Cl₂ then washed with water.

- 5 The organic solution was dried over Na₂SO₄ and concentrated *in vacuo*. The remaining oil was purified via silica gel chromatography to give 670 mg (62%) of the desired tin compound. This product was subsequently dissolved in 15 mL of THF. To this was added DIPEA (1 mL), Pd₂dba₃ (115 mg, .125 mmol) and cyclopentanecarbonyl chloride (230 mg 1.73 mmol). The reaction was then warmed
- 10 to 60 °C and stirred for 10 additional hr. After cooling to room temperature the reaction was poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The organic solution was dried over Na₂SO₄ and concentrated *in vacuo*. The remaining residue was purified via silica gel chromatography, giving 415 mg (72%) of the desired ketone. The ketone was treated with CH₂Cl₂/TFA and stirred for 10
- 15 additional hours. The solvent was removed *in vacuo* and the remaining solid was recrystallized from MeOH to give the title compound (329 mg, 91%) as a white solid. ¹H NMR (400 MHz, DMSO) 1.62-1.67 (m, 4H), 1.73-1.80 (m, 2H), 1.92-1.98 (m, 2H), 3.90 (quint, 1H), 7.77 (t, 1H), 8.11 (dd, 1H), 8.19 (d, 1H), 8.27 (d, 1H), 8.41 (d, 1H), 8.53 (s, 1H), 8.84 (d, 1H), 12.55 (s, 1H)

20


Other compounds produced via the above-described methodology using appropriate starting materials and making non-critical variations include:

- 2-[(3-Benzoylbenzoyl)amino]-5-chlorobenzoic acid
- 2-[(4-Acetylbenzoyl)amino]-5-bromobenzoic acid
- 25 2-[(4-Benzoylbenzoyl)amino]-5-bromobenzoic acid
- 2-[(3-Acetylbenzoyl)amino]-5-bromobenzoic acid
- 5-Bromo-2-({3-[(hydroxyimino)(phenyl)methyl]benzoyl}amino)benzoic acid
- (+)-5-Bromo-2-({3-[hydroxy(phenyl)methyl]benzoyl}amino)benzoic acid
- (-)-5-bromo-2-({3-[hydroxy(phenyl)methyl]benzoyl}amino)benzoic acid
- 30 **2-[(3-Benzoylbenzoyl)amino]-5-nitrobenzoic acid**
- 2-[(3-Benzoylbenzoyl)amino]-5-cyanobenzoic acid**
- 5-Cyano-2-({3-[(hydroxyimino)(phenyl)methyl]benzoyl}amino)benzoic acid**
- 5-Cyano-2-({3-[(methoxyimino)(phenyl)methyl]benzoyl}amino)benzoic acid**

Solid Phase Synthesis

Additional methodologies for producing compounds of this invention are shown below.

5 Scheme 3.1




R_3 is a C_{1-4} alkyl optionally substituted with 1-3 halo, -OH, NO_2 , or -CN.

Development of a solid phase route to ketones **1** was effected by a similar route and is summarized in Scheme 3.2. Chlorine was selected as the anthranilic acid 5-substituent instead of the 5-bromine of the ketone leads in order to avoid the potential for competing reactions in the ensuing palladium-catalyzed stannylation. Solid-supported aryl halide **8** was prepared by reaction of chloroisatoic anhydride with Wang resin. Coupling with halo ($\text{X} = \text{Br}$ or I) aryl chlorides then afforded

benzamides **9**, which were stannylated with hexamethyl distannane under the influence of palladium catalyst using the same conditions that were applied in Scheme 3.1. The subsequent carbonylation reactions were found to be optimal using the slightly modified conditions of Ellman.⁸ Eliminating the ligand altogether and adding potassium carbonate as another proton scavenger slightly enhanced the rate of the reactions and the product purities in the end. Carbon monoxide was not necessary to eliminate aryl-aryl coupling by-products. One other modification in the synthetic conditions was to decrease the amount of TFA used in the cleavage cocktail in order to avoid trace amounts of a cleavage impurity.


Scheme 3.2




Generation of Oximes and Amines from Solid-Supported Ketones

Chemistry was developed for amine (**12**) and oxime (**13**) derivatization of the ketones on solid-phase (Scheme 3.3). Following TFA cleavage (Scheme 3.4), the amines could be successfully purified by trapping the products on sulfonic acid resin and then washing off with 2 N NH₄OH/methanol. The remaining compounds were subjected to preparative HPLC purification.

Scheme 3.3



Scheme 3.4



5

Ketones

Step 1: Preparation of 8

- 10 To 4.5 grams of Wang resin (Irori Unisphere, 1.36 mmol/g loading, 6.12 mmol) in a 125 mL serum bottle, 60 mL of DMF were added followed by 6.1 grams (5 eq., 30.6 mmol) of 5-chloroisotoic anhydride and 3.74 grams (5 eq., 30.6 mmol) of 4-dimethylaminopyridine. The serum bottle was purged with nitrogen, capped, and shaken on an orbital mixer at 60 °C. Initially, the reagent cocktail was not
- 15 homogeneous, but after several hours, a concentrated solution had formed around the swelled resin. After 18 hours, the reaction slurry was cooled and transferred to a 60 mL syringe-barrel reaction vessel. The reagent cocktail was then drained and the resin washed as follows: 3 X (acetonitrile, DMF), then 3 X (acetonitrile, methylene chloride). The resin was treated a second time with 60 mL of DMF, 6.1 grams (5 eq.,
- 20 30.6 mmol) of 5-chloroisotoic anhydride, and 3.74 grams (5 eq., 30.6 mmol) of 4-dimethylaminopyridine. Following mixing at 60 °C for 6 hours, the reagent cocktail was again drained and the resin washed as above. In a vacuum oven at 25 °C, the resin was dried for 72 hours to give a final weight of 5.36 grams (1.14 mmol/g loading).

Step 2: Preparation of 9

To 6.7 mmol of the halo benzoic acids suspended in 20 mL of methylene chloride, 20 μ L of DMF and 1.17 mL (1.7 grams, 13.4 mmol, 2 eq.) of oxalyl chloride were added.

5 The flasks were sealed and stirred with occasional release of gas build-up. After stirring overnight, the reaction mixtures had become almost completely homogeneous with no more gas build-up. Solvent and excess oxalyl chloride were then evaporated *in vacuo* to dryness. The acid chlorides were re-dissolved in 10 mL of methylene chloride and added to 1 gram of resin 8 (1.14 mmol/gram loading, 1.14 mmol)

10 swollen with 10 mL of pyridine in 25 mL vials. Some fuming was observed initially. The mixtures were purged with nitrogen for 10 seconds then the vials capped, and the mixtures shaken at room temperature for 4 hours. By that time, the resins had taken on a light orange color and a tan precipitate had formed in the supernatant. The reagent solutions were then drained in syringe-barrel reaction vessels and the resins

15 rinsed five times with alternating acetonitrile and methylene chloride washes. The resins were kept wet with methylene chloride until used in the next step. Cleavage aliquots (40 % TFA/CH₂Cl₂) had purities of > 80% by HPLC and were registered as PHA compounds (Table 1).

20 Step 3: Preparation of 10

A stock solution of palladium acetate (0.1 eq., 0.01 mmol, 0.0022 g per 1 mL), triphenylphosphine (0.25 eq., 0.025 mmol, 0.0065 g per 1 mL), and diisopropylethylamine (0.5 eq., 0.05 mmol, 0.0065 g, 0.0087 mL per 1 mL) in 6.5 mL DMF (degassed with N₂) was prepared. To each of the resins (9) in 8 mL vials, 1 mL

25 of stock catalyst solution was added, followed by 0.042 mL of hexamethyl ditin (2.0 eq., 0.2 mmol, 0.065 g). Each vial was purged with nitrogen and then capped. The reaction mixtures were then heated to 60 °C and mixed in an orbital shaker for 17 h. By that time, the resins had all turned black in color. Following cooling, the reaction mixtures were transferred to filter vessels, and reagents were drained. This was

30 followed by washing three times with DMF, three times with alternating acetonitrile/DMF, three times with alternating acetonitrile/methylene chloride, and twice with THF. Cleavage aliquots were taken (cleaved in 40/60 TFA/CH₂Cl₂) to check for completion of reaction by monitoring the protodestannylation products.

Step 4: Preparation of 11

To each of the 8 mL vials holding resins **10**, 2 mL of a THF (degassed with carbon monoxide) stock solution containing: 0.0046 g of tris (dibenzylidene acetone)
5 dipalladium (0) (0.05 eq., 0.005 mmol, per 2 mL THF); 0.0052 g of triphenylphosphine (0.2 eq, 0.02 mmol, per 2 mL THF); and 0.139 mL diisopropyl ethylamine (8 eq., 0.80 mmol, 0.103 g, 0.139 mL per 2 mL) were added. Commercially available acid chlorides (8 eq., 0.8 mmol) were then added. The reaction vessels were purged with carbon monoxide, capped and shaken at 60 °C for
10 18 h. When cool, the reaction mixtures were filtered through fritted syringe barrels, then the resins rinsed six times with alternating acetonitrile/methylene chloride washes and dried under vacuum at room temperature.

Step 5: Preparation of 1

15 To each of the fritted vessels containing resins **11**, 2 mL of the cleavage cocktail (40/60 TFA/CH₂Cl₂) were added and the mixtures swirled for 45 minutes. Cleavage filtrates were then collected in tared vials followed by stripping of solvents *in vacuo*. The residues were analyzed by HPLC and ESMS separately. The library was then purified by preparative HPLC. Results for the library both pre- and post-purification
20 are compiled in Table 5.

Preparation of Oximes 13

Ketone precursors to the oxime derivatives were produced as shown above. To 0.1 gram (~0.12 mmol) of the ketone resins **11** in a 48 well Robbins Block, 2 mL of
25 pyridine were added followed by 10 equivalents (1.2 mmol) of each alkoxyamine (hydroxylamine hydrochloride; methoxyamine hydrochloride; o-benzyloxyamine hydrochloride; and o-allylhydroxylamine hydrochloride). The reaction block was sealed and mixed overnight at room temperature in the rotating oven. After 20 hours, the resins resins were drained and washed with 3 X (MeOH,
30 CH₂Cl₂) and 3 X (MeCN, CH₂Cl₂). Methanol was used early in the wash cycle because MeCN and CH₂Cl₂ left a precipitate in the supernatant at that point. Treatment of the resins with 40 % TFA/CH₂Cl₂ for 45 minutes afforded crude

products. Four of the library compounds (shown in Table 3) were then successfully purified (>90 % pure) via LC/MS.

Amine Derivatives

Preparation of Amines 12

Into four 8 mL vials containing 0.1 grams (~0.12 mmols) of ketone resin **11**, 1.5 mL of toluene along with 0.12 grams (0.42 mmol) of titanium isopropoxide and 2.5 equivalents (0.30 mmol) of each respective amine were added. The vials were purged with nitrogen, sealed with teflon-lined caps, and mixed at room temperature for 16 hours on an orbital shaker. At that time, 0.5 mL of THF, 0.1 mL of acetic acid, and 0.24 grams (1.14 mmol) of sodium triacetoxyborohydride were added and the slurry was mixed at room temperature. After 4 hours, the reagents were drained and the resin washed: 3 X (MeOH, DMF), 4X (MeOH, CH₂Cl₂). Treatment of the resin with 40 % TFA/CH₂Cl₂ for 45 minutes afforded crude products in the purities included in Table 6. Crude product identities were confirmed by ES/MS.

Step 1: Preparation of 8

To 10.0 grams of Wang resin (Irori Unisphere, 1.36 mmol/g loading, 13.6 mmol) in a 250 mL serum bottle, 90 mL of DMF were added followed by 13.4 grams (5 eq., 68 mmol) of 5-chloroisotoic anhydride and 8.3 grams (5 eq., 68 mmol) of 4-dimethylaminopyridine. The serum bottle was purged with nitrogen, capped, and shaken on an orbital mixer at 60 °C. Initially, the reagent cocktail was not homogeneous, but after several hours, a concentrated solution had formed around the swelled resin. After 18 hours, the reaction slurry was cooled and transferred to a 60 mL syringe-barrel reaction vessel. The reagent cocktail was then drained and the resin washed as follows: 3 X (acetonitrile, DMF), then 3 X (acetonitrile, methylene chloride). The resin was treated a second time with 90 mL of DMF, 13.4 grams (5 eq., 68 mmol) of 5-chloroisotoic anhydride, and 13.4 grams (5 eq., 68 mmol) of 4-dimethylaminopyridine. Following mixing at 60°C for 6 hours, the reagent cocktail was again drained and the resin washed as above. In a vacuum oven at 25°C, the resin was dried for 72 hours to give a final weight of 10.46 grams (1.30 mmol/g loading).

Step 2: Preparation of 9 (R = H)

To 6.2 grams (25 mmol) of the meta- and para- iodo benzoic acids suspended in 70 mL of methylene chloride, 40 μ L of DMF and 4.4 mL (6.35 grams, 50 mmol, 2 eq.) of oxalyl chloride were added. The serum bottles were sealed and stirred with occasional release of gas build-up. After stirring for 5 hours, the reaction mixtures had become almost completely homogeneous with no more gas build-up. Solvent and excess oxalyl chloride were then evaporated *in vacuo* to dryness. The acid chlorides were re-dissolved in 30 mL of methylene chloride and added to 4 gram of resin **8** (1.30 mmol/gram loading, 5.2 mmol) swollen with 30 mL of pyridine in 125 mL serum bottles. Some fuming was observed initially. The mixtures were purged with nitrogen for 10 seconds then the vials capped, and the mixtures shaken at room temperature for 4 hours. By that time, the resins had taken on a light orange color and a tan precipitate had formed in the supernatant. The reagent solutions were then drained in syringe-barrel reaction vessels and the resins rinsed five times with alternating acetonitrile and methylene chloride washes. The resins were then dried *in vacuo* to afford 5.14 g of the meta-iodo product and 5.09 g of the para-iodo product. Cleavage aliquots were >95 % pure by HPLC, with their identities confirmed by ESMS.

Step 3: Preparation of **10** (R = H)

A stock solution of palladium acetate (0.012 M), triphenylphosphine (0.03 M), and diisopropylethylamine (0.06 M) in 80 mL DMF (degassed with N₂) was prepared. To 4.0 grams (~5.0 mmol) of each resin (**9**) in 125 mL serum bottles, 40 mL of the stock catalyst solution were added, followed by 2.0 mL of hexamethyl ditin (2.0 eq., 9.6 mmol, 3.14 g). Each bottle was purged with nitrogen and then capped. The reaction mixtures were then heated to 60 °C and mixed in an orbital shaker for 17 h. By that time, the two resins had turned black in color. Following cooling, the reaction mixtures were transferred to filter vessels, and reagents were drained. This was followed by washing three times with DMF, three times with alternating acetonitrile/DMF, three times with alternating acetonitrile/methylene chloride, and twice with THF. Cleavage aliquots were taken (cleaved in 40/60 TFA/CH₂Cl₂) to check for completion of reaction by monitoring the protodestannylation products. Following cleavage, the meta-substituted resin gave 87 % of the expected destannylated product by HPLC, while the para-substituted isomer gave 70 %. Little

to no iodide starting material remained. The major impurity in both cases was an unidentified peak with $[M+H]^+ = 369$ m/z.

Step 4: Preparation of **11**

5 To each carboxylic acid weighed into a 20 mL vial (2.88 mmol), 6.5 mL of THF, 10 μ L of DMF, and 0.293 ml of oxalyl chloride (0.95 eq., 2.7 mmol, 3.35 g) were added. The vials were sealed and reaction mixtures shaken at room temperature for 4 hours with occasional release of evolved gas. In the meantime, the two stannylated resins (**10**) were distributed into Irori minikans (60 mg per kan), and the 72 kans were then
10 distributed into twelve 125 mL serum bottles (six kans per bottle). To each of the bottles, 20 mL of a nitrogen degassed THF stock solution containing: tris (dibenzylidene acetone) dipalladium (0) (0.001 M); potassium carbonate (0.02 M); and diisopropyl ethylamine (0.10 M) were added. The THF solutions of acid chlorides (2.88 mmol, 6 eq.) were then added to their respective set of six bottles. The
15 capped reaction vessels were purged with nitrogen, degassed, and shaken at 65 °C for 18 h. When cool, the resin containing kans were rinsed five times with alternating acetonitrile/ methylene chloride washes and dried under vacuum at room temperature. A cleavage aliquot revealed that ketone formation had gone to completion.

20 Step 5a: Preparation of Resin-Bound Amines **12**

To a 125 mL serum bottle containing 24 Irori cans loaded with resin **11**, 30 mL of toluene were added, followed by 1.23 grams (6.0 mmol, 3.5 eq.) of titanium isopropoxide and 0.25 grams (4.3 mmol, 2.5 eq.) of propyl amine. The bottle was
25 degassed to remove air bubbles from the Irori kans, then purged with nitrogen, sealed and mixed for 17 hours at room temperature. At that time, 10 mL of toluene, 2 mL of acetic acid, and 3.5 grams (16.3 mmol, 9.5 eq.) of sodium triacetoxy borohydride were added, and bottle re-purged and sealed, and mixed for 14 hours. Reagents were then drained and the resins washed three times with methanol and five times with
alternating methanol/methylene chloride.

30

Step 5b: Preparation of Resin-Bound Oximes **13**

To a 125 mL serum bottle containing 24 Irori kans loaded with resin **11**, 40 mL of pyridine were added followed by 1.2 grams (17.2 mmols, 10 eq.) of hydroxylamine

hydro chloride. . The bottle was degassed to remove air bubbles from the Irori kans, then purged with nitrogen, sealed and mixed for 17 hours at room temperature. At that time, reagents were drained and the resins were washed three times with methanol, and five times with alternating methanol/methylene chloride.

5

Step 6: Preparation of 15

The 72 kans containing resins **12,13** were distributed into tared 8 mL vials and treated with 3 mL of TFA/CH₂Cl₂ (40/60). The vials were degassed, capped, and mixed at room temperature for 1.5 hours. The kans were then plucked out of the vials using a
10 syringe needle and washed with another 1 mL of CH₂Cl₂. Solvent in the vials was evaporated *in vacuo* (Genevac), leaving product residue.

Preparation of 5-iodoisatoic anhydride

To a red-brown solution of 2-amino-5-iodobenzoic acid (25 grams, 95 mmol) in 300
15 mL of dioxane, 9.58 grams (32.3 mmol) of triphosgene were carefully added. The resulting slurry was refluxed for 4 hours. By that time, all starting material had disappeared by HPLC. The solid product was then filtered, washed once with ethyl ether, then dried overnight in a vacuum oven at 40 °C. The tan colored needles amounted to 22.9 grams (83 %). HPLC (MRH1 method): $t_R = 2.15$ min. (100 %); ¹H
20 NMR (400 MHz, DMSO-*d*₆) δ 8.12 (s, 1 H), 8.00 (d, J = 8.6 Hz, 1 H), 6.95 (d, J = 8.5 Hz, 1 H); MS (ES) m/z (rel. intensity) 288 (M-, 100), 244 (5), 289 (5); 577 (10).

Preparation of 6-Chloroindoline

In a 250 mL round bottom flask, 12.4 grams of sodium cyanoborohydride (198 mmol,
25 2 eq.) were added portion-wise over 5 minutes to a solution of 15 grams (98.9 mmol) of 6-chloroindole. After stirring for 22 hours, the mixture had become a brown solution and analysis by HPLC (MRH 1 method) revealed no starting material remaining and a mixture of two product peaks. The mixture was diluted with 100 mL of water, then made basic with ~200 mL of 6N sodium hydroxide. The desired
30 product was extracted into 3 X 400 mL of methylene chloride. The extracts were then dried over anhydrous magnesium sulfate and evaporated *in vacuo* leaving a cloudy oil. The crude product was chromatographed over a plug of silica in 100 % methylene chloride giving a mixed fraction ($R_f = 0.9$ and 0.7), a pure product fraction ($R_f = 0.7$),


and a baseline fraction ($R_f = 0.0 - 0.2$). The pure fraction was evaporated to dryness *in vacuo* to yield a clear, colorless oil weighing 10.90 grams (72 %). It was stored at 4°C and saved for future use. ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 6.95 (d, $J = 5$ Hz, 1 H), 6.46 (d, $J = 5$ Hz, 2 H), 3.43 (t, $J = 6$, 2 H), 2.86 (t, $J = 6$, 2 H).

5

10 **Example 4: AMIDE DERIVATIVES**

Standard procedure for attaching 5-bromoanthranilic acid to hydroxymethyl styrene resin,:

15




To a slurry of 24.8 g (36.7 mmol) hydroxymethyl styrene resin in 1 L DMF was added 24 g (197 mmol) 4-dimethylamino pyridine and 50 g (207 mmol) 5-bromoisatoicanhydride. The mixture was stirred at 60 °C for 18 hours and room temperature for four hours. The mixture was then filtered and the resin washed repeatedly alternating with dichloromethane and DMF (3x) then repeatedly alternating with dichloromethane and methanol (3x) followed by methanol (3x). The resin was dried over night in a vacuum oven.

25


Resin 2 and 3:

Standard procedure for attaching 3 or 4- N-boc-amino benzoic acid to resin 1.




To 5.1 g (21.5 mmol) 3-N-boc-aminobenzoic acid in 200 mL of anhydrous THF was added 100 μ L DMF and 2.3 mL (25.8 mmol) oxalyl chloride in five portions over 20 minutes. After 40 minutes the mixture was concentrated in vacuo and then dissolved in 50 mL dichloromethane. This was added to a slurry of 3.79 g (4.32 mmol) resin 1 in 150 mL dichloromethane and 3.7 mL diisopropylethyl amine. The mixture was heated to reflux over night. The resin was then collected by vacuum filtration and washed repeatedly alternating with dichloromethane and methanol (4x) followed by methanol (3x) and dried in a vacuum oven. The same procedure was followed to
 10 prepare resin 3 from 4-N-boc-aminobenzoic acid.

Standard procedure for the acylation of resins 2 and 3 with acid chlorides, isocyanates, and isothiocyanates.




On average 55 mg (Ca. 0.055 mmol) resin was treated with 33% TFA in DCM for two hours. The resin was collected by filtration and washed repeatedly alternating with dichloromethane and methanol (4x) followed by methanol (3x) and dried in a vacuum oven. The resin is then treated with 0.6 mmol of the acylating reagent and 0.86 mmol diisopropylethyl amine in DCM and shaken over night. The resin was then collected by vacuum filtration and washed repeatedly alternating with dichloromethane and methanol (4x) followed by methanol (3x) and dried in a vacuum oven
 20

Standard procedure for the acylation of resins 2 and 3 with sulfonyl chlorides:



On average, to 60 mg (Ca. 0.06 mmol) resin in 2 mL DCM was added 10 equivalents of a sulfonyl chloride and 174 μ L (0.6 mmol) 2-tert-butylimino-2-diethyl-amino-1,3-dimethylperhydro-1,3,2-diazaphosphorine (BEMP). After mixing overnight, the resin was collected by vacuum filtration and washed repeatedly alternating with dichloromethane and methanol (4x) followed by methanol (3x) and dried in a vacuum oven. The resin was then treated with 2 mL of 40 % TFA in DCM for one hour and then collected by vacuum filtration and washed repeatedly alternating with dichloromethane and methanol (4x) followed by methanol (3x) and dried in a vacuum oven.

Standard cleavage procedure to provide products.



The resin was treated with 1.5 mL THF and 0.5 mL 1 N sodium hydroxide over night. The mixtures were filtered and the collected filtrate was treated with 250 mg of IR-120 acidic resin for 2.5 hours. The mixtures were filtered and the filtrates concentrated to provide the following products. If initial purity was less than 80 % by HPLC those products were purified by chromatography.

Several compounds were produced by the above-described methodologies.

2-{{3-(benzoylamino)benzoyl}amino}-5-bromobenzoic acid

5-bromo-2-{{3-(2-furoylamino)benzoyl}amino}benzoic acid

5-bromo-2-{{3-[(thien-2-ylacetyl)amino]benzoyl}amino}benzoic acid

- 5-bromo-2-({3-[(mesitylcarbonyl)amino]benzoyl}amino)benzoic acid
 5-bromo-2-({4-[(mesitylcarbonyl)amino]benzoyl}amino)benzoic acid
 2-({3-[(1,3-benzodioxol-5-ylcarbonyl)amino]benzoyl}amino)-5-bromobenzoic acid
 5-bromo-2-({3-[(2,4-dimethoxybenzoyl)amino]benzoyl}amino)benzoic acid
 5 5-bromo-2-[(3-{{(phenylthio)acetyl}amino}benzoyl)amino]benzoic acid
 5-bromo-2-({3-[(methoxyacetyl)amino]benzoyl}amino)benzoic acid
 2-({3-[(anilino)carbonyl]amino)benzoyl}amino)-5-bromobenzoic acid
 5-bromo-2-{{3-{{(2,4-difluorophenyl)amino}carbonyl}amino)benzoyl}amino}benzoic acid
 10 5-bromo-2-{{3-{{[(3-cyanophenyl)amino]carbonyl}amino)benzoyl}amino}benzoic acid
 5-bromo-2-{{3-{{[(3-chlorophenyl)amino]carbonyl}amino)benzoyl}amino}benzoic acid
 5-bromo-2-({3-{{[(3-(methylthio)phenyl)amino}carbonyl]amino}benzoyl}amino)benzoic acid
 15 2-{{3-{{[(3-acetylphenyl)amino]carbonyl}amino)benzoyl}amino}-5-bromobenzoic acid
 5-bromo-2-({4-[(phenylsulfonyl)amino]benzoyl}amino)benzoic acid
 5-bromo-2-{{3-{{[(4-(trifluoromethoxy)phenyl)sulfonyl]amino}benzoyl}amino}benzoic acid
 20 5-bromo-2-{{4-{{[(4-(trifluoromethoxy)phenyl)sulfonyl]amino}benzoyl}amino}benzoic acid
 5-bromo-2-[(4-{{[(3,4-dichlorophenyl)sulfonyl]amino}benzoyl}amino)benzoic acid
 5-bromo-2-({4-[(thien-2-ylacetyl)amino]benzoyl}amino)benzoic acid
 25 5-bromo-2-({3-[(5-nitro-2-furoyl)amino]benzoyl}amino)benzoic acid
 5-bromo-2-({4-[(5-nitro-2-furoyl)amino]benzoyl}amino)benzoic acid
 5-bromo-2-{{4-{{[(2,4-difluorophenyl)amino]carbonyl}amino)benzoyl}amino}benzoic acid
 5-bromo-2-{{3-{{[(3,5-dichlorophenyl)amino]carbonyl}amino)benzoyl}amino}benzoic acid
 30 5-bromo-2-{{3-{{[(5-chloro-2-methoxyphenyl)amino]carbonyl}amino)benzoyl}amino}benzoic acid

5-bromo-2-{{3-({[(4-phenoxyphenyl)amino]carbonyl}amino)benzoyl}amino}benzoic acid

5-bromo-2-{{4-({[(4-phenoxyphenyl)amino]carbonyl}amino)benzoyl}amino}benzoic acid

5 2-{{3-({[(4-acetylphenyl)amino]carbonyl}amino)benzoyl}amino}-5-bromobenzoic acid

5-bromo-2-{{4-({[(4-nitrophenyl)amino]carbonothioyl}amino)benzoyl}amino}benzoic acid

10 5-bromo-2-{{3-({[(2-(trifluoromethyl)phenyl)amino]carbonothioyl}amino)benzoyl}amino}benzoic acid

5-bromo-2-{{3-({[(3,4,5-trimethoxyphenyl)amino]carbonothioyl}amino)benzoyl}amino}benzoic acid

5-bromo-2-{{3-({[(3-(methylthio)phenyl)amino]carbonothioyl}amino)benzoyl}amino}benzoic acid

15 2-{{3-({[(3-acetylphenyl)amino]carbonothioyl}amino)benzoyl}amino}-5-bromobenzoic acid

5-bromo-2-{{3-({[(phenylsulfonyl)amino]benzoyl}amino)benzoic acid


5-bromo-2-{{3-({[(3,4-dichlorophenyl)sulfonyl]amino)benzoyl}amino}benzoic acid

5-bromo-2-{{4-({[(4-methylphenyl)sulfonyl]amino)benzoyl}amino}benzoic acid


20

Analogues with an alternative linkage, such as ureas, in place of the sulfonamides described in Example 1 were also synthesized.

Scheme 4.1




25

Methyl 4-[(2,3-dihydro-1H-indol-1-ylcarbonyl)amino]benzoate

Methyl-4-aminobenzoate (1.00 g, 7.29 mmol) in DCM (50 mL) was slowly added to a solution of phosgene (1.93 M /toluene, 7.5 mL, 14.5 mol, 2.0 equiv) in DCM (200
 5 mL) at 0°C, followed by the addition of diisopropylethyl amine (1.14 mL, 6.56 mmol, 0.9 equiv). The mixture was allowed to warm to rt, then stirred for 1 h, and then concentrated in vacuo to ca 5 mL. The suspension was redissolved in DCM followed by the addition of indoline (2.45 mL, 21.87 mmol, 3.0 equiv) and diisopropylethyl amine (1.14 mL, 6.56 mmol, 0.9 equiv). The resulting mixture was stirred for 2h, at
 10 rt, then washed with 1N HCl, brine, dried (MgSO₄) filtered and concentrated in vacuo. The residue was recrystallized from EtOH to afford 1.67 g of **5.7** as a white solid.

¹H NMR (300 MHz, CDCl₃) δ 8.04-8.01 (m, 2 H), 7.90 (d, *J* = 7.9 Hz, 1 H), 7.58-7.55 (m, 2 H), 7.28-7.20 (m, 2 H), 7.01 (t, *J* = 8.2 Hz, 1 H), 6.70 (s, 1 H), 4.12 (t, *J* = 8.3 Hz, 2 H), 3.91 (s, 3 H), 3.26 (t, *J* = 8.2 Hz, 2 H).


15

4-[(2,3-Dihydro-1H-indol-1-ylcarbonyl)amino]benzoic acid

Methyl 4-[(2,3-dihydro-1H-indol-1-ylcarbonyl)amino]benzoate (1.30 g, 4.37 mmol) was placed in dioxane (50 mL) with 5 N NaOH (10 mL) and the resulting solution was heated at 70 °C for 7h. The reaction was cooled to rt, acidified, diluted with EtOAc and washed with H₂O, brine, dried (MgSO₄) filtered and concentrated in vacuo. The residue was recrystallized from EtOH to afford 776 mg (63%) of a white solid.

¹H NMR (300 MHz, DMSO-*d*₆) δ 8.82 (s, 1 H), 7.87 (d, *J* = 8.6 Hz, 3 H), 7.71 (d, *J* = 8.7 Hz, 2 H), 7.22-7.14 (m, 2 H), 6.92 (t, *J* = 7.3 Hz, 1 H), 4.16 (t, *J* = 8.4 Hz, 2 H), 3.18 (t, *J* = 8.5 Hz, 2 H).

5-Bromo-2-({4-[(2,3-dihydro-1H-indol-1-ylcarbonyl)amino]benzoyl}amino)benzoic acid, PNU-290877




4-[(2,3-dihydro-1H-indol-1-ylcarbonyl)amino]benzoic acid (627 mg, 2.22 mmol) was dissolved in DCM (30 mL) followed by the addition of oxalyl chloride (490 µL, 5.55 mmol, 2.5 equiv) and DMF (30 µL). The mixture was stirred for 1h, then diluted with heptane (10 mL), concentrated in vacuo to dryness. The residue was redissolved in DCM (50 mL) followed by the addition of methyl-2-amino-5-bromo benzoate (510 mg, 2.2 mmol, 1.0 equiv.) and pyridine (360 µL, 4.4 mmol, 2.0 equiv.) The reaction was stirred for 3 h at rt, then washed with 1 N HCl, 1 N NaOH, H₂O, brine, dried (MgSO₄) filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (heptane/ EtOAc 19/1, 9/1, 4/1, 1/1, 0/1) to afford 198 mg (18%) of a white solid as the methyl ester. The ester (177 mg, 0.35 mmol) was dissolved in dioxane (10 mL) followed by the addition of 5 N NaOH (5 mL). The reaction was

stirred for 3h at rt, diluted with EtOAc, washed with 1 N HCl, brine, dried (MgSO₄), filtered and concentrated in vacuo. The residue was recrystallized from EtOH to afford 76 mg (44%) of a white solid.

¹H NMR (300 MHz, DMSO-*d*₆) δ 8.88 (s, 1 H), 8.69 (d, *J* = 9.0 Hz, 1 H), 8.13 (d, *J* = 2.4 Hz, 1 H), 7.86-7.78 (m, 6 H), 7.21-7.14 (m, 2 H), 6.93 (t, *J* = 8.6 Hz, 1 H), 4.17 (t, *J* = 8.2 Hz, 2 H), 3.19 (t, *J* = 8.2 Hz, 1 H).

Example 5: ALKYL DERIVATIVES


10 Preparation of 3-(Phenylethynyl)benzoic acid




A flask containing ethyl 3-iodobenzoate (2.21g, 8.00 mmol, Lancaster), copper (I) iodide (550 mg, 2.88 mmol, Alfa), and tetrabutylammonium iodide (5.9 g, 16 mmol, Aldrich) was placed under argon. DMF (40 mL), diisopropylethylamine (4.5 mL, 26 mmol, Aldrich), and tri-*t*-butylphosphine (1.8 g of 10 wt% solution in hexane, 0.89 mmol, Strem) were added by syringe. Tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct (220 mg, 0.21 mmol, Aldrich) was added as a solid under a flow or argon. The mixture was stirred for 5 minutes, and phenylacetylene (0.88 mL, 8.0 mmol, Lancaster) was added by syringe. After 40 minutes, the mixture was added to a separatory funnel with 200 mL of saturated aqueous NaHCO₃. Product was extracted into 3 X 100 mL of EtOAc. The combined EtOAc was washed with 4 X 200 mL of water and then dried over MgSO₄. Product was adsorbed onto silica and purified by chromatography using a Biotage Flash 40 M silica cartridge with a gradient from 25% - 40% CH₂Cl₂ in heptane. The ethyl 3-(phenylethynyl)benzoate was isolated as 1.82 g of brown oil that was contaminated with tri-*t*-butylphosphine. 990 mg of this oil was dissolved in dioxane (15 mL) and treated with 1 M aqueous sodium hydroxide (6 mL), and the mixture was stirred for 3.5 hours. It was then added to a separatory funnel with 100 mL of 1 M aqueous HCl and 100 mL of CH₂Cl₂. A few milliliters of THF were added to help with solubility. The organics were washed with an additional 100 mL of HCl followed by 100 mL of water and then dried over MgSO₄. Solvent was removed leaving 782 mg of tan solid that was still contaminated with phosphine.

Most of this material was carried on without further purification. For the purposes of characterization, the remainder was recrystallized from ethanol/heptane yielding a white solid.

5 **5-Bromo-2-{{3-(phenylethynyl)benzoyl}amino}benzoic acid**




To 3-(phenylethynyl)benzoic acid (569 mg, 2.56 mmol) in CH_2Cl_2 (20 mL) was added DMF (40 μL) and oxalyl chloride (450 μL , 5.16 mmol). The mixture was stirred for 2.5 hours, and the solvent and excess oxalyl chloride were removed by rotary evaporation. The residue was dissolved in CH_2Cl_2 (15 mL), and methyl 2-amino-5-bromobenzoate (504 mg, 2.19 mmol, Avocado) in pyridine (6 mL) was added. The mixture was stirred overnight and then added to a separatory funnel with 100 mL of CH_2Cl_2 . This solution was washed with 2 X 100 mL of 1 M aqueous HCl and 100 mL of brine. The CH_2Cl_2 was evaporated in the presence of silica gel, and the product was purified by chromatography using a Biotage Flash 40 M silica cartridge with a gradient from 50% - 60% CH_2Cl_2 in heptane as eluent. Yield was 694 mg of white solid as the methyl ester. To a mixture of the methyl ester (485 mg, 1.12 mmol) in dioxane (15 mL) was added 1 M aqueous sodium hydroxide (2.2 mL). The mixture was stirred for 2.75 hours. The reaction mixture was added to a separatory funnel with 100 mL of 1 M aqueous HCl, and the product was extracted into 100 mL of CH_2Cl_2 . The CH_2Cl_2 was washed with an additional 100 mL of 1 M aqueous HCl followed by 100 mL of water. It was then dried over MgSO_4 and evaporated. The residue was recrystallized from hot ethanol/THF. The solids were washed with ethanol followed by heptane and then dried at 100 $^\circ\text{C}$ under vacuum yielding 295 mg of white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 12.06 (s, 1 H), 8.60 (d, $J = 9.2$ Hz, 1 H), 8.12 (d, $J = 2.0$ Hz, 1 H), 8.10 (s, 1 H), 7.97 (d, $J = 7.6$ Hz, 1 H), 7.87 (dd, $J = 9.2$, 2.5 Hz, 1 H), 7.83 (d, $J = 8.1$ Hz, 1 H), 7.66 (t, $J = 7.6$ Hz, 1 H), 7.59-7.63 (m, 2 H), 7.45-7.48 (m, 3 H).

Preparation of 3-(2-Phenylethyl)benzoic acid

A mixture of 3-(phenylethynyl)benzoic acid (418 mg, 1.88 mmol) and palladium on carbon (315 mg, 10%, Aldrich) in 1:1 methanol/THF (20 mL) was stirred under 1
 5 ATM of hydrogen overnight. The mixture was then filtered through a plug of celite and concentrated yielding 406 mg of white solid. This material was carried forward without further purification. For the purposes of characterization, a small amount of the product was recrystallized from toluene.

10


5-Bromo-2-[[3-(2-phenylethyl)benzoyl]amino]benzoic acid

To 3-(2-phenylethyl)benzoic acid (292 mg, 1.29 mmol) in CH_2Cl_2 (20 mL) was added DMF (20 μL) and oxalyl chloride (225 μL , 2.58 mmol). The mixture was stirred for
 15 2.5 hours, and the solvent and excess oxalyl chloride were removed by rotary evaporation. The residue was dissolved in CH_2Cl_2 (10 mL), and methyl 2-amino-5-bromobenzoate (248 mg, 1.08 mmol, Avocado) in pyridine (4 mL) was added. The mixture was stirred overnight and then added to a separatory funnel with 100 mL of CH_2Cl_2 . This solution was washed with 2 X 100 mL of 1 M aqueous HCl and 100
 20 mL of brine. The CH_2Cl_2 was evaporated in the presence of silica gel, and the product was purified by chromatography using a Biotage Flash 40 M silica cartridge with a gradient from 50% - 100% CH_2Cl_2 in heptane as eluent. Yield was 361 mg of white solid as the methyl ester. To a mixture of the methyl ester (285 mg, 0.65 mmol) in dioxane (10 mL) was added 1 M aqueous sodium hydroxide (1.0 mL). The mixture
 25 was stirred at room temperature for 1 hour and then heated in a 50 $^\circ\text{C}$ oil bath for 15 minutes. The reaction mixture was added to a separatory funnel with 100 mL of 1 M


aqueous HCl, and the product was extracted into 100 mL of CH₂Cl₂. The CH₂Cl₂ was washed with an additional 100 mL of 1 M aqueous HCl followed by 100 mL of water. It was then dried over MgSO₄ and evaporated. The residue was recrystallized from hot ethanol. The solids were washed with heptane and then dried at 100 °C under vacuum yielding 88 mg of white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.10 (s, 1 H), 8.68 (d, *J* = 9.1 Hz, 1 H), 8.12 (d, *J* = 2.5 Hz, 1 H), 7.83-7.87 (m, 2 H), 7.75-7.78 (m, 1 H), 7.46-7.51 (m, 2 H), 7.16-7.31 (m, 5 H), 2.91-3.02 (m, 4 H).

Example 6:

Thioamide linkers.



2-[(3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]phenyl)carbonothioyl]amino]-5-cyanobenzoic acid




General procedure A: Methyl 2-[(3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]phenyl)carbonyl] amino]-5-cyanobenzoate (989 mg, 1.99 mmol) and Lawesson's reagent (4.5 g, 11.1 mmol) were combined in a flask equipped with a reflux condensor. The flask was evacuated and purged with N₂ several times. Tol (30 mL) was added and the reaction was refluxed overnight. The reaction was cooled to rt and filtered to remove excess Lawesson's reagent. The filtrate was absorbed in SiO₂

and the product was purified by silica gel chromatography using Hept/EtOAc (19:1, 9:1, 3:17, 4:1). The product was triturated with MeOH to afford 670 mg (66%) of an orange solid as the methyl ester. ¹H NMR (DMSO-*d*₆) δ 12.40 (s, 1 H), 8.35 (d, *J* = 2 Hz, 1 H), 8.29 (s, 1 H), 8.19 (dd, *J* = 8, 2 Hz, 1 H), 8.14 (d, *J* = 8 Hz, 1 H), 8.06 (d, *J* = 8 Hz, 1 H), 7.98 (d, *J* = 8 Hz, 1 H), 7.73 (t, *J* = 8 Hz, 1 H), 7.49 (d, *J* = 9 Hz, 1 H), 7.30-7.25 (m, 2 H), 4.02 (t, *J* = 8 Hz, 2 H), 3.79 (s, 3 H), 2.97 (t, *J* = 8 Hz, 2 H).

General procedure B: to a solution of the methyl ester (300 mg, 0.605 mmol) dissolved in THF (7 mL) and H₂O (1.5 mL) was added LiOH-H₂O (450 mg, 10.7 mmol) and the reaction was heated to 45°C for 6 hr. The solution was diluted with MTBE, washed with 2 N HCl and brine, dried (MgSO₄), concentrated, and triturated with MeOH to afford 252 mg (84%) of an orange solid. ¹H NMR (DMSO-*d*₆) δ 8.62 (d, *J* = 8 Hz, 1 H), 8.36 (dd, *J* = 12, 2 Hz, 1 H), 8.18 (d, *J* = 8 Hz, 1 H), 8.12 (dd, *J* = 8, 2 Hz, 1 H), 7.95 (d, *J* = 8 Hz, 1 H), 7.71 (t, *J* = 8 Hz, 1 H), 7.48 (d, *J* = 9 Hz, 1 H), 7.27-7.25 (m, 2 H), 4.02 (t, *J* = 8 Hz, 2 H), 2.96 (t, *J* = 8 Hz, 2 H).


Methyl 2-{[3-(chlorosulfonyl)benzoyl]amino}-5-cyanobenzoate



To a suspension of 3-(chlorosulfonyl)benzoic acid (10.8 g, 49.0 mmol) in CH₂Cl₂ (105 mL) and three drops of DMF was added oxalyl chloride (12.5 mL) and the reaction was stirred at rt overnight. The solution was concentrated *in vacuo*, diluted with CH₂Cl₂ (100 mL), and the solution was divided into two reactions. A 50 mL (24.5 mmol) aliquot of the acid chloride was added to a solution of PHA-522499 (4.49 g, 25.5 mmol) dissolved in CH₂Cl₂ (50 mL) and pyridine (3.0 mL) and stirred at rt overnight. The solution was diluted with MTBE, washed with 2 N HCl and brine, concentrated, triturated with MTBE to afford 7.91 g (85%) of methyl 2-{[3-(chlorosulfonyl)benzoyl]amino}-5-cyanobenzoate as a tan solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.73 (s, 1 H), 8.67 (d, *J* = 9 Hz, 1 H), 8.37 (d, *J* = 2 Hz, 1 H), 8.25 (s, 1


H), 8.12 (dd, $J = 9, 2$ Hz, 1 H), 7.92 (d, $J = 8$ Hz, 1 H), 7.88 (d, $J = 8$ Hz, 1 H), 7.60 (t, $J = 8$ Hz, 1 H), 3.93 (s, 3 H).

5 **5-cyano-2-{{3-(pyrrolidin-1-ylsulfonyl)benzoyl}amino}benzoic acid**




General procedure C: To a solution of methyl 2-{{3-(chlorosulfonyl)benzoyl}amino}-5-cyanobenzoate (1.863 g, 4.92 mmol) dissolved in CH_2Cl_2 (40 mL) was added
 10 pyrrolidine (1.5 mL, 18.0 mmol) and stirred at rt for 3 hr. The reaction was diluted with MTBE, washed with 2 N HCl and brine, concentrated, and triturated with MeOH to afford 1.70 g (84%) of methyl 5-cyano-2-{{3-(pyrrolidin-1-ylsulfonyl)benzoyl}amino}benzoate as a tan solid. ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 11.75 (s, 1 H), 8.61 (d, $J = 9$ Hz, 1 H), 8.38 (d, $J = 2$ Hz, 1 H), 8.33 (s, 1 H), 8.25 (d, $J = 8$ Hz, 1 H), 8.14 (dd, $J = 9, 2$ Hz, 1 H), 8.10 (d, $J = 8$ Hz, 1 H), 7.90 (t, $J = 8$ Hz, 1 H), 3.91 (s, 3 H), 3.24-3.19 (m, 4 H), 1.71-1.66 (m, 4 H). Methyl 2-{{3-(chlorosulfonyl)benzoyl}amino}-5-cyanobenzoate (378 mg, 1.0 mmol) was dissolved in 15 mL of CHCl_3 . Pyrrolidine (145 mg, 2.0 mmol) and Et_3N (1 mL) were then added and the reaction stirred at room temperature for 12 hr. The mixture was poured
 20 into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na_2SO_4 and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography, providing 297 mg (72%) of the desired methyl ester. The ester was treated with LiOH in 1:1:1 THF/MeOH/ H_2O for 12 hrs followed by acidification and extraction with EtOAc. The organic solution was dried
 25 over Na_2SO_4 and then concentrated *in vacuo*. The title compound (249 mg, 87%) was obtained as a white solid after recrystallization from MeOH. ^1H NMR (300 MHz, DMSO) 1.67 (m, 4H), 3.20 (m, 4H), 7.88 (t, 1H), 8.09-8.14 (m, 2H), 8.26 (d, 1H), 8.33 (s, 1H), 8.42 (d, 1H), 8.83 (d, 1H), 12.56 (s, 1H)

5-Cyano-2-([3-(pyrrolidin-1-ylsulfonyl)phenyl]carbonothioyl)amino)benzoic acid



Prepared according to general procedure A: Methyl 5-cyano-2-([3-(pyrrolidin-1-ylsulfonyl)benzoyl]amino)benzoate (1.12 g, 2.70 mmol) and Lawesson's reagent (5.5 g, 13.6 mmol) afforded 450 mg of a mixture of the methyl ester and Lawesson's reagent after purifying by silica gel chromatography twice. The crude material was hydrolyzed according to general method B to afford 253 mg (29%) over two steps of an orange solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.80 (d, *J* = 9 Hz, 1 H), 8.42 (d, *J* = 2 Hz, 1 H), 8.33 (s, 1 H), 8.23 (d, *J* = 8 Hz, 1 H), 7.97-7.91 (m, 2 H), 7.75 (t, *J* = 7 Hz, 1 H), 3.23-3.19 (m, 4 H), 1.71-1.65 (m, 4 H).


5-cyano-2-([3-(morpholin-4-ylsulfonyl)benzoyl]amino)benzoic acid



Methyl 2-([3-(chlorosulfonyl)benzoyl]amino)-5-cyanobenzoate (378 mg, 1.0 mmol) was dissolved in 15 mL of CHCl₃. Morpholine (156 mg, 2.0 mmol) and Et₃N (1 mL) were then added and the reaction stirred at room temperature for 12 hr. The mixture was poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na₂SO₄ and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography, providing 373 mg (87%) of the desired methyl ester. The ester was treated with LiOH in 1:1:1 THF/MeOH/H₂O for 12 hrs followed by acidification and extraction with EtOAc. The organic solution was dried over Na₂SO₄ and then concentrated *in vacuo*. The title compound (298 mg, 82%) was obtained as a white solid after recrystallization from

MeOH. ^1H NMR (400 MHz, DMSO) 2.94 (m, 4H), 3.65 (m, 4H), 7.96 (t, 1H), 8.03 (d, 1H), 8.13 (dd, 1H), 8.27-8.31 (m, 2H), 8.42 (d, 1H), 8.82 (d, 1H), 12.55 (s, 1H)


5-Cyano-2-([3-(morpholin-4-ylsulfonyl)phenyl]carbonothioyl)amino)benzoic acid




Prepared according to general method A and B: Methyl 5-cyano-2-([3-(morpholin-4-ylsulfonyl)benzoyl]amino)benzoate (1.02 g, 2.38 mmol) and Lawesson's reagent (4.78 g, 11.8 mmol) afforded 532 g (50%) of the ester, 35527-bdw-118 as an orange solid. The ester (495 mg, 1.09 mmol) was hydrolyzed by general procedure B to afford 87 mg (20%) of an orange solid. ^1H NMR (300 MHz, DMSO- d_6) δ 9.72 (d, J = 8 Hz, 1 H), 8.41 (d, J = 2 Hz, 1 H), 8.27-8.25 (m, 2 H), 7.95 (dd, J = 9, 6 Hz, 1 H), 7.90 (d, J = 9 Hz, 1 H), 7.79 (t, J = 6 Hz, 1 H).

Example 7: X-Y Derivatives


Scheme 7.1



Scheme 7.2




Scheme 7.3




5

Scheme 7.4




Methyl 2-(bromomethyl)-5-cyanobenzoate



Methyl 5-cyanobenzoate (4.50 g, 25.6 mmol), NBS (5.03 g, 28.25 mmol) and AIBN (150 mg) were dissolved in dichloroethane (160 mL). The mixture was irradiated with a photolamp for 2h. The mixture was cooled to rt and concentrated in vacuo. The residue was purified by silica gel chromatography (DCM/heptane 1/9, 1/4, 1/1, 1/0) to afford 4.79 g (73%) of methyl 2-(bromomethyl)-5-cyanobenzoate. ¹H NMR (300 MHz, CDCl₃) δ 8.29 (d, *J* = 1.7 Hz, 1 H), 7.79 (dd, *J* = 8.0, 1.7 Hz, 1 H), 7.63 (d, *J* = 8.0 Hz, 1 H), 4.97 (s, 2 H), 4.00 (s, 3 H).

Methyl 2-{{bromo(triphenyl)phosphoranyl}methyl}-5-cyanobenzoate




10

Methyl 2-(bromomethyl)-5-cyanobenzoate (2.80 g, 10.9 mol) was added to a solution of triphenylphosphine (2.87 g, 10.9 mmol) in toluene (50 mL). The resulting mixture was heated at reflux for 3h, cooled to rt, the precipitate was isolated by filtration, washed with pentane to afford 4.64 g (82%) of methyl 2-{{bromo(triphenyl)phosphoranyl}methyl}-5-cyanobenzoate as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.22 (s, 1 H), 8.08 (d, *J* = 7.9 Hz, 1 H), 8.79-7.51 (m, 16 H), 5.63 (d, *J* = 16.2 Hz, 2 H), 3.48 (s, 3 H).

15


Methyl 2-methyl-5-nitrobenzoate




20

2-Methyl-5-nitrobenzoate (5.0 g, 27.6 mmol) was dissolved in MeOH (0.4 L) followed by the addition of H₂SO₄ (7 mL). The mixture was heated at reflux for 36 h, then cooled to rt and concentrated to ca 100 mL. The solution was diluted with MTBE neutralized with 6N NaOH, washed with 1N NaOH, brine, dried (MgSO₄), filtered and concentrated in vacuo to afford 4.72 g (87%) of methyl 2-methyl-5-nitrobenzoate as a white solid.


25

Methyl 5-amino-2-methylbenzoate

Methyl 2-methyl-5-nitrobenzoate (5.0 g, 25.6 mmol) was dissolved in EtOH with
 5 Raney nickel under a 35 psi atmosphere of H₂. The reaction was stirred for 20 h, then
 filtered through Celite washed with MeOH and concentrated in vacuo to afford 4.2 g
 (100%) of methyl 5-amino-2-methylbenzoate.

Methyl 2-(bromomethyl)-5-nitrobenzoate


10 Methyl 2-methyl-5-nitrobenzoate (2.0 g, 10.2 mmol) NBS (2.73 g, 15.3 mmol) and
 AIBN (50 mg) were dissolved in dichloroethane (100 mL). The mixture was irradiated
 with a photolamp for 3h. The mixture was cooled to rt and concentrated in vacuo.
 The residue was purified by silica gel chromatography (heptane/EtOAc 1/0, 19/1, 9/1)
 15 to afford 2.40 g (85%) of methyl 2-(bromomethyl)-5-nitrobenzoate.

Methyl 2-[[bromo(triphenyl)phosphoranyl]methyl]-5-nitrobenzoate

Methyl 2-(bromomethyl)-5-nitrobenzoate (666 mg, 2.43 mmol) was added to a
 20 solution of triphenylphosphine (640 mg, 2.4 mmol) in toluene (20 mL). The resulting
 mixture was heated at reflux for 3h, cooled to rt, the precipitate was isolated by

filtration, washed with pentane to afford 1.2 g (92%) of methyl 2-
 {[bromo(triphenyl)phosphoranyl]methyl}-5-nitrobenzoate as a white solid.


Methyl 5-cyano-2-methylbenzoate




5

Methyl 5-amino-2-methylbenzoate (4.2 g, 25.4 mmol) was dissolved in MeOH/H₂O (20 mL/46 mL) was cooled with icebath followed by the addition of HCl (54 mL), NaNO₂ (2.63 g, 38.1 mmol, in H₂O 60 mL). The mixture was stirred for ½ h, then neutralized with solid NaHCO₃, extensive gasevolution. Then a cold mixture of KCN
 10 (2.48 g, 38 mmol) and CuCN (2.9 g, 33 mmol) in a H₂O (40 ml)/ EtOAc (80 mL) was added. The reaction was stirred for ½ h, then filtered through Celite, extracted with EtOAc then washed with H₂O, brine, dried (MgSO₄), filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (heptane/DCM 19/1, 9/1, 1/1, 1/0) to afford 1.89 g (42%) of a white solid. ¹H NMR (300 MHz, CDCl₃) δ
 15 8.23 (d, *J* = 1.7 Hz, 1 H), 7.68 (dd, *J* = 1.8, 7.9 Hz, 1 H), 7.38 (d, *J* = 7.9 Hz, 1 H), 3.94 (s, 3 H).

Methyl 5-chloro-2-methylbenzoate




20 Methyl 5-chloro-2-methylbenzoate (25 g, 147 mmol) was dissolved in MeOH (0.6 L) followed by the addition of H₂SO₄ (50 mL). The mixture was heated at reflux for 12 h, then cooled to rt and concentrated to ca 200 mL. The solution was diluted with MTBE, washed with H₂O, 1N NaOH, brine, dried (MgSO₄), filtered and concentrated in vacuo to afford 24.9 g (92%) of methyl 5-chloro-2-methyl-benzoate as a white
 25 solid. ¹H NMR (300 MHz, CDCl₃) δ 7.91 (d, *J* = 2.3 Hz, 1 H), 7.38 (dd, *J* = 2.3, 8.1 Hz, 1 H), 7.19 (d, *J* = 8.2 Hz, 1 H), 3.91 (s, 3 H).

Methyl 2-(bromomethyl)-5-chlorobenzoate

Methyl 5-chloro-2-methyl benzoate (10.0 g, 54 mmol) NBS (10.6 g, 59.5 mmol) and AIBN (200 mg) were dissolved in dichloroethane (300 mL). The mixture was irradiated with a photolamp for 2h. The mixture was cooled to rt and concentrated in vacuo. The residue was purified by silica gel chromatography (heptane/DCM 9/1, 4/1, 1/1) to afford 11.8 g (83%) of methyl 2-(bromomethyl)-5-chlorobenzoate. ¹H NMR (300 MHz, CDCl₃) δ 7.98 (d, *J* = 2.1 Hz, 1 H), 7.49 (dd, *J* = 2.2, 8.2 Hz, 1 H), 7.43 (d, *J* = 8.2 Hz, 1 H), 4.93 (s, 2 H), 3.97 (s, 3 H).


10

Methyl 2-[[bromo(triphenyl)phosphoranyl]methyl]-5-chlorobenzoate

Methyl 2-(bromomethyl)-5-chlorobenzoate (11.8 g, 44.6 mmol) was added to a solution of triphenylphosphine (11.6 g, 44.6 mmol) in toluene (400 mL). The resulting mixture was heated at reflux for 3h, cooled to rt, the precipitate was isolated by filtration, washed with pentane to afford 18.7 g (80%) of methyl 2-[[bromo(triphenyl) phosphoranyl] methyl]-5-chlorobenzoate as a white solid. ¹H NMR (300 MHz, CDCl₃) δ 7.85-7.68 (m, 5 H), 7.63-7.57 (m, 12 H), 7.38-7.28 (m, 1 H), 5.88 (d, *J* = 15.0 Hz, 2 H), 3.43 (s, 3 H).


20

2-((Z)-2-{3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]phenyl}ethenyl)-4-nitrobenzoic acid



Methyl 2-[[bromo(triphenyl)phosphoranyl]methyl]-5-nitrobenzoate (1.20 g, 2.24 mmol) was added to DMSO (30 mL) followed by NaH (100 mg, 2.4 mmol), gas evolution was observed, and the resulting mixture was heated at 60 °C for 2h. Then
 5 3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzaldehyde (800 mg, 2.5 mmol) in toluene (50 mL) was added the reaction was stirred at rt for 2h, then at 60 °C for 2h. The mixture was diluted with MTBE, washed with H₂O, brine, dried (MgSO₄), filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (DCM/MeOH 1/0, 19/1) to afford 760 mg (68%) of a Z/E mixture
 10 (4/1). The solid was dissolved in THF/MeOH (2/1, 60 mL) and 6N NaOH (6 mL) was added. The mixture was stirred at rt for 1 h, then diluted with MTBE, washed with 1N HCl, H₂O, brine, dried (MgSO₄), filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (DCM/MeOH 1/0, 19/1) to afford 574 mg (77%). This was recrystallized from MeOH. The mother liquid was
 15 recrystallized several time to afford 182 mg. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.66 (d, *J* = 2.4 Hz, 1 H), 8.14-8.12 (m, 1 H), 7.63-7.57 (m, 1 H), 7.49-7.18 (m, 8 H), 6.84 (d, *J* = 12.3 Hz, 1 H), 3.65 (t, *J* = 8.4 Hz, 2 H), 2.86 (t, *J* = 8.4 Hz, 2 H).


20 **2-((E)-2-[[3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]phenyl]ethenyl]-4-nitrobenzoic acid,**



^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.56 (d, $J = 2.4$ Hz, 1 H), 8.33-8.31 (m, 1 H), 8.18 (d, $J = 16.5$ Hz, 1 H), 8.08-8.03 (m, 2 H), 7.92 (d, $J = 7.8$ Hz, 1 H), 7.75-7.73 (m, 1 H), 7.62 (t, $J = 7.8$ Hz, 1 H), 7.51-7.47 (m, 2 H), 7.27-7.23 (m, 2 H), 3.98 (t, $J = 8.4$ Hz, 2 H), 2.94 (t, $J = 8.4$ Hz, 2 H).


5

5-Chloro-2-((E)-2-{3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]phenyl}ethenyl)benzoic acid




Methyl 2-[[bromo(triphenyl)phosphoranyl]methyl]-5-chlorobenzoate (392 mg, 0.74 mmol) was added to THF (10 mL) in icebath, followed by LiCl (260 mg, 6.2 mmol), and *n*-BuLi (300 μL , 0.74 mmol). The reaction was stirred at rt for 10 min, then 3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzaldehyde (200 mg, 0.6 mmol) was added and the reaction was stirred at rt for 2h. The mixture was diluted with MTBE, washed with H_2O , brine, dried (MgSO_4), filtered and concentrated in vacuo. The residue was purified by silica gel plug (DCM) to afford 271 mg of a Z/E mixture. The solid was dissolved in toluene (10 mL) followed by the addition of thiophenol (32 μL , 0.28 mmol) and AIBN (14 mg, 0.08 mmol). The reaction was heated at reflux for 12 h, then concentrated in vacuo. The residue was dissolved in THF (60 mL) and 6N NaOH (5 mL) was added. The mixture was stirred at 100 $^\circ\text{C}$ for 4 h, then diluted with MTBE, washed with 1N HCl, H_2O , brine, dried (MgSO_4), filtered and concentrated in vacuo. The residue was recrystallized from MeOH to afford 123 mg. ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 7.97-7.85 (m, 5 H), 7.70-7.60 (m, 3 H), 7.48 (d, $J = 8.2$ Hz, 1 H), 7.33-7.24 (m, 3 H), 3.97 (t, $J = 8.4$ Hz, 2 H), 2.93 (t, $J = 8.4$ Hz, 2 H).

5-Cyano-2-((E)-2-{3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]phenyl}ethenyl)benzoic acid




Methyl 2-[[bromo(triphenyl)phosphoranyl]methyl]-5-cyanobenzoate (1.36 g, 2.6 mmol) was added to DMSO (20 mL) followed by NaH (105 mg, 2.6 mmol), gas evolution was observed, and the resulting mixture was heated at 60 °C for 2h. Then
 5 3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzaldehyde (564 mg, 1.7 mmol) in toluene (50 mL) was added the reaction was stirred at rt for 1h, then at 60 °C for 1h. The mixture was diluted with MTBE, washed with H₂O, brine, dried (MgSO₄), filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (DCM/heptane 1/1, 1/0) to afford 616 mg (73%) of a Z/E mixture.
 10 The solid was dissolved in THF (60 mL) and 1N NaOH (10 mL) was added. The mixture was stirred at rt for 12 h, then diluted with MTBE, washed with 1N HCl, H₂O, brine, dried (MgSO₄), filtered and concentrated in vacuo to afford 567 mg (95%). This was purified by preparative reverse phase HPLC to afford 144 mg of pure (E) and 99 mg of (Z). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.24 (s, 1 H), 8.05-7.89 (m, 5 H), 7.76-7.73 (m, 1 H), 7.63 (t, *J* = 7.7 Hz, 1 H), 7.49-7.44 (m, 2 H), 7.27-7.24 (m, 2 H), 3.98 (t, *J* = 8.5 Hz, 2 H), 2.93 (t, *J* = 8.5 Hz, 2 H).
 15

5-Cyano-2-((Z)-2-[[3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]phenyl]ethenyl)benzoic acid



20 ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.33 (d, *J* = 1.7 Hz, 1 H), 7.84-7.81 (m, 1 H), 7.59-7.57 (m, 1 H), 7.47-7.12 (m, 8 H), 6.82 (d, *J* = 12.2 Hz, 1 H), 3.66 (t, *J* = 8.5 Hz, 2 H), 2.88 (t, *J* = 8.3 Hz, 2 H).

2-(2-{3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]phenyl}cyclopropyl)-5-cyanobenzoic acid



5 Diazomethane solution (400 ml, from 36 g Dizald, for procedure see Denmark, S. E.; Stavenger, R. A.; Faucher, A-M.; Edwards, J. P. *J. Org. Chem.* **1997**, 62, 3375) was added to a solution of methyl 5-cyano-2-(2-{3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl] phenyl}ethenyl)benzoate (850 mg, 1.7 mmol) and Pdca (100 mg) in DCM (150 mL). Extensive gas evolution was observed, the resulting mixture was stirred for

10 12 h, then HOAc (5 mL) was added, filtered through Celite, washed with 1N NaOH, brine, dried (MgSO₄), filtered and concentrated in vacuo to afford 982 mg of a solid. The residue in DCM (100 mL) was cooled with icebath and O₃ was bubbled through for 30 min. Then NaBH₄ (500 mg) was added and the mixture was stirred for 30 min at rt. The mixture was passed through a silica plug and concentrated in vacuo. The


15 residue was purified by silica gel chromatography (heptane/DCM 9/1, 4/1, 1/1, 0/1) to afford 124 mg of the desired cyclopropane. The solid was dissolved in THF (25 mL) and 6N NaOH (5 mL) was added, the resulting mixture was stirred for 16h at rt, then diluted with MTBE, washed with 1N HCl, H₂O, brine, dried (MgSO₄) filtered and concentrated in vacuo. The residue was purified by silica gel chromatography

20 (DCM/MeOH 1/0, 19/1, 9/1, 4/1) to afford 51 mg (6%). ¹H NMR (300 MHz, CDCl₃) δ 8.27 (d, *J* = 1.6 Hz, 1 H), 7.79 (d, *J* = 8.1 Hz, 1 H), 7.60-7.57 (m, 3 H), 7.40 (d, *J* = 5.3 Hz, 2 H), 7.25 (d, *J* = 8.1 Hz, 1 H), 7.18-7.16 (m, 1 H), 7.04 (s, 1 H), 3.95 (t, *J* = 8.3 Hz, 2 H), 3.18-3.13 (m, 1 H), 2.87 (t, *J* = 8.3 Hz, 2 H), 2.24-2.19 (m, 1 H), 1.65-1.60 (m, 1 H), 1.54-1.49 (m, 1 H).

25

Example 8:

In other embodiments, the invention includes benzoxazine derivatives of the formula




5 wherein

R_2 is an electron withdrawing group; and

R_4 is an optionally substituted aryl, provided that the aryl is not simultaneously substituted with a sulfonamide and a urea or thiourea, and further provided that the aryl is not solely substituted at the ortho-position relative to Y.

10

2-{3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]phenyl}-4-oxo-4H-3,1-benzoxazine-6-carbonitrile



15 2-({3-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl}amino)-5-cyanobenzoic acid (PHA-524523, 884 m, 1.84 mmol) was dissolved in anhydrous THF (30 mL) and Et_3N (0.563 mL, 4.04 mmol) under N_2 . Addition of ethyl chloroformate (0.193 mL, 2.02 mmol, Aldrich) to the yellow solution produced a white precipitate, which was stirred overnight at RT. The solvent was evaporated and the resultant residue

20 suspended in CH_2Cl_2 (100 mL). The organic layer was washed 2x with 1.0M HCl, 1x with water and 1x with brine (100 mL each). The crude product was purified on a Biotage Flash 40M (90 g) silica cartridge using a step gradient of 0-1% CH_3OH in CH_2Cl_2 . After evaporation the resultant solid was dried under vacuum at 100 °C to

afford 280 mg (33%) of white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.65 (d, J = 1.9 Hz, 1 H), 8.52 (s, 1 H), 8.47 (d, J = 8.0 Hz, 1 H), 8.36 (dd, J = 8.4, 1.9 Hz, 1 H), 8.11 (d, J = 8.4 Hz, 1 H), 7.92 (d, J = 8.4 Hz, 1 H), 7.85 (t, J = 7.9 Hz, 1 H), 7.53 (d, J = 8.6 Hz, 1 H), 7.30 (d, J = 8.6 Hz, 1 H), 7.26 (s, 1 H), 3.99 (t, J = 8.4 Hz, 2 H), 2.94 (t, J = 8.4 Hz, 2 H).


Example 9: Library Synthesis

General Experimental

^1H NMR spectra were measured using a Bruker AVANCE 300 spectrometer at rt in $\text{DMSO}-d_6$ at an operating frequency of 300.13 MHz and are referenced to residual $\text{DMSO}-d_6$ (2.54 ppm) unless otherwise noted. All coupling constants are reported in Hz. All non-combinatorial reactions were performed under a nitrogen atmosphere.

Synthetic Procedures Using Wang Resins

Scheme 9.1




20

To a dry, 2-L polypropylene bottle equipped with a nitrogen inlet and an overhead stirrer was added Wang resin (21, 38.6 g, 49.7 mmol, 1.3 mmol/g, Novabiochem), DMF (600 mL), 5-bromoisatoic anhydride (22, 60.0 g, 248 mmol, dissolved in 100 mL of DMF), and DMAP (30.3 g, 248 mmol, dissolved in 100 mL of DMF). The reaction was heated under nitrogen to 65 °C and stirred for 12 h. The reaction was

then filtered and washed as follows: DMF, CH₃CN, DMF, CH₃CN, DMF, CH₃CN, CH₃CN, CH₂Cl₂, CH₃CN, CH₂Cl₂, CH₃CN, and CH₂Cl₂. The washed resin was transferred back to the 2-L reaction flask and treated a second time with DMF (600 mL), 5-bromoisatoic anhydride (60.0 g, 248 mmol, dissolved in 100 mL of DMF), and
 5 DMAP (30.3 g, 248 mmol, dissolved in 100 mL of DMF). The reaction was stirred at 65 °C for 4 h and then filtered and washed with DMF, CH₃CN, DMF, CH₃CN, DMF, CH₃CN, CH₃CN, CH₂Cl₂, CH₃CN, CH₂Cl₂, CH₃CN, and CH₂Cl₂) to afford (48.57 g) of **23** as an off-white resin. CNH analysis: Calcd (1.3 mmol): N, 1.82, Found: N, 1.67% (loading = 1.2 mmol/g).

10


Scheme 9.2

15

To a suspension of a 3-chlorosulfonylbenzoic derivative (**24**, 31.6 mmol) in CH₂Cl₂ (100 mL) was added DMF (two drops), followed by oxalyl chloride (31.6 mL of a 2 M solution in CH₂Cl₂, 63.2 mmol) under a nitrogen atmosphere. Gas evolution and disappearance of the suspension was noted during the course of the reaction. After the
 20 reaction was stirred for 18 h, the acid chloride was concentrated to dryness, azeotroped with toluene (2 x 25 mL), and then placed on a high vacuum. Dry anthranilic acid-derivatized Wang resin (7.0 g, 8.4 mmol) was added to an 8-oz wide-mouth bottle, followed by CH₂Cl₂ (35 mL) and pyridine (35 mL). The acid chloride was dissolved in CH₂Cl₂ (20 mL) and added to resin, effecting HCl (g)
 25 evolution. The reaction jar was flushed with nitrogen, capped and shaken for 4 h.

The resin was then filtered and washed (CH_2Cl_2 , MeCN, CH_2Cl_2 , MeCN, CH_2Cl_2 , MeCN, CH_2Cl_2 , CHCl_3 , CH_2Cl_2 , THF, MeCN, THF, CH_2Cl_2 ; 50 mL each wash) to afford **25** as a tan resin.


5 **Scheme 9.3**



Sulfonyl chloride resin (**25**, 50 mg, 60 μmol) was added down the columns of a 96-
 10 well microtiter filter plate using a CH_2Cl_2 isopycnic slurry. After draining the wells, the plate was inserted into a solid phase reaction apparatus. Amines (300 μL of a 0.75 M solution, 225 μmol) were then added across the rows, followed by triethylamine (250 μL of a 1.8 M solution) and CH_2Cl_2 (250 μL). The plate was capped and spun on an overhead rotisserie for 16 h. After removal of the plate from the solid phase
 15 reaction apparatus, the wells drained and each well was washed (DMF, CH_3CN , DMF, CH_3CN , DMF, CH_3CN , CH_3CN , CH_2Cl_2 , CH_3CN , CH_2Cl_2 , CH_3CN , and CH_2Cl_2).


The plate was again inserted into the solid phase reaction apparatus and a 15%
 20 solution of TFA in CH_2Cl_2 (625 μL) was added. The plate was spun on an overhead rotisserie for 3 h and the crude sulfonamides were then drained into a 1-mL 96-well plate. The resin was washed with CH_2Cl_2 (1.5 mL) and the washes collected in additional 1-mL plates. LC/MS samples were prepared by transferring 40 μL of solution to a separate 96-well plate, concentrating the samples and then dissolving in
 25 DMSO (125 μL) and diluting with acetonitrile (750 μL).

Scheme 9.4




To a dry, 2-L polypropylene bottle equipped with a nitrogen inlet and an overhead stirrer was added Wang resin (**11**, 15.1 g, 21.1 mmol, 1.4 mmol/g, Novabiochem),
 5
 DMF (500 mL), 5-cyanoisatoic anhydride (**10**, 20.0 g, 106 mmol, dissolved in 100 mL DMF), and DMAP (13.0 g, 106 mmol, dissolved in 100 mL DMF). The mixture was heated under nitrogen to 53 °C and stirred for 16 h. The reaction was then filtered and washed with 500 μL of the following solvents: DMF, CH_3CN , DMF, CH_3CN , DMF,
 10
 CH_3CN , DMF, DMF, CH_2Cl_2 , CH_2Cl_2 , CH_2Cl_2 , CH_2Cl_2 , DMF, DMF, and DMF. The resin was transferred back to the 2-L reaction flask and treated a second time with DMF (500 mL), 5-cyanoisatoic anhydride (**10**, 20.0 g, 106 mmol, dissolved in 100 mL DMF), and DMAP (13.0 g, 106 mmol, dissolved in 100 mL DMF). The reaction was stirred at 60 °C for 22 h and then filtered and washed with 500 μL of CH_3CN , DMF,
 15
 CH_3CN , DMF, CH_3CN , DMF, CH_3CN , CH_2Cl_2 , CH_3CN , CH_2Cl_2 , CH_3CN , CH_2Cl_2 , to afford 15.3 g of **12** as a pale yellow resin. Elemental analysis: N, 3.20 % (loading = 1.14 mmol/g).⁵

Scheme 9.5



Dry 5-cyano anthranilic acid-derivatized Wang resin (**5**, 5.0 g, 1.0 mmol/g loading, 5.0 mmol) was added to an 8-oz wide mouth bottle, followed by CH_2Cl_2 (30 mL) and pyridine (30 mL). The acid chloride (**4**) was dissolved in CH_2Cl_2 (30 mL) and added to the resin, effecting HCl (gas) evolution. The jar was flushed with nitrogen, capped, and shaken for 64 h. The resin was then filtered and washed (DMF, CH_3CN , DMF, CH_3CN , DMF, CH_3CN , DMF, THF, THF, THF, CH_3CN , CH_2Cl_2 , CH_3CN , CH_2Cl_2 , CH_3CN , CH_2Cl_2 ; 400 mL each wash) to afford **6**.

Scheme 9.6



Sulfonyl chloride resin (**6**, 50 mg, 50 μmol) was added to the wells of a 96-well filter plate using a CH_2Cl_2 isopycnic slurry. After draining the wells, the plate was inserted into a solid phase reaction apparatus. Amines (250 μL of a 2 M solution, 500 μmol) were then added, followed by triethylamine (250 μL of a 2 M solution) and CH_2Cl_2 (250 μL). The plate was then capped and spun on an overhead rotisserie for 20 h. After removal of the plate from the solid phase reaction block, the wells were drained and washed (DMF, CH_3CN , DMF, CH_3CN , DMF, CH_3CN , H_2O , THF, H_2O , THF, H_2O , THF, CH_3CN , CH_2Cl_2 , CH_3CN , CH_2Cl_2 , CH_3CN , CH_2Cl_2 ; 375 μL each wash).


The plate was again inserted into the solid phase reaction apparatus and a 50% solution of TFA in CH_2Cl_2 (500 μL) was added. The plate was spun on an overhead rotisserie for 3 h and the crude sulfonamides (**7**) were then drained into a standard 96-well plate. The resin was washed with 250 μL of additional 50% TFA solution. Products were concentrated under nitrogen and then analyzed by LC/MS (see general LC/MS procedure).

The crude samples were dissolved in THF, and eluted through a plug of Celite[®].

LC/MS showed a reduced amount of impurity in all of the samples. The samples that were less than 70% pure were then eluted through a plug of silica gel using THF as the mobile phase and the samples were analyzed by LC/MS.

5


Scheme 9.7



10

To a standard 96-well filter plate was added 50 mg (60 μ mol) of 5-bromoanthanilic acid derivatized Wang resin as an isopycnic solution in CH₂Cl₂ (3). After the wells were drained, the plate was inserted into a plate clamp assembly. The acid chloride diversity set (2) was dissolved in CH₂Cl₂ (300 μ L) and added to the plate, followed by TEA (250 μ L, 1 M CH₂Cl₂, 250 μ mol) and CH₂Cl₂ (300 μ L). The plate was capped and spun on an overhead rotisserie for 16 h. After removal of the plate from the plate clamp assembly, the wells were drained and the resin washed with 500 μ L of the following solvents: CH₂Cl₂, MeCN, CH₂Cl₂, MeCN, CH₂Cl₂, MeCN, CH₂Cl₂, CHCl₃, CH₂Cl₂, THF, MeCN, THF, CH₂Cl₂. The plate was reinserted into the plate clamp assembly and the washed resin was treated with 750 μ L of 25% TFA/CH₂Cl₂ solution for 3 h. The solution was then filtered from the Wang resin and collected in a separate plate to afford the crude amides (4). The plates were concentrated and analyzed by LC/MS (see general LC/MS procedure).


Scheme 9.8



After concentration of the acid chloride solutions (**2**), methyl-2-amino-5-bromobenzoate (**5**, 125 μ L, 1 M THF, 125 μ mol/well) was added to the plate followed by potassium carbonate (1 mL, 0.38 M THF, 380 μ mol/well). The reactions were capped, heated to 50 $^{\circ}$ C and shaken for 12 h. Triethylenetetramine resin (160 mg, 464 μ mol) was added to the wells to scavenge the excess acid chloride and the plate spun for 2.5 h. The crude methyl esters were purified (if necessary) using a column consisting of basic alumina (ca 200 mg), SAX (ca 200 mg), and SCX (ca 400 mg, activated with 1% HOAc/MeOH) in descending order. The products were eluted with THF and the fractions analyzed by LC/MS.


LiOH [375 μ L, 1 M H₂O/THF (50:50), 3 equiv)] was added to the esters and the plate was capped and spun for 1 h. The THF was then removed in vacuo. The crude solids were suspended in methyl ethyl ketone (MEK, 500 μ L) and extracted with 2 N HCl (250 μ L). The MEK layer was removed and the aqueous layer extracted again with MEK (500 μ L). The combined organic layers were washed with 50% brine solution, passed through a plug of sodium sulfate, collected in a 1-mL plate, and dried under nitrogen to afford the amide products (**6**). The solids were then analyzed using LC/MS (see general LC/MS procedure).

Scheme 9.9



To each vial of an array of 1-mL vials arranged in a 96-well format was added 44 mg (50 μmol) of 5-cyanoanthranilic acid-derivatized Wang resin (**5**) as an isopycnic solution in CH_2Cl_2 . The acid chloride diversity set² (**8**, 500 μmol) was dissolved in CH_2Cl_2 (300 μL) and added to the vials, followed by TEA (250 μL , 2 M CH_2Cl_2 , 500 μmol), and CH_2Cl_2 (300 μL). The vials were capped, heated to 60 $^\circ\text{C}$, and shaken for 21 h. After completion of the reaction, the resin was transferred to a 96-well filter plate and washed with of the following solvents: DMF, CH_3CN , DMF, CH_3CN , DMF, CH_3CN , H_2O , THF, H_2O , THF, H_2O , THF, CH_3CN , CH_2Cl_2 , CH_3CN , CH_2Cl_2 , CH_3CN , CH_2Cl_2 , CH_3CN , CH_2Cl_2 (500 μL /wash). The plate was placed into a clamp assembly and each well was treated with 500 μL of 50% TFA/ CH_2Cl_2 solution for 2 h.³ The resultant solution was then filtered from the Wang resin, collected in a separate plate, and dried under nitrogen to afford the crude amides (**9**).

Scheme 9.10




Resin-bound 4-Acetoxybenzoyl Anthranilic Acid. To a 500-mL round bottom flask under nitrogen was added 4-acetoxybenzoic acid (20.7 g, 115.5 mmol) and CH_2Cl_2 (200 mL). After cooling the flask to 0 $^\circ\text{C}$, oxalyl chloride (57.8 mL of a 2 M solution, 116 mmol) and a few drops of DMF were added. The reactions were allowed to warm to room temperature and stirred for 3 h. These solutions were directly transferred to a

2-L serum flask containing 5-bromoanthranillic acid resin (**21**, 7.0 g, 7.7 mmol), pyridine (100 mL) and CH₂Cl₂ (100 mL). The resulting mixtures were stirred under nitrogen overnight and then filtered into a glass fritted funnel. The resin was then washed with DMF (3 x 100 mL), CH₂Cl₂ (5 x 100 mL), and MeOH (5 x 100 mL).


- 5 The resin was then dried in a vacuum oven at 60 °C for 72 h to afford **22** (8.0 g). A sample was cleaved from the resin by stirring in 25% TFA in CH₂Cl₂ for 3 h: ¹H NMR (acetone-*d*₆) δ 2.31 (s, 3H), 7.35 (d, *J* = 2.1, 1H), 7.37 (d, *J* = 2.0, 1H), 7.82 (d, *J* = 2.5, 1H), 7.86 (d, *J* = 2.5, 1H), 8.07 (dd, *J* = 2.1, 8.7, 1H), 8.27 (d, *J* = 2.5, 1H), 8.90 (d, *J* = 9.0, 1H).

10




- Resin-bound 4-Hydroxybenzoyl Anthranilic Acid.** To a 250-mL serum bottle was added acetoxy resin **23** (7.0 g, 7.7 mmol), CH₂Cl₂ (70 mL), and piperidine (150 mL, 2 M CH₂Cl₂). The slurry was stirred for 2 h at room temperature. The resins were then filtered and washed with DMF (3 x 100 mL), Et₃N (1 M CH₂Cl₂, 2 x 100 mL), and MeOH (2 x 100 mL), CH₂Cl₂ (40 mL), MeOH (40 mL), CH₂Cl₂ (40 mL), MeOH (40 mL), CH₂Cl₂ (40 mL), and MeOH (40 mL). The resin was then dried for 72 h in a vacuum oven at room temperature to afford 6.6 g of **24** as a yellow resin.

20




Synthesis of Resin-Bound Phenol 12a. To a 200-mL Wheaton bottle equipped with an overhead stirrer was added resin-bound acetate (**11a**, 5.0 g) followed by piperidine (150 mL of a 2 M solution in CH₂Cl₂, 300 mmol). The reaction was stirred for 2 h at room temperature. The resin was then filtered from the reaction mixture, washed with DMF, DMF, DMF, Et₃N (1 M in CH₂Cl₂), MeOH, CH₂Cl₂, MeOH, CH₂Cl₂, MeOH, CH₂Cl₂, MeOH, CH₂Cl₂, MeOH, CH₂Cl₂, (50 mL each), and dried in a vacuum oven at 50 °C overnight to afford resin-bound phenol **12a** as a brownish solid.



Mitsunobu Reaction (Procedure A). To each well of a fritted 96-well plate was added phenol resin (**12a-c**, 20.0 mg, 20.0 μmol) as an isopycnic solution (20% THF in CH₂Cl₂) and the plate was placed in a solid phase reaction assembly. The alcohol diversity element (200 μL of a 1 M solution in THF, 200 μmol) was then added, followed by triphenylphosphine (200 μL of a 1 M solution in THF, 200 μmol). The wells were flushed with nitrogen, capped, and placed in the -20 °C freezer for 1 h. While in the freezer, DIAD [200 μL of a cooled (-20 °C), freshly made 1 M solution in THF] was added to each well. The plate was removed from the freezer after 1 h and then spun on the rotisserie for 16 h. The reaction mixture was drained from the plate and the resin then washed with THF, THF, THF (the plate was capped and spun on an overhead rotisserie for 30 min), THF, MeOH, THF, MeOH, THF, MeOH, MeOH, CH₂Cl₂, MeOH, CH₂Cl₂, MeOH, CH₂Cl₂, MeOH, CH₂Cl₂, MeOH, CH₂Cl₂, MeOH, CH₂Cl₂, MeOH (the plate was capped and spun on an overhead rotisserie for 30 min), CH₂Cl₂, CH₂Cl₂, CH₂Cl₂; 500 μL each solvent. The crude aryl ethers were then cleaved from the resin using 500 μL of 50% TFA in CH₂Cl₂. The resulting products (**13a-c**) were concentrated under a nitrogen stream and analyzed by HPLC/MS.


Mitsunobu Reaction (Procedure B). To 72 wells of a fritted 96-well plate was added phenol resin as an isopycnic solution (**12a-c**, 20.0 mg, 20.0 μmol) and the plate was placed in a solid phase reaction assembly. The alcohol diversity element (200 μL of a 1 M solution in THF, 200 μmol) was then added, followed by triphenylphosphine (200 μL of a 1 M solution in THF, 200 μmol) and Et_3N (200 μL of a 1 M solution in THF, 200 μmol). The wells were flushed with N_2 , capped, and placed in the -20°C freezer for 1 h. While in the freezer, DIAD [200 μL of a cooled (-20°C), freshly made 1 M solution in THF] was added to each well. The plate was removed from the freezer after an hour and then spun on the rotisserie for 16 h. The reaction mixture was drained from the plate and the resin then washed with THF, THF, THF (the plate was capped and spun on an overhead rotisserie for 30 min), THF, MeOH, THF, MeOH, THF, MeOH, MeOH, CH_2Cl_2 , MeOH, CH_2Cl_2 , MeOH, CH_2Cl_2 , MeOH, CH_2Cl_2 , MeOH, CH_2Cl_2 , MeOH, CH_2Cl_2 , MeOH (the plate was capped and spun on an overhead rotisserie for 30 min), CH_2Cl_2 , CH_2Cl_2 , CH_2Cl_2 ; 500 μL each solvent. The crude aryl ethers were then cleaved from the resin using 500 μL of 50% TFA in CH_2Cl_2 . The resulting products (**13a-c**) were concentrated under a nitrogen stream and analyzed by HPLC/MS.



20

Synthesis of Acetate 15. To a 250-mL round bottom flask was added a solution of methyl-2-amino-5-bromobenzoate [**14**, 5.0 g, 21.7 mmol dissolved in pyridine (10 mL) and CH_2Cl_2 (10 mL)], followed by *o*-acetoxybenzoyl chloride⁵ (4.7 g, 33.8 mmol dissolved in 60 mL of CH_2Cl_2). The mixture was stirred overnight under a nitrogen atmosphere. Polyamine resin (4.0 g) was then added to the reaction mixture and the reaction was stirred for 4 h. After filtration and concentration of the reaction mixture, a white residue was obtained. The residue was recrystallized from CH_2Cl_2 to afford 8.0 g (94%) of **15** as a white solid: ^1H NMR ($\text{DMSO}-d_6$) δ 2.24 (s, 3H), 3.86 (s, 3H),

7.30 (d, $J = 8.1$, 1H), 7.46 (dt, $J = 1.1$, 7.6, 1H), 7.66 (dt, $J = 1.7$, 8.0, 1H), 7.82 (dd, $J = 1.7$, 7.7, 1H), 7.86 (dd, $J = 2.5$, 8.9, 1H), 8.06 (d, $J = 2.5$, 1H), 8.38 (d, $J = 8.9$, 1H).




5

Synthesis of Phenol 16. To a 50-mL round bottom flask was added *o*-acetoxy methyl ester **15** (1.0 g, 2.9 mmol), CH₂Cl₂ (10 mL) and piperidine (2.0 mL of a 2 M solution in CH₂Cl₂, 4.0 mmol). After the reaction mixture was stirred for 3 h, the solvent was removed and the crude residue dried under high vacuum overnight. The residue was then dissolved in CH₂Cl₂ and acid chloride resin (2.0 g, 2.1 mmol) was added to scavenge excess piperidine. The mixture was stirred for 4 h, filtered, and concentrated to afford 0.54 g (60%) of phenol **16** as a white solid: ¹H NMR (DMSO-*d*₆) δ 3.90 (s, 3H), 6.98 (t, $J = 7.6$, 1H), 7.02 (d, $J = 7.6$, 1H), 7.44 (dt, $J = 1.8$, 8.2, 1H), 7.82 (dd, $J = 2.5$, 9.0, 1H), 7.93 (dd, $J = 1.8$, 7.9, 1H), 8.08 (d, $J = 2.5$, 1H), 8.60 (d, $J = 9.0$, 1H).

15


Scheme 9.11



20

Resin-Bound *m*-Iodo Benzamide 23. Acid chloride **22** was redissolved in CH₂Cl₂ (30 mL) and added to resin-bound 5-chloroanthranilic acid (**20**, 3 g, 1.06 mmol/g loading, 3.18 mmol) swollen with pyridine (30 mL) in a 500-mL serum flask equipped with an overhead stirrer. The flask was purged with nitrogen and the resin stirred for


16 h. The resin was filtered from the reaction mixture and washed with alternating CH_3CN and CH_2Cl_2 washes (8 x 300 mL) to afford **23**.



5

Resin-Bound Stannylate 24. To a CH_2Cl_2 slurry of *m*-iodo resin (**23**, 1 g, 1.06 mmol/g) in a 250-mL serum flask was added 1 mL of the following solutions; palladium acetate (0.0022 g/ 1 mL, 0.01 mmol, 0.1 equiv.), triphenyl phosphine (0.0065 g/mL, 0.025 mmol, 0.25 equiv), DIPEA (0.0065 g/mL, 0.05 mmol, 0.5 equiv) in DMF. Hexamethyl ditin (0.065 g, 0.2 mmol, 2.0 equiv) was added to the flask, which was then purged with nitrogen and heated to 60 °C for 18 h. The reaction mixture was drained and the resin washed with alternating DMF, CH_3CN and CH_2Cl_2 (10 x 150 mL) to yield **24** as a dark brown resin.

10



15

Resin Bound Library of Aryl Ketones. Hexamethyl ditin derivatized Wang resin (**24**, 24 mg, 24 μmol) was added as an isopycnic solution (degassed THF) to an array of 1-dram vials arranged in a 96-well format. Tris(dibenzylidene acetone) dipalladium (0) (22 mg, 24 μmol , 1.0 equiv) was added to each vial (in a solution of degassed THF). DIPEA (20 μL) was added to each vial followed by K_2CO_3 (10 mg)

20

and degassed THF (0.5 mL). The vials were capped and shaken. The vials were uncapped and the acid chloride diversity elements⁷ (10 equiv) were then added, the vials purged with nitrogen for 5 sec, capped, shaken and heated 60 °C for 20 h. After the reactions cooled to room temperature, the resin was transferred to a 96-well polypropylene fritted plate. The resin was washed (CH₃CN, DMF, CH₃CN, DMF, CH₃CN, DMF, H₂O, THF, H₂O, THF, H₂O, THF, CH₃CN, CH₂Cl₂, CH₃CN, CH₂Cl₂, CH₃CN, CH₂Cl₂, CH₂Cl₂, CH₂Cl₂, 250 µL each wash) and the plate inserted into a solid phase reaction block. A solution of 50% TFA in CH₂Cl₂ (600 µL) was added to the plate. The plate was capped and spun on an overhead rotisserie for 3 h. The crude aryl ketones (**25**) were then drained into a 96-well collection plate, concentrated to dryness, and analyzed by HPLC/MS.

Purification Procedures

Liquid-liquid extraction (basic). To a 96-well plate of crude samples was added methyl ethyl ketone (MEK, 500 µL) and 2 N NaOH (500 µL). The plates were capped and shaken. After the plates were uncapped, the organic layer was separated from the aqueous layer.

Liquid-liquid extraction (acidic). The aqueous layer of the above extraction was treated with 6 N HCl (500 µL) and extracted with MEK (1 mL). The plates were capped, shaken, and the organic layer was separated from the aqueous layer.

Hydromatrix[®] extraction (AMRI SEC-C-44). A set of 2-mL square-well plates were filled with Hydromatrix[®] and washed with MEK and CH₂Cl₂ (500 µL/well). The plates were then placed in a vacuum oven (T = 35 °C) overnight. After cooling, the Hydromatrix[®] was treated with 2 N HCl (600 µL)⁷ and the plates were stacked. The crude library samples were dissolved in MEK and pipetted onto the columns. MEK was used to elute the compounds, and several 2-mL fractions were collected.

Crystallization


After treatment with Hydromatrix[®], several compounds crystallized out of the 50% MeOH/MEK solution. The liquid was removed from the well, and the solid dissolved in DMSO (250 µL) and transferred to a Marsh tube.


- 5 **HPLC analysis method.** The purity of the library was determined from the relative peak area of the UV absorbance. The identity of the compound was determined by MS confirmation of the molecular weight. The samples from this library were best prepared from DMSO solutions of the crude compounds. To a 96-well LC/MS plate was added ca 30 µL of DMSO solution (solution concentration was typically ca 30
- 10 mM). DMSO (ca 50 µL) and MeCN (ca 750 µL) were then used to dilute the samples.

HPLC Conditions


- 15 Column: Zorbax SB-C18 (4.6 x 75 mm, 3.5 microns)
Gradient: A solvent: 100% MeCN (0.075% HCO₂H), B solvent: 100% H₂O (0.075% HCO₂H)
Flow: 2 mL/min
Detection wavelength: 220 nm (UV)
- 20 Autosampler: Gilson 215 Liquid Handler
Pump: Shimadzu LC-10AD VP
Detector: Shimadzu UV-VIS Detector SPD-10A VP
Injection volume: 40 µL
Mass Spectrometer: PESCIEX API 150EX

Preparation of Benzoic Acid Derivatives for Library Synthesis


10



To a 250-mL round-bottom flask cooled to 0 °C under nitrogen was added
 5 chlorosulfonic acid (50 mL, 752 mmol), followed by *o*-bromobenzoic acid (**3**, 10.0 g, 49.7 mmol) in small portions over 2 min to give a brownish solution. The solution was warmed to room temperature and heated to 115 °C overnight. The reaction mixture was then cooled to room temperature and poured over ice (ca 750 g).¹ The resulting precipitate was filtered, washed with water and dried in a vacuum oven at 80
 10 °C for 7 h to afford 12.81 g (86%) of **4** as an off-white solid: ¹H NMR (DMSO-*d*₆) δ 7.75 (d, *J* = 10.1 Hz, 1H), 7.65 (d, *J* = 10.1 Hz, 1H), 8.46 (s, 1H), 13.96 (br s, 1H).




15 Chlorosulfonic acid (50 mL 752 mmol) was added to a 250-mL round-bottom flask and cooled to 0 °C in the presence of nitrogen. *p*-Bromobenzoic acid (**5**, 10.0 g, 49.7 mmol) was added in small portions over 2 min to give a brownish solution. The solution was warmed to room temperature and heated to 145 °C overnight. The reaction mixture was then cooled to room temperature and poured over ice (ca 750
 20 g).¹ The resulting precipitate was filtered, washed with water and dried in a vacuum oven at 80 °C for 7 h to afford 13.21 g (89%) of **6** as a tan solid: ¹H NMR (DMSO-*d*₆) δ 7.60 (dd, *J* = 2.1, 8.3 Hz, 1H), 7.69 (d, *J* = 8.2 Hz, 1H), 8.31 (d, *J* = 2.1 Hz, 1H), 14.05 (br s, 1H).



Chlorosulfonic acid (50 mL, 752 mmol) was added to a 250-mL round-bottom flask and cooled to 0 °C in the presence of nitrogen. *o*-Toluic acid (**7**, 10.0 g, 73.4 mmol) was added in small portions over 2 min to give a brownish solution. The solution was

5 warmed to room temperature and heated to 145 °C overnight. The reaction mixture was then cooled to room temperature and poured over ice (ca 750 g).¹ The resulting precipitate was filtered, washed with water and dried in a vacuum oven at 80 °C for 7 h to afford 15.53 g (90%) of **8** as an off-white solid: ¹H NMR (DMSO-*d*₆) δ 2.53 (s, 3H), 7.26 (d, *J* = 7.9 Hz, 1H), 7.63 (d, *J* = 7.9 Hz, 1H), 8.07 (s, 1H), 13.60 (br s, 1H).


10



Chlorosulfonic acid (50 mL, 752 mmol) was added to a 250-mL round-bottom flask and cooled to 0 °C in the presence of nitrogen. *p*-Anisic acid (**9**, 10.0 g, 73.4 mmol) was added in small portions over 2 min to give a yellow solution. The solution was

15 warmed to room temperature and heated to 63 °C for 1 h. The reaction mixture was then cooled to room temperature and poured over ice (ca 750 g).¹ The resulting precipitate was filtered, washed with water and dried in a vacuum oven at 70 °C for 12 h to afford 14.62 g (85%) of **10** as a white solid: ¹H NMR (DMSO-*d*₆) δ 3.84 (s, 3H), 7.06 (d, *J* = 8.7 Hz, 1H), 7.70 (dd, *J* = 2.3, 8.7 Hz, 1H), 8.31 (d, *J* = 2.3 Hz, 1H),

20 13.82 (br s, 1H).




Solid *p*-anisic acid (**11**, 10.0 g, 66 mmol) was added to an ice-cooled, 250-mL round-bottom flask containing chlorosulfonic acid (50 mL, 752 mmol) under nitrogen. The

25 solution was heated at 65 °C for 1 h and turned bright yellow. The reaction mixture was cooled to room temperature and poured over ice (ca 750 g). The resulting

precipitate was then filtered, washed with water and dried in a vacuum oven at 70 °C for 8 h to yield 13.18 g (80%) of **12** as a pale yellow solid: ¹H NMR (DMSO-*d*₆) δ 3.88 (s, 3H), 7.06 (d, *J* = 8.7 Hz, 1H), 7.90 (dd, *J* = 2.4, 8.6 Hz, 1H), 8.31 (d, *J* = 2.3 Hz, 1H), 13.82 (br s, 1H).

5

General Procedure for the Conversion of Acids to Acid Chlorides in a Plate Format




10

To a plate of 2-mL glass reaction tubes arranged in a standard 96-well format was added the diversity set of carboxylic acids (**1**, 250 μL, 1 M THF, 250 μmol). The samples were concentrated in a Genevac HT-4 (20% heat with no heat boost for 1 h). A solution of 1% DMF/CH₂Cl₂ (50 μL) was added to the wells, followed by CH₂Cl₂ (250 μL). The carboxylic acid plate was placed in a nitrogen-filled glove bag and oxalyl chloride (125 μL, 2 M CH₂Cl₂, 250 μmol) was added. After the addition of CH₂Cl₂ (250 μL), a capmat with 96 predrilled holes was fitted on the plate. The plate was shaken on an orbital shaker in a N₂ filled glove bag for 6-8 h.

15

20 Preparation of Isatioc Anhydride Derivatives




To a dry, 4-L round bottom flask was added 175 g (810 mmol) of 2-amino-5-bromobenzoic acid (**19**), triphosgene (83 g, 278 mmol), and dioxane (3 L). The suspension was stirred under N₂ and heated to reflux. The reaction was found to be complete by TLC and NMR after stirring at reflux for 3 h, but did not become homogenous at any time. After cooling to room temperature, the reaction was filtered

25

and the precipitate washed with ether. The solid was dried in the vacuum oven at 40 °C to afford 5-bromoisatoic anhydride (**20**, 151.1 g, 72%) as a white solid: ^1H NMR (DMSO- d_6) δ 7.29 (d, J = 8.7, 1H), 7.91 (dd, J = 2.5, 8.7, 1H), 8.09 (d, J = 2.3, 1H).


- 5 Sodium cyanoborohydride (4.88 g, 77.8 mmol) was added to a solution of 6-chloroindoline (5.9 g, 38.9 mmol) in acetic acid (100 mL). Gas evolution was evident at the beginning of the reaction. After stirring for 10 h, the solution was diluted with water (100 mL) and 6 N NaOH was added until the pH of the reaction mixture was 12-13. The resulting mixture was extracted with CH_2Cl_2 (3 x 200 mL), and the
- 10 combined organic layers dried over MgSO_4 . Flash column chromatography on silica gel (35% EtOAc/hexanes) yielded 2.3 g (39%) of a clear liquid: ^1H NMR (DMSO- d_6) δ 2.87 (t, J = 8.4 Hz, 2H), 3.44 (t, J = 8.4 Hz, 2H), 6.45 (d, J = 1.8 Hz, 1H), 6.47 (dd, J = 1.8, 7.6 Hz, 1H), 6.96 (d, J = 7.3 Hz, 1H).

15




- To a 3-L, three-necked, round bottom flask equipped with a reflux condenser was added methyl-2-amino-5-bromobenzoate (**7**, 125 g, 543 mmol), copper cyanide (56.2
- 20 g, 624 mmol), and NMP (1 L). The reaction was heated to 200 °C and stirred for 4 h under nitrogen. The dark brown reaction mixture was allowed to cool and a brown precipitate was formed. The mixture was poured into a 16-L beaker containing sodium cyanide solution (1 kg NaCN in 6 L H_2O) followed by the addition of EtOAc (4 L). The precipitate was dissolved by agitation and the layers were separated. The
- 25 aqueous layer was extracted with EtOAc (2 x 1.5 L) and the combined organic layers were washed with 10% NaCN solution (2 L), H_2O (2 L) and then dried over MgSO_4 . The light brown solution was concentrated and then dried in a vacuum oven overnight.

The ester was then dissolved in EtOH (2 L) and added to a 3-L round bottom flask followed by KOH solution (96.7 g of KOH in 500 mL H₂O). The reaction mixture was heated to 50 °C and stirred for 2 h. The resultant dark-brown solution was poured into a chilled 2 N HCl solution (1.5 L), creating a yellowish precipitate. The solid was collected on a sintered glass filter frit, washed with cold water, and dried at 35 °C in a vacuum oven overnight to give 64.0 g (73%) of 5-cyanoanthranilic acid: ¹H NMR (DMSO-*d*₆) δ 7.16 (d, *J* = 8.7, 1H), 7.79 (dd, *J* = 2.5, 8.7, 1H), 7.87 (d, *J* = 2.4, 1H).



To a dry 4-L round bottom flask was added 5-cyanoanthranilic acid (**9**, 64 g, 395 mmol), triphosgene (39.4 g, 131 mmol) and dioxane (2 L). The suspension was stirred under N₂ and heated to reflux. The reaction mixture became homogeneous after stirring at reflux for 2 h. As the carbonylation product was formed, white precipitate appeared in the solution. After stirring at reflux for an additional 3 h, the reaction was cooled to room temperature, filtered, and the precipitate washed with ether. The solid was dried in the vacuum oven to afford 5-cyanoisatoic anhydride (**10**, 51.5 g, 68%) as a pale yellow solid: ¹H NMR (DMSO-*d*₆) δ 6.86 (d, *J* = 9.3, 1H), 7.55 (dd, *J* = 2.6, 9.0, 1H), 8.04 (d, *J* = 2.4, 1H).















3-Iodobenzoyl Chloride. To a suspension of *m*-iodobenzoic acid (**21**, 5.0g, 20.1 mmol) suspended in CH₂Cl₂ (60 mL) was added DMF (2 drops), followed by oxalyl chloride (20.1 mL of a 2 M solution in CH₂Cl₂, 40.2 mmol) under nitrogen atmosphere. After stirring for 18 h, the reaction mixture was nearly homogeneous.





Acid chloride **22** was then concentrated, azeotroped with toluene (2 x 25 mL), and placed on a high vacuum.







Example 10: Additional Compounds Useful For Sterilization, Sanitation, Antisepsis, and Disinfection





The following compounds may be synthesized using the methodology described above or via methods known in the art.





Compound No., Structure	Compound No., Structure
<p>L-140191</p> 	<p>L-140209</p> 
<p>L-140209A</p> 	<p>L-140229</p> 
<p>L-140229A</p> 	<p>L-140240</p> 







Compound No., Structure	Compound No., Structure
<p data-bbox="277 174 415 205">L-159112</p>  <chem data-bbox="427 233 673 730">COCCN(S(=O)(=O)c1ccc(cc1)NC(=O)Nc2cc(Cl)ccc2C(=O)O)CCOC</chem>	<p data-bbox="846 174 984 205">L-159113</p>  <chem data-bbox="995 233 1242 730">COCCN(S(=O)(=O)c1ccc(cc1)NC(=O)Nc2cc(Br)ccc2C(=O)O)CCOC</chem>
<p data-bbox="277 779 415 810">L-159117</p>  <chem data-bbox="427 827 673 1325">COCCN(S(=O)(=O)c1ccc(cc1)NC(=O)Nc2cc(I)ccc2C(=O)O)CCOC</chem>	<p data-bbox="846 779 984 810">L-159120</p>  <chem data-bbox="1015 827 1214 1297">Clc1ccc(NC(=O)c2ccc(S(=O)(=O)N3CCOCC3)cc2)cc1C(=O)O</chem>
<p data-bbox="277 1367 415 1398">L-159121</p>  <chem data-bbox="443 1415 643 1885">Brc1ccc(NC(=O)c2ccc(S(=O)(=O)N3CCOCC3)cc2)cc1C(=O)O</chem>	<p data-bbox="846 1367 984 1398">L-159124</p>  <chem data-bbox="1015 1415 1214 1885">Ic1ccc(NC(=O)c2ccc(S(=O)(=O)N3CCOCC3)cc2)cc1C(=O)O</chem>





Compound No., Structure	Compound No., Structure
<p data-bbox="277 180 407 212">L-159127</p>  <chem data-bbox="423 239 675 783">Clc1ccc(cc1NC(=O)c2ccc(cc2)S(=O)(=O)Nc3ccc(cc3)C#N)C(=O)O</chem>	<p data-bbox="844 180 974 212">L-159128</p>  <chem data-bbox="990 239 1242 783">Brc1ccc(cc1NC(=O)c2ccc(cc2)S(=O)(=O)Nc3ccc(cc3)C#N)C(=O)O</chem>
<p data-bbox="277 825 407 856">L-159131</p>  <chem data-bbox="446 882 643 1434">Clc1ccc(cc1NC(=O)c2ccc(cc2)S(=O)(=O)NCc3ccc(cc3)C(F)(F)F)C(=O)O</chem>	<p data-bbox="844 825 974 856">L-159133</p>  <chem data-bbox="1015 882 1211 1434">Ic1ccc(cc1NC(=O)c2ccc(cc2)S(=O)(=O)NCc3ccc(cc3)C(F)(F)F)C(=O)O</chem>







Compound No., Structure	Compound No., Structure
<p data-bbox="277 180 407 212">L-159139</p> 	<p data-bbox="846 180 976 212">L-159157</p> 
<p data-bbox="277 825 423 856">L-159157A</p> 	<p data-bbox="846 825 976 856">L-159158</p> 
<p data-bbox="277 1381 423 1413">L-159158A</p> 	<p data-bbox="846 1381 976 1413">L-159161</p> 







Compound No., Structure	Compound No., Structure
<p data-bbox="277 186 428 218">L-159161A</p>  <chem data-bbox="446 241 649 714">Clc1ccc(N(S(=O)(=O)c2ccc(cc2)NC(=O)c3cc(I)ccc3C(=O)O)C(=O)N)cc1</chem>	<p data-bbox="841 186 976 218">L-159164</p>  <chem data-bbox="990 241 1193 714">CCCN(C1=CC=CC=C1)S(=O)(=O)c2ccc(cc2)NC(=O)c3cc(Cl)ccc3C(=O)O</chem>
<p data-bbox="277 753 406 785">L-159165</p>  <chem data-bbox="422 808 625 1260">CCCN(C1=CC=CC=C1)S(=O)(=O)c2ccc(cc2)NC(=O)c3cc(Br)ccc3C(=O)O</chem>	<p data-bbox="841 753 969 785">L-159168</p>  <chem data-bbox="990 808 1193 1260">CCCN(C1=CC=CC=C1)S(=O)(=O)c2ccc(cc2)NC(=O)c3cc(I)ccc3C(=O)O</chem>







Compound No., Structure	Compound No., Structure
<p data-bbox="272 178 402 212">L-159171</p> 	<p data-bbox="841 178 971 212">L-159172</p> 
<p data-bbox="272 913 423 947">L-159172A</p> 	<p data-bbox="841 913 971 947">L-159176</p> 







Compound No., Structure	Compound No., Structure
<p data-bbox="266 182 396 216">L-170148</p> 	<p data-bbox="829 182 959 216">L-170154</p> 
<p data-bbox="266 802 396 835">L-170160</p> 	<p data-bbox="829 802 959 835">L-170166</p> 
<p data-bbox="266 1394 428 1428">L-170166A</p> 	<p data-bbox="829 1394 959 1428">L-170178</p> 







Compound No., Structure	Compound No., Structure
<p data-bbox="264 182 418 216">L-170178A</p> 	<p data-bbox="829 182 967 216">L-170184</p> 
<p data-bbox="264 858 402 892">L-170190</p> 	<p data-bbox="829 858 967 892">L-170196</p> 







Compound No., Structure	Compound No., Structure
<p data-bbox="271 174 406 210">L-170210</p> 	<p data-bbox="837 174 972 210">L-170216</p> 
<p data-bbox="271 783 406 819">L-181367</p> 	<p data-bbox="837 783 972 819">L-181368</p> 
<p data-bbox="271 1381 406 1417">L-181370</p> 	<p data-bbox="837 1381 972 1417">L-181371</p> 







Compound No., Structure	Compound No., Structure
<p data-bbox="266 168 402 197">L-181379</p> 	<p data-bbox="834 168 971 197">L-181382</p> 
<p data-bbox="266 770 402 800">L-181383</p> 	<p data-bbox="834 770 971 800">L-181385</p> 
<p data-bbox="266 1365 402 1394">L-181388</p> 	<p data-bbox="834 1365 971 1394">L-181389</p> 







Compound No., Structure	Compound No., Structure
<p data-bbox="269 174 402 205">L-181391</p> 	<p data-bbox="837 174 971 205">L-181392</p> 
<p data-bbox="269 741 402 772">L-181394</p> 	<p data-bbox="837 741 971 772">L-181395</p> 
<p data-bbox="269 1297 402 1329">L-181397</p> 	<p data-bbox="837 1297 971 1329">L-181398</p> 







Compound No., Structure	Compound No., Structure
<p data-bbox="267 174 397 210">L-181400</p> 	<p data-bbox="841 174 971 210">L-181401</p> 
<p data-bbox="267 741 397 777">L-181403</p> 	<p data-bbox="841 741 971 777">L-181404</p> 
<p data-bbox="267 1297 397 1333">L-181406</p> 	<p data-bbox="841 1297 971 1333">L-181407</p> 







Compound No., Structure	Compound No., Structure
<p data-bbox="261 180 391 212">L-181409</p> 	<p data-bbox="829 180 959 212">L-181410</p> 
<p data-bbox="261 785 391 816">L-181412</p> 	<p data-bbox="829 785 959 816">L-181413</p> 
<p data-bbox="261 1390 391 1421">L-181419</p> 	<p data-bbox="829 1390 959 1421">L-181421</p> 





Compound No., Structure	Compound No., Structure
<p>L-181423</p>  <chem>O=C(O)c1cc(I)ccc1NC(=O)c2ccc(cc2)S(=O)(=O)Nc3ccc(Cl)cc3</chem>	<p>L-181424</p>  <chem>O=C(O)c1cc(F)ccc1NC(=O)c2ccc(cc2)S(=O)(=O)Nc3ccc(Cl)cc3</chem>
<p>L-181427</p>  <chem>CN(C)S(=O)(=O)c1ccc(cc1)C(=O)Nc2cc(F)ccc2C(=O)O</chem>	<p>L-181429</p>  <chem>COc1cc(Cl)ccc1NS(=O)(=O)c2ccc(cc2)C(=O)Nc3cc(Br)ccc3C(=O)O</chem>
<p>L-181430</p>  <chem>COc1cc(Cl)ccc1NS(=O)(=O)c2ccc(cc2)C(=O)Nc3cc(Cl)ccc3C(=O)O</chem>	<p>L-181432</p>  <chem>COc1cc(Cl)ccc1NS(=O)(=O)c2ccc(cc2)C(=O)Nc3cc(I)ccc3C(=O)O</chem>







Compound No., Structure	Compound No., Structure
<p data-bbox="248 184 378 216">L-181433</p>  <chem data-bbox="370 237 686 751">COc1cc(Cl)ccc1NS(=O)(=O)c2ccc(cc2)C(=O)Nc3ccc(F)cc3C(=O)O</chem>	<p data-bbox="813 174 943 205">L-181435</p>  <chem data-bbox="938 226 1239 720">COc1cc(Cl)ccc1NS(=O)(=O)c2ccc(cc2)C(=O)Nc3ccc(Br)cc3C(=O)O</chem>
<p data-bbox="248 783 386 814">L-181436</p>  <chem data-bbox="381 846 682 1329">COc1cc(Cl)ccc1NS(=O)(=O)c2ccc(cc2)C(=O)Nc3ccccc3C(=O)O</chem>	<p data-bbox="813 783 951 814">L-181438</p>  <chem data-bbox="950 835 1250 1318">COc1cc(Cl)ccc1NS(=O)(=O)c2ccc(cc2)C(=O)Nc3cc(C)ccc3C(=O)O</chem>
<p data-bbox="248 1371 394 1402">L-181439</p>  <chem data-bbox="393 1434 693 1917">COc1cc(Cl)ccc1NS(=O)(=O)c2ccc(cc2)C(=O)Nc3cc(F)ccc3C(=O)O</chem>	<p data-bbox="813 1371 959 1402">L-181442</p>  <chem data-bbox="961 1423 1261 1906">COc1cc(Cl)ccc1NS(=O)(=O)c2ccc(cc2)C(=O)Nc3cc(Cl)ccc3C(=O)O</chem>





Compound No., Structure	Compound No., Structure
<p>L-181445</p> 	<p>L-186544</p> 
<p>L-199155</p> 	<p>L-199156</p> 
<p>L-199157</p> 	<p>L-199158</p> 







Compound No., Structure	Compound No., Structure
<p data-bbox="267 178 397 220">L-199159</p> 	<p data-bbox="836 178 966 220">L-199160</p> 
<p data-bbox="267 808 397 850">L-199161</p> 	<p data-bbox="836 808 966 850">L-199162</p> 
<p data-bbox="267 1375 397 1417">L-199163</p> 	<p data-bbox="836 1375 966 1417">L-199164</p> 





Compound No., Structure	Compound No., Structure
<p data-bbox="269 170 402 201">L-199165</p> 	<p data-bbox="837 170 971 201">L-199166</p> 
<p data-bbox="269 766 402 798">L-199167</p> 	<p data-bbox="837 766 971 798">L-199168</p> 
<p data-bbox="269 1381 402 1413">L-199169</p> 	<p data-bbox="837 1381 971 1413">L-199170</p> 





Compound No., Structure	Compound No., Structure
<p data-bbox="277 170 402 197">L-199171</p>  <p>The structure of L-199171 consists of a 3-bromo-4-((4-((2-methyl-2,3,4,5-tetrahydro-1H-indolizin-5-ylideneamino)sulfonyl)phenyl)carbamoyl)benzoic acid moiety. It features a benzene ring with a bromine atom at the 3-position and a carboxylic acid group at the 1-position. An amide group at the 4-position connects to a para-phenylene ring, which is further connected via a sulfonyl group to a nitrogen atom. This nitrogen is part of a fused bicyclic system, specifically a 2,3,4,5-tetrahydro-1H-indolizine derivative, with a methyl group on the nitrogen and a hydroxyl group on the adjacent carbon.</p>	<p data-bbox="842 170 967 197">L-199172</p>  <p>The structure of L-199172 is similar to L-199171, featuring the same 3-bromo-4-((4-((2-methyl-2,3,4,5-tetrahydro-1H-indolizin-5-ylideneamino)sulfonyl)phenyl)carbamoyl)benzoic acid moiety. However, the nitrogen atom of the sulfonyl group is part of a different fused bicyclic system, specifically a 4-chloro-1,2,3,4-tetrahydroquinolin-2(1H)-one derivative, which includes a carbonyl group at the 2-position and a chlorine atom at the 4-position.</p>
<p data-bbox="277 770 402 798">L-199173</p>  <p>The structure of L-199173 features the same 3-bromo-4-((4-((2-methyl-2,3,4,5-tetrahydro-1H-indolizin-5-ylideneamino)sulfonyl)phenyl)carbamoyl)benzoic acid moiety. In this case, the nitrogen atom of the sulfonyl group is part of a piperidine ring. The piperidine ring is substituted with a phenylamino group (-NH-Ph) at the 4-position.</p>	<p data-bbox="842 770 967 798">L-199174</p>  <p>The structure of L-199174 features the same 3-bromo-4-((4-((2-methyl-2,3,4,5-tetrahydro-1H-indolizin-5-ylideneamino)sulfonyl)phenyl)carbamoyl)benzoic acid moiety. The nitrogen atom of the sulfonyl group is part of a complex polycyclic system, specifically a 1,2,3,4,5,6-hexahydro-1H-benzocyclopenta[b]pyridine derivative, which includes a hydroxyl group on one of the ring carbons.</p>









Compound No., Structure	Compound No., Structure
<p>L-199175</p> 	<p>L-199176</p> 
<p>L-199177</p> 	<p>L-199178</p> 
<p>L-199179</p> 	<p>L-199180</p> 









Compound No., Structure	Compound No., Structure
<p data-bbox="261 174 391 205">L-199181</p>  <p>The structure of L-199181 consists of a 3-bromo-4-((4-((5-bromo-1,2,3,4-tetrahydronaphthalen-1-yl)sulfonyl)phenyl)carbamoyl)benzoic acid moiety. It features a central benzene ring with a carboxylic acid group at position 1, a bromine atom at position 3, and a carbamoyl group at position 4. The carbamoyl group is linked to a para-substituted phenyl ring, which is in turn connected via a sulfonyl group to a 5-bromo-1,2,3,4-tetrahydronaphthalen-1-yl group.</p>	<p data-bbox="833 174 963 205">L-199182</p>  <p>The structure of L-199182 consists of a 3-bromo-4-((4-((1,2,3,4-tetrahydroindolizin-1-yl)sulfonyl)phenyl)carbamoyl)benzoic acid moiety. It features a central benzene ring with a carboxylic acid group at position 1, a bromine atom at position 3, and a carbamoyl group at position 4. The carbamoyl group is linked to a para-substituted phenyl ring, which is in turn connected via a sulfonyl group to a 1,2,3,4-tetrahydroindolizin-1-yl group.</p>
<p data-bbox="261 810 391 842">L-199183</p>  <p>The structure of L-199183 consists of a 3-bromo-4-((4-((5-fluoro-1,2,3,4-tetrahydroindolizin-1-yl)sulfonyl)phenyl)carbamoyl)benzoic acid moiety. It features a central benzene ring with a carboxylic acid group at position 1, a bromine atom at position 3, and a carbamoyl group at position 4. The carbamoyl group is linked to a para-substituted phenyl ring, which is in turn connected via a sulfonyl group to a 5-fluoro-1,2,3,4-tetrahydroindolizin-1-yl group.</p>	<p data-bbox="833 810 963 842">L-199184</p>  <p>The structure of L-199184 consists of a 3-bromo-4-((4-((1,2,3,4-tetrahydroindolizin-1-yl)sulfonyl)phenyl)carbamoyl)benzoic acid moiety. It features a central benzene ring with a carboxylic acid group at position 1, a bromine atom at position 3, and a carbamoyl group at position 4. The carbamoyl group is linked to a para-substituted phenyl ring, which is in turn connected via a sulfonyl group to a 1,2,3,4-tetrahydroindolizin-1-yl group.</p>









Compound No., Structure	Compound No., Structure
<p data-bbox="245 184 375 216">L-199185</p> 	<p data-bbox="813 174 943 205">L-199186</p> 
<p data-bbox="253 758 383 789">L-199187</p> 	<p data-bbox="821 747 951 779">L-199188</p> 
<p data-bbox="261 1314 391 1346">L-199189</p> 	<p data-bbox="829 1293 959 1325">L-199190</p> 











Compound No., Structure	Compound No., Structure
<p data-bbox="240 184 370 226">L-199191</p> 	<p data-bbox="808 184 938 226">L-199192</p> 
<p data-bbox="256 814 386 856">L-199193</p> 	<p data-bbox="824 814 954 856">L-199194</p> 









Compound No., Structure	Compound No., Structure
<p data-bbox="251 178 381 220">L-199199</p> 	<p data-bbox="820 168 950 210">L-217790</p> 
<p data-bbox="251 850 389 892">L-217791</p> 	<p data-bbox="828 840 966 882">L-218343</p> 







Compound No., Structure	Compound No., Structure
<p>L-502902</p> 	<p>L-502903</p> 
<p>L-502904</p> 	<p>PHA-500140</p> 
<p>PHA-500152</p> 	<p>PHA-500200</p> 
<p>PHA-500218</p> 	<p>PHA-500219</p> 







Compound No., Structure	Compound No., Structure
<p>PHA-500230</p> 	<p>PHA-500236</p> 
<p>PHA-500248</p> 	<p>PHA-500284</p> 
<p>PHA-502605</p> 	<p>PHA-502606</p> 
<p>PHA-520185</p> 	<p>PHA-520200</p> 







Compound No., Structure	Compound No., Structure
<p>PHA-520221</p> 	<p>PHA-520245</p> 
<p>PHA-520412</p> 	<p>PHA-520413</p> 
<p>PHA-520414</p> 	<p>PHA-520416</p> 
<p>PHA-523506</p> 	<p>PHA-523507</p> 







Compound No., Structure	Compound No., Structure
PHA-523508 	PHA-523509 
PHA-523510 	PHA-523511 
PHA-523512 	PHA-523513 
PHA-523514 	PHA-523515 
PHA-523516 	PHA-523517 









Compound No., Structure	Compound No., Structure
PHA-523518 	PHA-523519 
PHA-523520 	PHA-523521 
PHA-524545E 	PHA-524553A 
PHA-525500 	PHA-525501 







Compound No., Structure	Compound No., Structure
<p data-bbox="219 189 397 231">PHA-525502</p> 	<p data-bbox="787 168 966 210">PHA-525503</p> 
<p data-bbox="235 609 414 651">PHA-525504</p> 	<p data-bbox="803 588 982 630">PHA-525505</p> 
<p data-bbox="251 1186 430 1228">PHA-525506</p> 	<p data-bbox="820 1165 998 1207">PHA-526641</p> 







Compound No., Structure	Compound No., Structure
<p data-bbox="224 191 397 226">PHA-526643</p> 	<p data-bbox="792 170 966 205">PHA-526648</p> 
<p data-bbox="240 787 418 823">PHA-526650</p> 	<p data-bbox="808 766 982 802">PHA-526651</p> 
<p data-bbox="264 1375 443 1411">PHA-526652</p> 	<p data-bbox="833 1354 1011 1390">PHA-526653</p> 







Compound No., Structure	Compound No., Structure
<p data-bbox="224 197 402 239">PHA-526655</p> 	<p data-bbox="795 176 974 218">PHA-526660</p> 
<p data-bbox="224 869 402 911">PHA-526661</p> 	<p data-bbox="795 848 974 890">PHA-526679</p> 
<p data-bbox="224 1310 402 1352">PHA-526681</p> 	<p data-bbox="795 1289 974 1331">PHA-526683</p> 







Compound No., Structure	Compound No., Structure
<p data-bbox="233 184 407 222">PHA-526705</p>  <chem data-bbox="329 254 708 625">COc1cc(OC)cc(COc2ccc(cc2)C(=O)Nc3ccc(cc3)C(=O)O)c1</chem>	<p data-bbox="802 170 976 207">PHA-526707</p>  <chem data-bbox="922 233 1247 642">CCOC(=O)C(CC)Oc1ccc(cc1)C(=O)Nc2ccc(cc2)C(=O)O</chem>
<p data-bbox="250 709 423 747">PHA-526712</p>  <chem data-bbox="431 758 610 1209">CCOC(=O)C(CC)Oc1ccc(cc1)C(=O)Nc2ccc(cc2)C(=O)O</chem>	<p data-bbox="818 688 992 726">PHA-530914</p>  <chem data-bbox="987 747 1195 1094">BrC1=CC=C(NC(=O)c2ccc(O)cc2)C(=O)O1</chem>
<p data-bbox="266 1255 440 1293">PHA-530915</p>  <chem data-bbox="410 1304 678 1608">BrC1=CC=C(NC(=O)c2ccc(O)cc2)C(=O)O1</chem>	<p data-bbox="834 1234 1008 1272">PHA-533232</p>  <chem data-bbox="984 1293 1247 1566">CCOc1ccc(cc1)C(=O)Nc2ccc(cc2)C(=O)O</chem>







Compound No., Structure	Compound No., Structure
<p>PHA-533237</p> 	<p>PHA-533243</p> 
<p>PHA-533244</p> 	<p>PHA-533247</p> 
<p>PHA-533249</p> 	<p>PHA-533252</p> 
<p>PHA-533253</p> 	<p>PHA-533257</p> 







Compound No., Structure	Compound No., Structure
<p data-bbox="245 170 418 205">PHA-533258</p> 	<p data-bbox="813 170 987 205">PHA-533259</p> 
<p data-bbox="256 764 430 800">PHA-533261</p> 	<p data-bbox="824 764 998 800">PHA-533262</p> 
<p data-bbox="266 1283 440 1318">PHA-533264</p> 	<p data-bbox="834 1283 1008 1318">PHA-533265</p> 









Compound No., Structure	Compound No., Structure
<p data-bbox="256 170 431 201">PHA-533266</p>  <chem data-bbox="435 226 620 674">COCCOc1ccc(cc1)C(=O)Nc2ccc(Br)cc2C(=O)O</chem>	<p data-bbox="824 170 1000 201">PHA-533268</p>  <chem data-bbox="1003 216 1188 695">CC(=O)NCCOc1ccc(cc1)C(=O)Nc2ccc(Br)cc2C(=O)O</chem>
<p data-bbox="256 758 431 789">PHA-533269</p>  <chem data-bbox="443 810 628 1314">CC#CCCCOc1ccc(cc1)C(=O)Nc2ccc(Br)cc2C(=O)O</chem>	<p data-bbox="824 758 1000 789">PHA-533272</p>  <chem data-bbox="1011 800 1196 1367">CCOCCOc1ccc(cc1)C(=O)Nc2ccc(Br)cc2C(=O)O</chem>
<p data-bbox="256 1430 431 1461">PHA-533273</p>  <chem data-bbox="443 1493 667 1944">COc1ccc(cc1)C2OC(=O)C2c3ccc(cc3)C(=O)Nc4ccc(Br)cc4C(=O)O</chem>	<p data-bbox="824 1430 1000 1461">PHA-533274</p>  <chem data-bbox="951 1482 1292 1892">COc1ccc(cc1)COc2ccc(cc2)C(=O)Nc3ccc(Br)cc3C(=O)O</chem>









Compound No., Structure	Compound No., Structure
<p data-bbox="248 174 423 216">PHA-533275</p> 	<p data-bbox="816 174 992 205">PHA-533276</p> 
<p data-bbox="248 762 423 804">PHA-533278</p> 	<p data-bbox="816 751 992 783">PHA-533281</p> 
<p data-bbox="248 1308 423 1350">PHA-533282</p> 	<p data-bbox="816 1297 992 1329">PHA-533285</p> 







Compound No., Structure	Compound No., Structure
<p data-bbox="245 174 423 205">PHA-533286</p> 	<p data-bbox="813 168 992 199">PHA-533289</p> 
<p data-bbox="256 730 435 762">PHA-533290</p> 	<p data-bbox="824 720 1003 751">PHA-533401</p> 
<p data-bbox="267 1276 446 1308">PHA-537084</p>  <p data-bbox="354 1717 760 1749">least retained isomer by RP-HPLC</p>	<p data-bbox="836 1266 1015 1297">PHA-537085</p> 







Compound No., Structure	Compound No., Structure
<p data-bbox="240 174 414 210">PHA-537089</p>  <p data-bbox="321 741 738 772">least retained isomer by RP-LC/MS</p>	<p data-bbox="808 163 982 199">PHA-537090</p>  <p data-bbox="885 709 1307 741">least retained isomer by RP-LC/MS</p>
<p data-bbox="256 804 430 840">PHA-537091</p> 	<p data-bbox="824 787 998 823">PHA-537092</p> 
<p data-bbox="272 1381 446 1417">PHA-537098</p> 	<p data-bbox="841 1365 1015 1400">PHA-537099</p> 







Compound No., Structure	Compound No., Structure
<p>PHA-537100</p> 	<p>PHA-537101</p> 
<p>PHA-537106</p> 	<p>PHA-537110</p> 
<p>PHA-537112</p> 	<p>PHA-537114</p> 







Compound No., Structure	Compound No., Structure
<p>PHA-537121</p> 	<p>PHA-537122</p> 
<p>PHA-537128</p> 	<p>PHA-537133</p> 
<p>PHA-537138</p> 	<p>PHA-537139</p> 
<p>PHA-537142</p> 	<p>PHA-537143</p> 







Compound No., Structure	Compound No., Structure
PHA-537144 	PHA-537150 
PHA-537152 	PHA-537155 
PHA-537157 	PHA-537158 
PHA-537162 	PHA-537202  most highly retained isomer by RP-LC/MS





Compound No., Structure	Compound No., Structure
<p>PHA-537203</p>  <p>most highly retained isomer by RP-LC/MS</p>	<p>PHA-537204</p>  <p>most highly retained isomer by RP-LC/M</p>
<p>PHA-538016</p> 	<p>PHA-539146</p> 
<p>PHA-539148</p> 	<p>PHA-539149</p> 







Compound No., Structure	Compound No., Structure
<p data-bbox="245 174 418 205">PHA-539150</p> 	<p data-bbox="813 174 987 205">PHA-539152</p> 
<p data-bbox="256 766 430 798">PHA-539153</p> 	<p data-bbox="824 766 998 798">PHA-539154</p> 
<p data-bbox="272 1358 446 1390">PHA-539155</p> 	<p data-bbox="841 1358 1015 1390">PHA-539156</p> 











Compound No., Structure	Compound No., Structure
<p>PHA-539164</p> 	<p>PHA-539168</p> 
<p>PHA-539169</p> 	<p>PHA-539170</p> 
<p>PHA-539171</p> 	<p>PHA-539172</p> 











Compound No., Structure	Compound No., Structure
<p data-bbox="240 176 412 218">PHA-539174</p> 	<p data-bbox="808 176 980 218">PHA-539175</p> 
<p data-bbox="240 743 428 785">PHA-539177</p> 	<p data-bbox="808 743 997 785">PHA-539179</p> 
<p data-bbox="240 1310 444 1352">PHA-539180</p> 	<p data-bbox="808 1310 1013 1352">PHA-539181</p> 











Compound No., Structure	Compound No., Structure
<p data-bbox="251 168 422 210">PHA-539183</p> 	<p data-bbox="820 168 990 210">PHA-539186</p> 
<p data-bbox="251 777 422 819">PHA-539187</p> 	<p data-bbox="820 777 990 819">PHA-539188</p> 
<p data-bbox="251 1354 422 1396">PHA-539190</p> 	<p data-bbox="820 1354 990 1396">PHA-539193</p> 











Compound No., Structure	Compound No., Structure
<p data-bbox="256 163 430 195">PHA-539194</p>  <p>The structure of PHA-539194 consists of a 4-bromophenyl ring substituted with a carboxylic acid group and an amide linkage. The amide nitrogen is connected to a benzoyl group, which is further linked to a para-substituted benzene ring. This benzene ring is connected via a sulfonamide group to another para-substituted benzene ring, which is terminated by a morpholine ring.</p>	<p data-bbox="824 153 998 184">PHA-539195</p>  <p>The structure of PHA-539195 features a 4-bromophenyl ring with a carboxylic acid group and an amide linkage. The amide nitrogen is connected to a benzoyl group, which is linked to a para-substituted benzene ring. This benzene ring is connected via a sulfonamide group to another para-substituted benzene ring, which is terminated by a diethylamino group.</p>
<p data-bbox="264 814 438 846">PHA-539197</p>  <p>The structure of PHA-539197 is similar to PHA-539195, featuring a 4-bromophenyl ring with a carboxylic acid group and an amide linkage. The amide nitrogen is connected to a benzoyl group, which is linked to a para-substituted benzene ring. This benzene ring is connected via a sulfonamide group to another para-substituted benzene ring, which is terminated by a diethylamino group.</p>	<p data-bbox="833 804 1006 835">PHA-539198</p>  <p>The structure of PHA-539198 consists of a 4-bromophenyl ring with a carboxylic acid group and an amide linkage. The amide nitrogen is connected to a benzoyl group, which is linked to a para-substituted benzene ring. This benzene ring is connected via a sulfonamide group to another para-substituted benzene ring, which is terminated by a diethylamino group.</p>











Compound No., Structure	Compound No., Structure
<p>PHA-539199</p> 	<p>PHA-539203</p> 
<p>PHA-539206</p> 	<p>PHA-539207</p> 
<p>PHA-539208</p> 	<p>PHA-539209</p> 







Compound No., Structure	Compound No., Structure
PHA-539234 	PHA-539235 
PHA-539245 	PHA-539246 
PHA-539247 	PHA-539248 
PHA-539249 	PHA-539250 
PHA-539251 	PHA-539252 







Compound No., Structure	Compound No., Structure
PHA-539253 	PHA-539254 
PHA-539255 	PHA-539256 
PHA-539257 	PHA-539258 
PHA-539259 	PHA-539260 
PHA-539262 	PHA-539263 





Compound No., Structure	Compound No., Structure
PHA-539264 	PHA-539265 
PHA-539266 	PHA-539267 
PHA-539268 	PHA-539269 
PHA-539270 	PHA-539271 
PHA-539276 	PHA-539277 







Compound No., Structure	Compound No., Structure
PHA-539278 	PHA-539285 
PHA-539293 	PHA-539294 
PHA-539295 	PHA-539296 
PHA-539297 	PHA-539298 
PHA-539302 	PHA-539303 









Compound No., Structure	Compound No., Structure
PHA-539305 	PHA-539307 
PHA-539308 	PHA-539310 
PHA-539312 	PHA-539313 
PHA-539314 	PHA-539317 
PHA-539318 	PHA-539322 









Compound No., Structure	Compound No., Structure
<p>PHA-539328</p> 	<p>PHA-539329</p> 
<p>PHA-539332</p> 	<p>PHA-539337</p> 
<p>PHA-539338</p> 	<p>PHA-543684</p> 









Compound No., Structure	Compound No., Structure
<p>PHA-543685</p> 	<p>PHA-543686</p> 
<p>PHA-543689</p> 	<p>PHA-543690</p> 
<p>PHA-543692</p> 	<p>PHA-543693</p> 

Compound No., Structure	Compound No., Structure
<p data-bbox="256 163 430 195">PHA-543695</p>  <p>The structure of PHA-543695 consists of a central benzene ring substituted with a carboxamide group (NH-C(=O)-) at position 1, a chlorine atom at position 2, a fluorine atom at position 3, and a sulfonamide group (-NH-SO₂-) at position 4. The sulfonamide group is further substituted with a 3-chloro-4-fluorophenyl ring.</p>	<p data-bbox="824 153 998 184">PHA-543698</p>  <p>The structure of PHA-543698 features a central benzene ring with a carboxamide group (NH-C(=O)-) at position 1, a hydroxyl group (-OH) at position 2, and a sulfonamide group (-NH-SO₂-) at position 4. The sulfonamide group is substituted with a 4-aminophenyl ring. The carboxamide group is further substituted with a 3-bromo-4-hydroxyphenyl ring.</p>
<p data-bbox="264 741 438 772">PHA-543700</p>  <p>The structure of PHA-543700 is a benzene ring substituted with a carboxamide group (NH-C(=O)-) at position 1, a bromine atom at position 2, and a sulfonamide group (-NH-SO₂-) at position 4. The sulfonamide group is substituted with a 2,3-dihydrobenzofuran ring.</p>	<p data-bbox="833 730 1006 762">PHA-543701</p>  <p>The structure of PHA-543701 is a benzene ring substituted with a carboxamide group (NH-C(=O)-) at position 1, a bromine atom at position 2, and a sulfonamide group (-NH-SO₂-) at position 4. The sulfonamide group is substituted with a 3-pyridyl ring. The carboxamide group is further substituted with a 3-bromo-4-hydroxyphenyl ring.</p>

Compound No., Structure	Compound No., Structure
<p data-bbox="248 163 423 195">PHA-543706</p> 	<p data-bbox="816 153 992 184">PHA-543708</p> 
<p data-bbox="248 842 435 873">PHA-551625</p> 	<p data-bbox="816 831 1003 863">PHA-551672</p> 
<p data-bbox="248 1318 446 1350">PHA-551675</p> 	<p data-bbox="816 1308 1015 1339">PHA-551716</p> 

Compound No., Structure	Compound No., Structure
<p>PHA-556420</p> 	<p>PHA-563330</p> 
<p>PHA-563331</p> 	<p>PHA-563333</p> 
<p>PHA-563335</p> 	<p>PHA-563340</p> 
<p>PHA-563341</p> 	<p>PHA-563342</p> 









Compound No., Structure	Compound No., Structure
PHA-563344 	PHA-563345 
PHA-563347 	PHA-563350 
PHA-563351 	PHA-563353 
PHA-563354 	PHA-563360 









Compound No., Structure	Compound No., Structure
PHA-563363 	PHA-563364 
PHA-563365 	PHA-563366 
PHA-563368 	PHA-563370 
PHA-563371 	PHA-563375 









Compound No., Structure	Compound No., Structure
PHA-563378 	PHA-563386
PHA-563388 	PHA-563389
PHA-563390 	PHA-563391
PHA-563392 	PHA-563393
PHA-563394 	PHA-563396







Compound No., Structure	Compound No., Structure
PHA-563397 	PHA-563398
PHA-563399 	PHA-563401
PHA-563404 	PHA-563406
PHA-563407 	PHA-563408
PHA-563409 	PHA-563411







Compound No., Structure	Compound No., Structure
PHA-563413 	PHA-563415
PHA-563417 	PHA-563419
PHA-563420 	PHA-563426
PHA-563427 	PHA-563440
PHA-563441 	PHA-563442









Compound No., Structure	Compound No., Structure
PHA-563449 	PHA-569976 
PHA-571150 	PHA-571151 
PHA-571152 	PHA-571153 
PHA-571154 	PHA-571155 

Compound No., Structure	Compound No., Structure
<p>PHA-571156</p> 	<p>PHA-571157</p> 
<p>PHA-571160</p> 	<p>PHA-571161</p> 
<p>PHA-571162</p> 	<p>PHA-571164</p> 
<p>PHA-571167</p> 	<p>PHA-571169</p> 









Compound No., Structure	Compound No., Structure
<p data-bbox="267 205 446 241">PHA-571170</p> 	<p data-bbox="831 205 1010 241">PHA-571172</p> 
<p data-bbox="267 661 446 697">PHA-571174</p> 	<p data-bbox="831 661 1010 697">PHA-571176</p> 
<p data-bbox="267 1117 446 1152">PHA-571182</p> 	<p data-bbox="831 1117 1010 1152">PHA-571183</p> 
<p data-bbox="267 1446 446 1482">PHA-571186</p> 	<p data-bbox="831 1446 1010 1482">PHA-571188</p> 









Compound No., Structure	Compound No., Structure
PHA-571189 	PHA-571194 
PHA-571196 	PHA-571197 
PHA-571198 	PHA-571199 









Compound No., Structure	Compound No., Structure
<p data-bbox="264 205 440 237">PHA-571202</p> 	<p data-bbox="836 205 1011 237">PHA-571203</p> 
<p data-bbox="264 751 440 783">PHA-571205</p> 	<p data-bbox="836 751 1011 783">PHA-571207</p> 
<p data-bbox="264 1255 440 1287">PHA-571208</p> 	<p data-bbox="836 1255 1011 1287">PHA-571214</p> 







Compound No., Structure	Compound No., Structure
<p>PHA-571215</p> 	<p>PHA-571216</p> 
<p>PHA-571219</p> 	<p>PHA-571224</p> 
<p>PHA-571226</p> 	<p>PHA-571228</p> 
<p>PHA-571230</p> 	<p>PHA-571231</p> 







Compound No., Structure	Compound No., Structure
PHA-571232 	PHA-571234
PHA-571235 	PHA-571237
PHA-571238 	PHA-571239
PHA-571240 	PHA-571241







Compound No., Structure	Compound No., Structure
<p>PHA-571242</p> 	<p>PHA-571243</p> 
<p>PHA-571246</p> 	<p>PHA-571249</p> 
<p>PHA-571253</p> 	<p>PHA-571255</p> 
<p>PHA-571257</p> 	<p>PHA-571258</p> 







Compound No., Structure	Compound No., Structure
<p>PHA-571260</p> 	<p>PHA-571262</p> 
<p>PHA-571263</p> 	<p>PHA-571264</p> 
<p>PHA-571265</p> 	<p>PHA-571267</p> 
<p>PHA-571269</p> 	<p>PHA-571270</p> 







Compound No., Structure	Compound No., Structure
<p>PHA-571271</p> 	<p>PHA-571272</p> 
<p>PHA-571273</p> 	<p>PHA-571280</p> 
<p>PHA-571281</p> 	<p>PHA-571282</p> 
<p>PHA-571283</p> 	<p>PHA-571285</p> 







Compound No., Structure	Compound No., Structure
<p data-bbox="264 207 440 241">PHA-571287</p> 	<p data-bbox="829 207 1008 241">PHA-571289</p> 
<p data-bbox="264 554 440 588">PHA-571292</p> 	<p data-bbox="829 554 1008 588">PHA-610940</p> 
<p data-bbox="264 1121 440 1155">PHA-610941</p> 	<p data-bbox="829 1121 1008 1155">PHA-610942</p> 









Compound No., Structure	Compound No., Structure
<p data-bbox="277 212 456 241">PHA-630426</p> 	<p data-bbox="842 212 1021 241">PHA-656807</p> 
<p data-bbox="277 680 456 709">PHA-656808</p> 	<p data-bbox="842 680 1021 709">PHA-656809</p> 
<p data-bbox="277 1184 456 1213">PHA-656810</p> 	<p data-bbox="842 1184 1021 1213">PHA-656811</p> 







Compound No., Structure	Compound No., Structure
<p>PHA-656820</p>  <chem>Clc1ccc(cc1)-c2ccc(cc2C(=O)O)NC(=O)c3ccc(cc3S(=O)(=O)N4CCOCC4)</chem>	<p>PHA-656859</p>  <chem>CCN(CC)S(=O)(=O)c1ccccc1C(=O)Nc2ccc(cc2C(=O)O)C#N</chem>
<p>PHA-656860</p>  <chem>C1=CC=C(C=C1)NC(=O)S(=O)(=O)c2ccccc2C(=O)Nc3ccc(cc3C#N)C(=O)O</chem>	<p>PHA-656861</p>  <chem>CN(C)S(=O)(=O)c1ccc(cc1C(=O)Nc2ccc(cc2C#N)C(=O)O)CC(O)c3ccccc3</chem>
<p>PHA-656862</p>  <chem>CN(C)S(=O)(=O)c1ccc(cc1C(=O)Nc2ccc(cc2C#N)C(=O)O)CCc3ccccc3</chem>	<p>PHA-656863</p>  <chem>CC1CCN(C1)S(=O)(=O)c2ccccc2C(=O)Nc3ccc(cc3C#N)C(=O)O</chem>





Compound No., Structure	Compound No., Structure
<p data-bbox="272 205 446 237">PHA-656866</p> 	<p data-bbox="841 205 1015 237">PHA-656867</p> 
<p data-bbox="272 772 446 804">PHA-656868</p> 	<p data-bbox="841 772 1015 804">PHA-656870</p> 
<p data-bbox="272 1339 446 1371">PHA-656871</p> 	<p data-bbox="841 1339 1015 1371">PHA-656872</p> 







Compound No., Structure	Compound No., Structure
<p data-bbox="264 201 443 233">PHA-656880</p> 	<p data-bbox="833 201 1011 233">PHA-656882</p> 
<p data-bbox="264 653 443 684">PHA-656883</p> 	<p data-bbox="833 653 1011 684">PHA-656884</p> 
<p data-bbox="264 1230 443 1262">PHA-656885</p> 	<p data-bbox="833 1230 1011 1262">PHA-656886</p> 







Compound No., Structure	Compound No., Structure
<p>PHA-656887</p>  <chem>O=C(O)c1cc(Cl)ccc1NC(=O)c2ccccc2C(=O)c3ccsc3</chem>	<p>PHA-656888</p>  <chem>O=C(O)c1cc(Cl)ccc1NC(=O)c2ccc(cc2C(=O)C3CCCC3)C(=O)c4ccccc4</chem>
<p>PHA-656889</p>  <chem>CC(C)(C)C(=O)c1ccc(cc1C(=O)Nc2cc(Cl)ccc2C(=O)O)C(=O)c3ccccc3</chem>	<p>PHA-656890</p>  <chem>O=C(O)c1cc(Cl)ccc1NC(=O)c2ccc(cc2C(=O)C3CC3)C(=O)c4ccccc4</chem>
<p>PHA-656891</p>  <chem>O=C(O)c1cc(Cl)ccc1NC(=O)c2ccc(cc2C(=O)CC3CCCC3)C(=O)c4ccccc4</chem>	<p>PHA-656892</p>  <chem>O=C(O)c1cc(Cl)ccc1NC(=O)c2ccc(cc2C(=O)c3cc(F)cc(F)c3)C(=O)c4ccccc4</chem>




Compound No., Structure	Compound No., Structure
<p>PHA-656893</p> 	<p>PHA-656894</p> 
<p>PHA-662253</p> 	<p>PHA-662254</p> 
<p>PHA-662412</p> 	<p>PHA-679756</p> 
<p>PHA-679759</p> 	<p>PHA-687570</p> 

Compound No., Structure	Compound No., Structure
<p data-bbox="267 199 446 241">PHA-708922</p> 	<p data-bbox="836 199 1015 241">PHA-708977</p> 
<p data-bbox="267 787 446 829">PHA-708979</p> 	<p data-bbox="836 787 1015 829">PHA-708987</p> 
<p data-bbox="267 1341 446 1383">PHA-713389</p> 	<p data-bbox="836 1341 1015 1383">PHA-713390</p> 

Compound No., Structure	Compound No., Structure
<p data-bbox="264 207 440 241">PHA-713391</p>  <p>The structure of PHA-713391 consists of a 5-chloro-1H-benzothiophene-2-carboxamide group linked via its amide nitrogen to a para-phenylene ring. This para-phenylene ring is further linked via its other amide nitrogen to another para-phenylene ring, which is substituted with a carboxylic acid group and a bromine atom at the meta position.</p>	<p data-bbox="834 207 1010 241">PHA-713392</p>  <p>The structure of PHA-713392 is similar to PHA-713391, but the meta-bromine substituent on the terminal para-phenylene ring is replaced by a carboxylic acid group.</p>
<p data-bbox="264 842 446 875">PHA-713393</p>  <p>The structure of PHA-713393 features a 4-phenylbenzamide group linked via its amide nitrogen to a para-phenylene ring. This para-phenylene ring is further linked via its other amide nitrogen to another para-phenylene ring, which is substituted with a carboxylic acid group and a bromine atom at the meta position.</p>	<p data-bbox="834 842 1016 875">PHA-713395</p>  <p>The structure of PHA-713395 is similar to PHA-713393, but the terminal phenyl ring is substituted with a nitrile group instead of a hydrogen atom at the para position.</p>

Compound No., Structure	Compound No., Structure
<p data-bbox="277 212 448 243">PHA-713397</p> 	<p data-bbox="839 212 1010 243">PHA-738531</p> 
<p data-bbox="277 831 448 863">PHA-738532</p> 	<p data-bbox="839 831 1010 863">PHA-740499</p> 
<p data-bbox="277 1157 448 1188">PHA-748361</p> 	<p data-bbox="839 1157 1010 1188">PNU-276556</p> 

Compound No., Structure	Compound No., Structure
<p>PNU-276672</p> 	<p>PNU-276873</p> 
<p>PNU-281164</p> 	<p>PNU-282858</p> 
<p>PNU-282859</p> 	<p>PNU-282860</p> 

Compound No., Structure	Compound No., Structure
<p>PNU-290881A</p> 	<p>PNU-291997</p> 
<p>PNU-292577</p> 	

Example 11: ACTIVITY DATA

MIC Test Method

The *in vitro* MICs of test compounds were determined by a standard agar dilution method. A stock drug solution of each analog was prepared in the preferred solvent, usually DMSO:H₂O (1:3). Serial 2-fold dilutions of each sample are made using 1.0 ml aliquots of sterile distilled water. To each 1.0 ml aliquot of drug was added 9 ml of molten Mueller Hinton agar medium. The drug-supplemented agar was mixed, poured into 15 x 100 mm petri dishes, and allowed to solidify and dry prior to inoculation.





Vials of each of the test organisms are maintained frozen in the vapor phase of a liquid nitrogen freezer. Test cultures are grown overnight at 35°C on the medium









appropriate for the organism. Colonies are harvested with a sterile swab, and cell suspensions are prepared in Trypticase Soy broth (TSB) to equal the turbidity of a 0.5 McFarland standard. A 1:20 dilution of each suspension was made in TSB. The plates containing the drug supplemented agar are inoculated with a 0.001 ml drop of the cell suspension using a Steers replicator, yielding approximately 10^4 to 10^5 cells per spot. The plates are incubated overnight at 35°C.









Following incubation the Minimum Inhibitory Concentration (MIC $\mu\text{g/ml}$), the lowest concentration of drug that inhibits visible growth of the organism, was read and recorded. The data is shown in Tables I and II.









10









Table 1: Activity Data







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
L-217792 	8	PHA-500334 	16
PHA-501684 	1	PHA-502339 	2







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-501685 	2	PHA-502339A 	8
PHA-501748 	2	PHA-509059 	0.5
PHA-504639 	4	PHA-513535 	2
PHA-515448 	2	PHA-513541 	64







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-515585 	1	PHA-515583 	8
PHA-516113 	2	PHA-516112 	8
PHA-519402 	0.5	PHA-516116 	0.5
PHA-521534 	1	PHA-518226 	2







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-522145 	32	PHA-520446 	16
PHA-524523 	0.125	PHA-520447 	1
PHA-524545 	0.25	PHA-520938 	1
PHA-526580 	1	PHA-521535 	>128







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-530687 	8	PHA-522146 	0.5
PHA-535548 	0.25	PHA-524524 	1
PHA-535549 	0.25	PHA-526578 	2
PHA-535553 	1	PHA-530685 	32







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-543140 	1	PHA-530989 	4
PHA-546926 	0.5	PHA-543139 	0.125
PHA-547267 	0.125	PHA-543141 	0.125







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-552831 	1	PHA-543681 	0.125
PHA-556214 	1	PHA-555027 	1
PHA-556658 	8	PHA-556657 	2







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-556663 	8	PHA-556661 	8
PHA-561055 	1	PHA-557035 	4
PHA-562733 	0.25	PHA-562731 	1







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-562862 	4	PHA-562745 	0.25
PHA-562863 	2	PHA-563275 	2
PHA-563274 	2	PHA-563277 	2







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-563276 	2	PHA-563279 	0.5
PHA-563278 	2	PHA-563281 	1
PHA-563280 	1	PHA-563283 	16









Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-563282 	1	PHA-563285 	2
PHA-563284 	2	PHA-564215 	0.5
PHA-563324 	>128	PHA-564750 	0.25









Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-564218 	1	PHA-566948  (-)-enantiomer	1
PHA-566947  (+)-enantiomer	0.5	PHA-568197  6.3/93.7 trans/cis	16
PHA-568196  98/2 mixture of trans/cis	1	PHA-568205 	2









Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-568206 	2	PHA-568376 	16
PHA-568378 	2	PHA-568420 	0.5
PHA-568461 	0.125	PHA-568422 	0.125







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-568907 	8	PHA-568424 	1
PHA-569044 	0.25	PHA-568425 	8
PHA-569064 	1	PHA-568906 	8







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-569887  Trans	0.25	PHA-569044A  HCl	0.5
PHA-569977 	16	PHA-569077 	1
PHA-570949 	1	PHA-569885  This is 97.9/2.1 cis/trans	16







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-571396 	4	PHA-569974 	1
PHA-571458 	4	PHA-570008 	0.125
PHA-615551 	1	PHA-570042 	2
PHA-630427 	4	PHA-571395 	4







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-630852 	4	PHA-571397 	4
PHA-630966 	0.25	PHA-610938 	1
PHA-630989 	4	PHA-630368 	0.5
PHA-662430 	1	PHA-630726 	4







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-662951 	32	PHA-630965 	0.25
PHA-666124 	32	PHA-631082 	0.25
PHA-681768 	1	PHA-662250 	1
PHA-686834 	4	PHA-662431 	1







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-707801 	4	PHA-664658 	4
PHA-708976 	32	PHA-670083 	0.5
PHA-708980 	16	PHA-682996 	64







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-708982 	128	PHA-687511  is >99 trans	4
PHA-708984 	32	PHA-708923 	32
PHA-708986 	64	PHA-708978 	32









Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-708989 	8	PHA-708981 	16
PHA-708991 	4	PHA-708983 	32
PHA-708993 	4	PHA-708985 	8









Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-708995 	0.125	PHA-708988 	32
PHA-708997 	8	PHA-708990 	8
PHA-713387 	128	PHA-708992 	4







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-713394 	128	PHA-708994 	8
PHA-713398 	4	PHA-708996 	16
PHA-713400 	16	PHA-713386 	128







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-713403 	64	PHA-713388 	16
PHA-713406 	64	PHA-713396 	8
PHA-713408 	64	PHA-713399 	16







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-713410 	1	PHA-713401 	32
PHA-717196 	4	PHA-713405 	128
PHA-728844 	0.25	PHA-713407 	32







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PNU-263533 		PHA-713409 	1
PNU-271584 		PHA-713411 	32
PNU-276296 		PHA-719201 	2
PNU-276637 		PHA-735753 	16







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PNU-276670  <chem>C21H17BrN2O5S</chem> Exact wt. 488.0042		PNU-268205  <chem>C17H13BrN3O4S</chem>	
PNU-276817  <chem>C14H10BrN2O6S</chem>	4	PNU-275747  <chem>C18H20ClN2O4S</chem>	
PNU-276854  <chem>C20H19BrN2O6S</chem>		PNU-276301  <chem>C17H15BrN2O5S</chem>	
PNU-276933  <chem>C20H19BrN2O6S</chem>		PNU-276638  <chem>C18H17BrN2O6S</chem> Exact wt. 467.9991	







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
<p>PNU-276988</p> 	16	<p>PNU-276728</p>  <p>C₂₂H₁₇BrN₂O₅S Exact wt. 500.0042</p>	2
<p>PNU-277231</p> 	1	<p>PNU-276770</p>  <p>C₁₇H₁₇BrN₂O₆S Exact wt. 455.9991</p>	
<p>PNU-280772</p> 		<p>PNU-276818</p> 	

Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PNU-283076 	1	PNU-276913 	
PNU-283599 	1	PNU-276952  racemic	
PNU-283603A  HCl	16	PNU-280727 	

Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PNU-288969 	0.25	PNU-282958 	
PNU-290821 	64	PNU-283318 	0.125
PNU-290877  See Comments	>128	PNU-283371 	4

Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PNU-290905 	1	PNU-283601A 	32
PNU-290906 	1	PNU-283604 	4
PNU-291061 	16	PNU-289815 	8

Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PNU-291410 	4	PNU-290882 	1
PNU-291570 	8	PNU-291010 	1
PNU-291571 	0.5	PNU-291011 	0.25

Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PNU-292070 	2	PNU-291129 	0.5
PNU-293032 	16	PNU-291130 	4
PNU-293905 	8	PNU-291408 	32





























Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-630331 	2	PNU-291517 	2
PNU-293795 	32	PNU-291679 	1
PNU-294595 	16	PNU-292379 	0.5
PHA-630330 	0.5	PNU-293049 	4









Table 2: Activity Data











Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
-------------------------	----------------	-------------------------	----------------









Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
L-170210 	16	L-170216 	
L-199199 		L-217790 	4







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
L-217791 	4	L-218343 	16
L-502902 	128	L-502903 	16
L-502904 	64	PHA-500140 	32





Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-500152 	32	PHA-500200 	4
PHA-500218 	64	PHA-500219 	32
PHA-500230 	>128	PHA-500236 	8
PHA-500248 	8	PHA-500284 	32
PHA-502605 	8	PHA-502606 	16







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-520185 	8	PHA-520200 	2
PHA-520221 	2	PHA-520245 	128
PHA-520412 	4	PHA-520413 	4
PHA-520414 	8	PHA-520416 	4







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-523506 	32	PHA-523507 	4
PHA-523510 	8	PHA-523508 	8
PHA-523511 	8	PHA-523509 	8
PHA-523513 	4	PHA-523512 	4
PHA-523516 	2	PHA-523514 	4







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-523517 	4	PHA-523515 	4
PHA-523518 	8	PHA-524553A  HCl	>128
PHA-523519 	4	PHA-525501 	8
PHA-523520 	2	PHA-525503 	2







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-523521 	16	PHA-525505 	16
PHA-524545E 	0.5	PHA-525506 	64
PHA-525500 	4	PHA-526643 	64





Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-525502 	8	PHA-526650 	2
PHA-525504 	16	PHA-526652 	1







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-526641 	8	PHA-526655 	16
PHA-526648 	0.25	PHA-526661 	16
PHA-526651 	0.25	PHA-526681 	8







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-526653 	>128	PHA-526705 	16
PHA-526660 	8	PHA-526712 	64
PHA-526679 	32	PHA-530915 	32







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-526683 	>128	PHA-533237 	16
PHA-526707 	2	PHA-533244 	4
PHA-530914 	32	PHA-533249 	8







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-533232 	64	PHA-533253 	32
PHA-533243 	32	PHA-533258 	32
PHA-533247 	32	PHA-533261 	8







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-533252 	32	PHA-533265 	128
PHA-533257 	16	PHA-533268 	64









Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-533259 	32	PHA-533272 	128
PHA-533262 	64	PHA-533274 	8
PHA-533264 	128	PHA-533276 	64









Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-533266 	128	PHA-533281 	64
PHA-533269 	16	PHA-533285 	64
PHA-533273 	64	PHA-533289 	64







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-533275 	8	PHA-533401 	0.5
PHA-533278 	32	PHA-537084  least retained isomer by RP-HPLC	2
PHA-533282 	>128	PHA-537089  least retained isomer by RP-LC/MS	32







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-533286 	128	PHA-537091 	8
PHA-533290 	64	PHA-537098 	16
PHA-537085 	16	PHA-537100 	16







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-537090  least retained isomer by RP-LC/MS	32	PHA-537106 	8
PHA-537092 	16	PHA-537112 	128
PHA-537099 	8	PHA-537121 	4

Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-537101 	4	PHA-537128 	8
PHA-537110 	64	PHA-537138 	32
PHA-537114 	16	PHA-537142 	4
PHA-537122 	16	PHA-537144 	8







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-537133 	8	PHA-537152 	8
PHA-537139 	4	PHA-537157 	32
PHA-537143 	16	PHA-537162 	16
PHA-537150 	32	PHA-537203  most highly retained isomer by RP-LC/MS	32







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-537155 	64	PHA-538016 	64
PHA-537158 	32	PHA-539146 	128
PHA-537202  most highly retained isomer by RP-LC/MS	8	PHA-539149 	64







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-537204  most highly retained isomer by RP-LC/MS	64	PHA-539152 	64
PHA-539148 	64	PHA-539154 	32
PHA-539150 	64	PHA-539156 	8











Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-539153 	32	PHA-539168 	64
PHA-539155 	32	PHA-539170 	64
PHA-539164 	128	PHA-539172 	1











Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-539169 	16	PHA-539175 	1
PHA-539171 	128	PHA-539179 	8
PHA-539174 	8	PHA-539181 	64











Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-539177 	4	PHA-539186 	0.5
PHA-539180 	1	PHA-539188 	16
PHA-539183 	8	PHA-539193 	32











Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-539187 	4	PHA-539195 	64
PHA-539190 	16	PHA-539198 	128
PHA-539194 	64	PHA-539203 	1











Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-539197 	64	PHA-539207 	2
PHA-539199 	32	PHA-539209 	0.5
PHA-539206 	2	PHA-539235 	128







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-539208 	16	PHA-539246 	8
PHA-539234 	128	PHA-539248 	8
PHA-539245 	>128	PHA-539250 	32
PHA-539247 	64	PHA-539252 	32
PHA-539249 	8	PHA-539254 	128







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-539251 	128	PHA-539256 	32
PHA-539253 	16	PHA-539258 	64
PHA-539255 	>128	PHA-539260 	64
PHA-539257 	8	PHA-539263 	32
PHA-539259 	128	PHA-539265 	32







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-539262 	32	PHA-539267 	0.5
PHA-539264 	8	PHA-539269 	32
PHA-539266 	2	PHA-539271 	>128
PHA-539268 	32	PHA-539277 	32
PHA-539270 	>128	PHA-539285 	16







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-539276 	32	PHA-539294 	128
PHA-539278 	2	PHA-539296 	64
PHA-539293 	>128	PHA-539298 	64
PHA-539295 	32	PHA-539303 	32
PHA-539297 	>128	PHA-539307 	>128









Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-539302 	>128	PHA-539310 	>128
PHA-539305 	64	PHA-539313 	>128
PHA-539308 	128	PHA-539317 	16
PHA-539312 	128	PHA-539322 	16
PHA-539314 	64	PHA-539329 	>128









Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-539318 	>128	PHA-539337 	32
PHA-539328 	>128	PHA-543684 	128
PHA-539332 	64	PHA-543686 	4











Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-539338 	64	PHA-543690 	32
PHA-543685 	>128	PHA-543693 	2
PHA-543689 	64	PHA-543698 	>128











Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-543692 	16	PHA-543701 	128
PHA-543695 	>128	PHA-543708 	16
PHA-543700 	64	PHA-551716 	128











Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-543706 	32	PHA-563331 	>128
PHA-551625 	2	PHA-563335 	8
PHA-551672 	8	PHA-563341 	8









Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-551675 	32	PHA-563344 	64
PHA-556420 	128	PHA-563347 	64
PHA-563330 	>128	PHA-563351 	>128
PHA-563333 	>128	PHA-563354 	2







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-563340 	64	PHA-563363 	16
PHA-563342 	2	PHA-563365 	16
PHA-563345 	16	PHA-563368 	>128
PHA-563350 	64	PHA-563371 	16









Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-563353 	128	PHA-563378 	16
PHA-563360 	32	PHA-563388 	>128
PHA-563364 	>128	PHA-563390 	32
PHA-563366 	4	PHA-563392 	16
PHA-563370 	32	PHA-563394 	16









Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-563375 	8	PHA-563398 	>128
PHA-563386 	32	PHA-563399 	16
PHA-563389 	64	PHA-563404 	8
PHA-563391 	>128	PHA-563407 	>128
PHA-563393 	128	PHA-563409 	64









Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-563396 	>128	PHA-563413 	128
PHA-563397 	32	PHA-563417 	>128
PHA-563401 	>128	PHA-563420 	16
PHA-563406 	64	PHA-563427 	>128
PHA-563408 	>128	PHA-563441 	64







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-563411 	128	PHA-563449 	64
PHA-563415 	128	PHA-571150 	0.5
PHA-563419 	64	PHA-571152 	8
PHA-563426 	64	PHA-571154 	128







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-563440 	64	PHA-571156 	16
PHA-563442 	>128	PHA-571160 	64
PHA-569976 	32	PHA-571162 	16









Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-571151 	8	PHA-571167 	32
PHA-571153 	64	PHA-571170 	64
PHA-571155 	32	PHA-571174 	64
PHA-571157 	32	PHA-571182 	64









Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-571161 	>128	PHA-571186 	128
PHA-571164 	8	PHA-571189 	64
PHA-571169 	32	PHA-571196 	64
PHA-571172 	32	PHA-571198 	>128









Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-571176 	64	PHA-571202 	128
PHA-571183 	32	PHA-571205 	32
PHA-571188 	8	PHA-571208 	64
PHA-571194 	4	PHA-571215 	8







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-571197 	16	PHA-571219 	32
PHA-571199 	64	PHA-571226 	64
PHA-571203 	32	PHA-571230 	16







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-571207 	32	PHA-571232 	>128
PHA-571214 	16	PHA-571235 	8
PHA-571216 	32	PHA-571238 	128







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-571224 	8	PHA-571240 	16
PHA-571228 	32	PHA-571242 	32
PHA-571231 	>128	PHA-571246 	32
PHA-571234 	8	PHA-571253 	16







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-571237 	16	PHA-571257 	64
PHA-571239 	128	PHA-571260 	32
PHA-571241 	16	PHA-571263 	16
PHA-571243 	4	PHA-571265 	16







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-571249 	16	PHA-571269 	16
PHA-571255 	>128	PHA-571271 	64
PHA-571258 	8	PHA-571273 	8
PHA-571262 	32	PHA-571281 	128









Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-571264 	32	PHA-571283 	16
PHA-571267 	32	PHA-571287 	2
PHA-571270 	8	PHA-571292 	32









Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-571272 	32	PHA-610941 	>128
PHA-571280 	>128	PHA-630426 	>128
PHA-571282 	16	PHA-656808 	64







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-571285 	64	PHA-656810 	2
PHA-571289 	32	PHA-656820 	>128
PHA-610940 	>128	PHA-656860 	8







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-610942 	>128	PHA-656862 	32
PHA-656807 	64	PHA-656866 	>128
PHA-656809 	64	PHA-656868 	>128







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-656811 	32	PHA-656871 	128
PHA-656859 	16	PHA-656880 	16
PHA-656861 	32	PHA-656883 	16







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-656863 	8	PHA-656885 	16
PHA-656867 	64	PHA-656887 	8
PHA-656870 	8	PHA-656889 	16
PHA-656872 	>128	PHA-656891 	16







Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-656882 	16	PHA-656893 	8
PHA-656884 	16	PHA-662253 	128
PHA-656886 	16	PHA-662412 	64
PHA-656888 	16	PHA-679759 	>128


Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-656890 	16	PHA-708922 	>128
PHA-656892 	8	PHA-708977 	>128
PHA-656894 	16	PHA-708987 	>128

Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
<p>PHA-662254</p> 	>128	<p>PHA-713390</p> 	>128
<p>PHA-679756</p> 	>128	<p>PHA-713392</p> 	>128
<p>PHA-687570</p> 	128	<p>PHA-713395</p> 	>128

Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-708979 	>128	PHA-738531 	64
PHA-713389 	>128	PHA-740499 	128
PHA-713391 	>128	PNU-276556 	

Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-713393 	>128	PNU-276873 	
PHA-713397 	>128	PNU-282858 	
PHA-738532 	32	PNU-282860 	

Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
PHA-748361 	8	PNU-291997 	1
PNU-276672 		PNU-281164 	>128
PNU-292577 	128	PNU-282859 	32

Compound No., Structure	SA 9218 MIC	Compound No., Structure	SA 9218 MIC
		<p>PNU-290881A</p>  <p>HCl</p>	4